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Abstract
Monitoring the Systemic Immune Response to Understand and Improve the Efficacy of
Immunotherapy for Metastatic Osteosarcoma

Justin E. Markel
Osteosarcoma (OS) is a complex tumor with no effective targeted therapies due to its genomic
heterogeneity and pleomorphism. The immune response it creates, particularly against metastatic
lesions, is considerable; however, various suppressive mechanisms induced by the tumor prohibit
its effectiveness. The presence of infiltrating lymphocytes suggests that therapeutic disinhibition
through checkpoint blockade could increase antitumor immunity, though none have been
successful in clinical trials. The complexities of the immune response to OS tumors have yet to be
unraveled; however, there is evidence to suggest that cell-mediated immunity (CMI, specifically
T cells, Natural Killer [NK] cells, and myeloid-lineage cells [MLCs]) plays an important role. New
technologies have made it possilble to assess large numbers of cell antigens simultaneously,
producing detailed information on the immune status of an individual. A snapshot of the
immunological status of an organ or tumor can be conveyed by means of an immunophenotype
(IPT), which uses cytometry, microarray, or gene set enrichment analysis to determine the relative
percent populations and activation states of immune cells. The majority of data collected on the
OS IPT are from primary tumors. Unlike metastatic tumros, primary tumors are easily removed by
surgeons and do not account for aossicated high mortality rates. As such, we have investigated the
systemic immune response to disease progression with and without immunotherapy. Using a
highly metastatic luciferase(+) K7M2 (luc-K7M2) orthotopic OS model in an immunocompetent
host, it was determined that the introduction of luciferase into tumor cells had little to no effect on
the overall antitumor immune response and clinical disease progression. A systems-wide
comparison of tumor-bearing and sham (surgery only) mice showed that there are significant
changes in the IPTs of tumor-bearing mice at various time points in disease progression, and that
these changes are consistent across different tissues. As disease progresses, T and NK cells are
gradually depleted, and macrophages (Mφs) adopt intermediate phenotypes through increased
expression of both M1 and M2 polarization markers. Moreover, NK cell depletion in blood is
specific to disease progression. T cells, under constant exposure to OS tumor antigens, become
overstimulated and upregulate exhaustion markers like programmed cell death protein 1 (PD-1)
and T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3). Further, a notable
systemic immune biomarker was uncovered using a co-expression ratio of immunosuppressive
programmed death ligand 1 (PD-L1) to immunostimulatory major histocompatibility complex
class II (MHC-II) on monocytic-myeloid-derived suppressor cells (M-MDSCs), a specific marker
of OS disease progression in blood. Monotherapy with monoclocal antibody anti(α)-PD-L1
reversed the malignancy-induced immunological disturbances but did coindice with increased
survival. Conversely, treatment of OS tumor-bearing mice with poly(lactic-co-glycolic) acid
(PLGA)-encapsulated interleukin(IL)-12 decreased metastatic rate and increased cure rate in a
immunophenotype-dependent manner that coincided with treatment-induced NK cell
proliferation. These results demonstrate that systemic immunophenotyping can be used to non-

invasively monitor OS patient disease progression and response to immunotherapeutics,
potentially offering clinicians the opportunity to modify treatment regimens in real-time.
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Chapter 1
Introduction and Literature Review
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Osteosarcoma Overview

Osteosarcoma Epidemiology

Osteosarcoma (OS) is a rare primary malignancy of bone, with 800-900 new cases
occurring in the United States per year with children and young adults accounting for the majority.
OS constitutes around 2% of all childhood cancers; OS in adults over 60 make up about 10% of
cases and is often associated with pre-existing Paget’s disease or past exposure to ionizing
radiation (1-3). Disease arising in older patients is axial (most commonly the pelvis) in 39.7% of
cases (4). While multiple histological subtypes exist, high-grade osteoblastic OS is the most
aggressive and constitutes the majority of cases in children and young adults (5). A classical
clinical presentation of OS is a teenager or young adult who fractures a long bone of the extremity
with a force that appears disproportionately minor compared to the damage. For patients with
localized disease of an extremity, the 5-year relative survival rate is 77%. The overall 5-year
survival rate for children and young adults is 60%; however, when metastatic, the 5-year survival
decreases dramatically (6). Metastatic disease is characterized as either pulmonary or
extrapulmonary, with the lung involved in 80% of cases (5). At diagnosis, adverse factors include
pulmonary metastasis, non-pulmonary metastases, and axial tumor site (7); in these cases, outcome
is very poor and no advances in treatment have been made in the last few decades (5).

Osteosarcoma Standard of Care
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Currently, OS standard of care treatment involves combinatorial neoadjuvant
chemotherapy, surgery, and post-operative adjuvant chemotherapy. Chemotherapeutics include an
alkylating agent such as cisplatin or isofosfamide, anthracycline antibiotics such as doxorubicin,
and antimetabolites like methotrexate (with leucovorin rescue). Even if metastases are not detected
initially, all cases of OS are considered micrometastatic at diagnosis (approximately 80% of
patients have subclinical pulmonary micrometastases) and are treated with chemotherapy in
addition to surgical resection (often limb amputation or limb salvage) with wide margins (5, 8).
Neoadjuvant chemotherapy has greatly increased the survival rate of OS patients, however, these
agents are highly cytotoxic and associated with significant systemic toxicities. Additionally,
multidrug chemoresistance (MDR) is a main reason for treatment failure in Stage IV patients (9).
Histological response (in terms of primary tumor necrosis) to neoadjuvant chemotherapy was
historically considered an important prognostic factor in OS (10). When metastatic to the lung,
chemotherapy is only effective when disease burden is low; larger legions (if resectable) must be
removed surgically and survival rates are poor (11).

Osteosarcoma Genetics and Epigenetics

OS tumors show high clonal heterogeneity, both as a consequence of its unstable genome
and selective pressures from chemotherapeutic agents. The OS genotype is in a constant state of
remodeling, particularly in the case of sarcomagenesis via chromosomal instability, which results
in losses and/or gains of entire chromosomes (12). Classically, OS tumors have been associated
with mutations in retinoblastoma (Rb) and p53 (5). Mutant p53 has been shown to be a predictor
of poor 2-year survival outcomes, and whole genome sequencing has recently revealed that over
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90% of OS tumors harbor either sequence or structural TP53 mutations (13). Mutations in RB1
contribute to mitotic missegregation and loss of heterozygosity, and much work has been done to
associate particular genotypes with patient outcomes (14-16). Moreover, deregulation of the RBE2F pathway alter the epigenetic landscape of OS tumors and leads to more aggressive phenotypes
(17). A meta-analysis published in 2015 concluded that RB1 mutations resulted in a 1.62-fold
increase in mortality, with decreased histological response to neoadjuvant chemotherapy and
significant increases in metastases (18). Cytotoxic chemotherapies also contribute to the genetic
heterogeneity of OS tumors. Cisplatin, one of the main agents used in OS chemotherapeutic
therapy, was shown to induce missense mutations of NF1 and activating KIT G565R mutations
(19). To date, no gene therapies have been approved for the treatment of OS (14).

Cell-Mediated Immunity

Innate Immunity: Overview

The human immune system is classified into two arms, namely the innate (early) and
adaptive (delayed) immune systems. These two arms can be further subdivided into cell-mediated
and humoral immunity. Cell-mediated immunity (CMI) is primarily concerned with the living
effector cells that physically amount the response, while humoral immunity includes the various
antimicrobial products secreted into the extracellular fluid, including antibodies of adaptive
immunity and complement proteins of innate immunity; this manuscript focuses exclusively on
CMI, which is most relevant to OS tumor immunology.
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The innate immune system constitutes the first level of response and is composed of a wide
variety of myeloid-lineage cells (MLCs) and a subset of lymphoid-lineage cells (LLCs) that are
produced in the primary lymphatic organ, bone marrow (BM), in the healthy adult (20). However,
both homeostatic and pathogenic processes expand immune cell production to secondary lymphoid
organs (i.e., lymph nodes, spleen, Peyer’s patches, and mucosal tissues) and liver in a process
called extramedullary hematopoiesis (21). Unlike T and B cell receptors (TCR and BCR,
respectively) of the adaptive immune system, innate immune system receptors (e.g., pattern
recognition receptors [PRRs]) such as the toll-like receptor (TLR) family, are strictly encoded in
germline DNA and respond to nonspecific pathogen- and damage-associated molecular patterns
(DAMPs and PAMPs, respectively). Some common PAMPS include gram negative bacterial
lipopolysaccharide (LPS), viral RNA and DNA genomes, and gram positive bacterial lipoteichoic
acid and peptidoglycan (22-26). DAMPs underly the basis for immunological responses to sterile
injury and include High Mobility Group Box 1 (HMGB1), mitochondrial DNA, heat-shock
proteins (HSPs), and uric acid among many others (27).
The first immune cells that a non-self entity meets upon entry into (or, in the case of cancer,
mutates into) are the resident immune cells of that particular organ. Tissue-resident immune cells
vary by organ, however, they most often include a phagocyte subtype (e.g., microglia in the brain,
Kupffer cells in the liver, dust cells in the lung, and osteoclasts in the bone) (28-32). In the absence
of an apparent threat, tissue-resident phagocytes play a central role in tissue homeostasis by
engulfing foreign materials and debris (33-36). When a threat is detected, soluble factors are
released throughout the surrounding tissue and sent via the blood to multipotent hematopoietic
stem cells (HSCs) of the BM. Normally quiescent in nature, these stem cells then begin
proliferating, differentiating, and producing progeny that migrate to target sites (37-39).
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In classical hematopoiesis, one of the earliest processes in HSC differentiation includes
commitment to either the myeloid or lymphoid lineage through the common myeloid and lymphoid
progenitors (CMP and CLP, respectively), with the lymphoid progenitor class showing greater
heterogeneity (40-43). Derived from the CLP, innate lymphoid cells (ILCs) are very similar to
antigen-specific T and B lymphocytes and mirror T lymphocyte subsets in form and function but
lack somatically-recombined antigen-specific receptors. Normally residing in non-immune tissues,
ILCs play important roles in tissue homeostasis and differentiate in response to cytokines such as
IL-15, IL-2, Flt3 ligand, and c-kit ligand (44-47). Of the signals that induce production of MLCs,
colony-stimulating factors (CSFs) are the most well-studied and include CFS-1 (also known as
macrophage[M]-CFS), CFS-2 (also known as granulocyte-macrophage[GM]-CSF), CFS-3 (also
known as granulocyte[G]-CFS), and interleukin(IL)-3 (also known as “multi”-CFS) (48).

Innate Immunity: Prominent Cellular Constituents

Granulocytes
Granulocytes are the most abundant leukocyte and include neutrophils, basophils, and
eosinophils; neutrophils account for the vast majority of circulating granulocytes, and in the
absence of heme malignancy or rare parasitic infections, can roughly be assumed to be equivalent
to the granulocyte count (49). Due to their short half-life, neutrophils are constantly replenished
by HSCs within the BM (50, 51). Along with tissue-resident immune cells, neutrophils are one of
the first immune cells encountered by a foreign invader. Due to the presence of vast reserves in
the BM, neutrophils can be mobilized at a moment’s notice and released in great numbers into the
bloodstream (52). Following a gradient of IL-8/C-X-C motif chemokine ligand(CXCL)8,
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neutrophils migrate to the site of insult where they employ a large arsenal of defense mechanisms
including phagocytosis, release of inflammatory mediators (including oxygen radicals and
cytotoxic chemicals via degranulation), and extrusion of their genetic material to form neutrophil
extracellular traps (NETs) (53-55).

The mononuclear phagocyte system (MPS): monocytes, macrophages (Mφ), and dendritic cells
(DC)
(1) Monocytes
Monocytes are the migratory precursors to tissue-resident phagocytes, Mφs and DCs.
Together, these three cell populations form what is known as the mononuclear phagocyte system
(MPS) and bridge innate and adaptive immunity by serving as antigen-presenting cells (APCs)
(56). APCs present processed antigen at their cell surface and provide lymphocytes with the
stimulatory and co-stimulatory signals necessary to amount an effective immune response (57).
Derived from the CMP, monocytes are mobilized from the BM and migrate to areas of active
infection and/or inflammation in response to chemokines like CC motif chemokine ligand(CCL)
2 and CCL7 (58). Although once thought of as merely a means to replenish phagocytes in
peripheral tissues, monocytes are now known to be distinct immunological effector cells in their
own right and not restricted to DC or Mφ differentiation (59). Like neutrophils, monocytes
phagocytose and release inflammatory mediators like tumor necrosis factor (TNF) (60). While
Mφs and DCs are responsible for the majority of antigen presentation, monocytes can also process
and present antigens to lymphocytes via the major histocompatibility complex (MHC) class II
molecule (MHC-II) (61, 62).
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(2) Mφs
There are two major categories of Mφs: (1) tissue-resident Mφs, which arise in
embryogenesis and actively preserve the integrity of the organ, and (2) monocyte-derived Mφs,
which travel from the BM and spleen to sites of injury and mediate pathogen clearance and wound
healing (63, 64). Tissue-resident phagocytes have a wide range of activities that vary with location.
In the lung, alveolar Mφs (also known as “dust” cells) actively clear the airways of particulate
matter and infectious agents (65). In the liver, Kupffer cells make up the majority of tissue-resident
Mφs in the body; residing in hepatic sinusoids, they protect hepatocytes from the constant
onslaught of microbes and other toxins introduced through the gut (66). In the spleen, marginal
metallophilic, marginal zone, and red pulp Mφs clear bloodborne pathogens and phagocytose
senescent red blood cells (67). In the BM, osteoclasts remodel the extracellular matrix by resorbing
bone (68). Microglia of the central nervous system (CNS) are an extremely specialized subset of
Mφs that maintain neuronal connections and assist in tissue repair (69).
Mφs are important APCs that activate antigen-restricted T lymphocytes, particularly in the
case of necrotic cell death (70). They are extremely plastic in both phenotype and function, and
their actions are context dependent. Depending on the nature of the microenvironment, Mφs will
modulate their expression of immunoregulatory molecules to adjust the likelihood of successful
lymphocyte activation. In response to signals from the surrounding microenvironment, Mφs adopt
generalized functionalities that favor immunosupportive or suppressive behaviors through a
process called Mφ polarization (71) (Figure 1). The nomenclature used to define Mφ polarization
is typically based upon expression profile but is continually evolving.
Induced by soluble mediators like cytokines and bacterial products, Mφ polarization exists
as a continuum between two extremes: M1 (classical activation, immunosupportive), and M2
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(alternative activation, immunosuppressive). Each subset has a unique function, populationdefining protein expression profile, secretome, and signaling milieu that induces polarization (7173). Nonpolarized (i.e., “M0”) Mφs polarize into M1s under the influence of immunosupportive
cytokines like IFN-γ and lipopolysaccharide (LPS), and are then primed to kill invading microbes.
Conversely, M2 Mφs restore homeostasis by phagocytosing debris, promoting angiogenesis, and
remodeling tissue. A plethora of M2 subtypes (M2a, b, c, etc.) have been classified thus far and
new functions are being discovered yearly (71-78). Notably, M1/M2 polarization is much more
well-defined in vitro, where the cytokine environment is tightly controlled. However, in vivo, Mφs
express a wide variety of both M1 and M2 markers. In these cases, it is more appropriate to refer
to Mφs as adopting either “M1-” or “M2-like” phenotypes, or simply referring to the particular
expression profile (79-82).
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Figure 1. Schematic depicting the differentiation of an unpolarized M0-macrophage towards an M1- or M2like phenotype. The cytokine environment to which the macrophage is exposed determines its differentiation
pathway, resulting in the upregulation of various intracellular and extracellular protein markers that together define
its expression profile. The expression profile can then be used to infer function, one of the major ones being its
corresponding secretion profile or “seceretome.”

(3) DCs
DCs constitutively express MHC-II and are the most proficient APC. Classically, they
carry antigens from a site of injury or infection to draining lymph nodes for presentation to
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lymphocytes. In response to microbial danger signals, DCs undergo maturation which includes
phenotypic and functional changes; matured DCs have significantly upregulated antigen
processing and presentation capabilities (83). Like Mφs, DCs differentiate into subsets with
specialized functions under the influence of various signals; these subsets are classified based upon
function, cell of origin, and expression of certain identifying proteins. When alerted of an infection,
DCs undergo a genetic convergence that selects for the proper subtype most suited to address the
immunological need (84-86).
The three main types of human DCs are plasmacytoid DCs (pDCs), conventional DCs
(cDCs), and monocyte-derived DCs (mDCs) (86, 87). pDCs have a short half-life, are not major
activators of T cells, and respond to viral genomes by producing large amounts of type 1 IFN.
cDCs are the prototypical MHC-IIhigh APC that migrate the lymph nodes to present antigen to
lymphocytes; they are further subdivided into type 1 (cDC1) and type 2 (cDC2) depending on
transcriptional activity and proficiency in presenting intra- or extracellular pathogens. mDCs are
inflammatory in nature, can promote a variety of pro-inflammatory immune responses, and may
be functionally dysregulated in neoplastic settings (87-92).

Innate Lymphoid Cells (ILCs) and Natural killer (NK) cells
Simply put, ILCs are lymphocytes that started down the T/B lymphocyte maturation
pathway from the CLP but, under the influence of Id protein 2-suppression, did not develop
somatically-recombined antigen-specific receptors (93). Collectively, they serve as the innate
immune counterpart to T lymphocytes of adaptive immunity. Like all cells of the innate immune
system, they are primed for an immediate response to a perceived threat and react to non-antigenspecific signals such as cytokines and chemokines, microbial products, and inflammatory
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mediators; however, their activities are regulated by mechanisms of both innate and adaptive
creation (94). Interestingly, some ILCs express MHC-II and can serve as APCs, thereby linking
adaptive and innate immunity together (95).
The most prominent ILC is the NK cell, which can be thought of as the cytotoxic T
lymphocyte (CTL) of innate immunity. However, NK cell activation is not restricted to the
recognition of specific antigens, and its decision to kill or not kill depends on a delicate balance of
activating and inhibitory signals on the extracellular surface of target cells (96). MHC class I
polypeptide-related sequence (MIC)A and MICB are two common cellular stress proteins
upregulated on infected and transformed cells; NK cells recognize these proteins with
immunoreceptor tyrosine-based activating motif(ITAM)-associated receptors, thereby favoring
cytotoxic activity (97, 98). Conversely, the presentation of self peptide on MHC class I molecules
leads to deactivation of NK cell activity via signaling through receptors associated with
immunoreceptor tyrosine-based inhibitory motifs (ITIMs) like killer-cell immunoglobulin-like
receptors (KIRs) and the type II C-type lectin-like membrane glycoprotein Ly49 (99). Cytokines
provide additional information to NK cells and are important for activation, maturation, and
proliferation. IL-2 and IL-12 promote while transforming growth factor(TGF)-β inhibits NK cell
effector functions; cytokine environments become particularly important in the context of a
developing malignancy (100-104).

Adaptive immunity: Overview

Adaptive immunity represents increased specificity and the ability to generate memory at
the cost of a delayed initial response (typically 4-7 days following exposure). Adaptive CMI is
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mediated by T lymphocytes, and adaptive humoral immunity is mediated by antibody-secreting
plasma B cells. Unlike cells of the innate immune system, T and B lymphocytes require specific
peptide antigens presented on MHC molecules to mount responses (105).
Derived from the CLP produced in the BM, T and B lymphocytes mature in the thymus
and BM, respectively, and circulate as naïve cells in pursuit of their cognate antigens. Antigen
specificity is determined by the BCRs and TCRs, which are generated through a process of somatic
recombination. In somatic recombination, V, D, and J gene segments are rearranged randomly to
produce a wide repertoire of receptors that bind a specific antigen complexed with a specific MHC
molecule. Once a naïve B or T cell finds its cognate pair, it differentiates under the presence of
various co-stimulatory signals into effector and memory cells through clonal selection (105-107).
Effector lymphocytes are tasked with eradicating the threat, while memory cells patrol the
circulation quiescently but proliferate quickly and robustly in response to subsequent antigen
exposures; it is the ability of the adaptive immune system to generate memory that forms the basis
of vaccine therapy and reduces the chances of reinfection by the same pathogen (105, 108).

Adaptive immunity: Prominent Cellular Constituents

T lymphocytes
T lymphocytes are a subset of immune cells that together make up the adaptive arm of
CMI, and are involved in the clearance of microorganisms and transformed cells. Following
hematopoiesis in the BM, immature lymphocytes travel to the thymus where they begin their
maturation process. Early on in their development, immature “thymocytes” express both CD4 and
CD8 co-receptors. The particular T cell subset is defined by the co-receptor expressed, and naïve
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T cells will retain only one upon exiting the thymus. CD4 and CD8 double-positive thymocytes
are not normally present in the peripheral circulation but may increase in numbers due to
malignancy (109, 110).
Each T lymphocyte is equipped with a unique TCR and either a CD4 or CD8 co-receptor
that recognizes an MHC molecule:peptide antigen complex; successful ligation of these two
receptors provides the primary stimulatory signal for activation. However, for complete activation,
a secondary signal must also be sent to the T cell via binding of its CD28 molecule to CD80/86 on
the surface of APCs (111). Upon simultaneous receipt of both stimulatory signals, naïve T cells
proliferate and differentiate into effector and memory T cells provided they are in the proper
cytokine environment. The translocation of stimulatory signals intracellularly occurs via
phosphorylation of the ITAMs associated with CD3, an integral membrane protein present on all
T cells regardless of subtype (105, 112-113). All of the aforementioned signals are required for an
effective response, and removal of any one component can result in a suboptimal response;
lymphocytes that receive only the primary signal become anergic and undergo apoptosis (114).

(1) Cytotoxic T lymphocytes (CTLs)
CTLs are directly involved in the killing of infected or transformed cells that express the
MHC class I molecule, which are all nucleated cells. They are distinguished from helper T cells
by the presence of the CD8 co-receptor, a defining protein of the CTL class that assists in binding
of the TCR to the MHC molecule:peptide complex. Infected and transformed cells constantly
digest and present protein antigens on their extracellular surface for sampling by circulating CTLs.
When the antigen is endogenous and not a product of malignant transformation (i.e., “self”), no
activation signals are sent and the T cell continues searching; however, when the antigen is of viral
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or neoplastic origin (i.e., “non-self”), the T cell becomes activated and, in the presence of the
various co-stimulatory signals and cytokines described above, differentiates into both memory and
effector T cells that equip the organism with antigen-specific cytotoxicity (105, 115-116). Target
cells are killed by the release of perforins and granzymes, which permeate the plasma membrane
and activate intracellular apoptosis pathways via caspase cleavage, respectively (117).

(2) Helper T lymphocytes
Helper T lymphocytes, defined by the presence of a CD4 glycoprotein co-receptor, are not
directly involved in the killing of infected or transformed cells but instead help coordinate adaptive
immune responses. Unlike CTLs, which find their cognate pair in the form of a peptide:MHC class
I molecule complex on the surface of nucleated cells, helper T cells recognize antigen complexed
with MHC-II on professional APCs. Also unlike CTLs, helper T cells undergo further
differentiation that delineates the type of immune response generated against a particular pathogen.
The most well-studied of these subsets include helper T cell type 1 (Th1) and 2 (Th2) that are
analogous to the M1/M2 general classification scheme discussed previously (118-123).

(3) Regulatory T lymphocytes
Regulatory T lymphocytes are a subset of helper T cells with immunosuppressive functions
that have an important role in the prevention of autoimmunity. There are two types of regulatory
T cells, the distinction between the two being related to the timing at which the lymphocyte
commits to the regulatory lineage. Natural regulatory T cells commit to the lineage early on in
development within the thymus, and are a major regulator of autoimmunity. Conversely, induced
regulatory T cells are a subpopulation derived from helper T cells under the influence of TGF-β
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(124-126). Regulatory T cells secrete anti-inflammatory cytokines and participate in the clearance
of effector T cells that persist following the resolution of an infection (127).

Adaptive immunity: T cell exhaustion (TCE)

T cell exhaustion (TCE) was a phenomenon first described in chronic viral infection, and
is defined by a reversible transcriptional reprogramming leading to stepwise loss of effector
functions. It is different from senescence, which is an irreversible state of cell cycle arrest induced
by telomere shortening (128-131). In addition to chronic infection, TCE can be induced by the
administration of exogenous immunostimulatory cytokines like IL-12, and by tumors (128, 132133). Phenotypically, exhausted T cells upregulate expression of programmed cell death protein
1 (PD-1) and T cell immunoglobulin and mucin-containing domain-3 (TIM-3). In the context of a
developing malignancy, APCs and tumor cells suppress PD-1+ T cells via expression of its ligand,
programmed death ligand 1 (PD-L1); it is also suggested that TIM-3-associated T cell suppression
is mediated through galectin-9 (134-137). Increases in PD-1 and TIM-3 expression coincide with
functional losses and occur in a stepwise manner; if the process is not reversed, these cells will
completely lose their pro-inflammatory functions and eventually undergo apoptosis (128).

Tumor Micro- and Macro-Environment Immunology

Overview
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Tumor micro- and macro-environment immunology is concerned with characterizing and
manipulating the immune response generated against tumor neoantigens both locally (micro) and
systemically (macro). The foundation of modern tumor immunology traces back to Coley’s toxin,
which was a mixture of pyogenic bacterial products injected into tumors that caused regression of
disease. Early on, there was controversy over whether tumors cells could be immunogenic, being
that the immune system classically recognizes and responds to non-self antigens only. Dr. Coley
realized that patients with infected tumors had a higher recovery rate and sought to recreate the
same scenario (138-140). It is now widely accepted that the immune system not only recognizes
transformed cells, but also participates in each step of the metastatic cascade. (141, 142). The field
has since matured to a point where the specific antitumor immune responses to various cancers
have been elucidated in great detail, leading to extremely effective immunotherapies for a variety
of cancers (143-148).

Tumor Immune Microenvironment
The tumor immune microenvironment (Figure 2) includes the tumor cells themselves,
associated stroma, perivascular cells, endothelial cells, and infiltrating leukocytes embedded in
extracellular matrix with an emphasis on the immune cells and the influence of the developing
tumor on their phenotype and function (149). Importantly, “micro”-environment analyses examine
the tumor itself as an organ-like system and consider only the immune cells within the tumor
border. The tumor microenvironment harnesses unique structural and spatial distribution of its
components that are distinct from normal healthy organs, including aberrant vascular architecture
and metabolism driven largely by hypoxia (150-153). Here, the interactions between tumor and
immune cells occur across relatively short distances, with greater probability for effects to be
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mediated via cell-cell interactions and autocrine/paracrine feedback loops. Tumors with high
nonsynonymous mutation rates (and therefore higher probability of producing neoepitopes) are
often associated with a more predominant immune infiltrate (154). While the specific components
of each tumor immune microenvironment are patient-dependent, many tumors follow
generalizable trends and can be classified into three categories including 1) immune-excluded, 2)
infiltrated-excluded, and 3) infiltrated-inflamed (155).

(1) Immune-excluded
Immune-excluded

tumor

immune

microenvironments,

sometimes

known

as

immunologically “cold” or “immune desert” tumors, have the lowest level of infiltrating immune
cells and represent the extreme lower end of the continuum. A study from 2018 analyzing the
tumor immune infiltrates from 177 patients across nine different tumor types showed that ovarian
cancer came the closest to being completely immune-excluded (156). Various reasons exist for
why some tumors have less immune infiltration than others, and include physical barriers,
decreased homing, lack of neoepiptope production by tumors cells, and immune privilege (157).

(2) Infiltrated-excluded
Infiltrated-excluded tumor immune microenvironments are sometimes lumped in with
other “cold” tumors, and may have a paucity of CTLs or CTLs around the outer tumor perimeter
only; infiltrated-excluded tumor immune microenvironments are often seen in tumors of epithelial
origin such as colorectal carcinoma and pancreatic ductal adenocarcinoma. Patients with tumors
of this subtype may have poorer prognoses, and most do not respond well to checkpoint blockade
immunotherapies, discussed below (154-158).
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(3) Infiltrated-inflamed
In contrast to immune-excluded and infiltrated-excluded tumors, infiltrated-inflamed
tumor immune microenvironments (otherwise known as “hot” tumors) have significant APC and
CTL infiltration that extends deep within the tumor core. Infiltrated-inflamed tumors are also
characteristic of cancers of epithelial origin and include melanoma and non-small cell lung cancer
(159, 160); patients with infiltrated-inflamed tumors show the strongest response to checkpoint
blockade immunotherapies (161-163).

Figure 2. Schematic depicting the relationship between tumor-infiltrating leukocytes and tumor cells within
the tumor immune microenvironment. A patient with, in this case a bone tumor, presents at diagnosis with a
complex network of interactions between tumor and immune system that shapes the phenotype of both the growing
malignancy and the immune cells themselves. The components of this system can be broken down into its cellular
constituents and analyzed to yield diagnostic and prognostic implications.
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Tumor Immune Macroenvironment
The tumor immune macroenvironment is a less well-established idea in the field of tumor
immunology and is not easily subdivided into distinctive groups like its microenvironment
counterpart. In its most general sense, the idea of a tumor macroenvironment considers the
emergent effects of tumor on systemic immunity beyond the immune cells confined within the
tumor border (155). The intimate connection between local and systemic antitumor immune
responses provides the theoretical framework behind the observed abscopal effect, where
treatments directed at primary tumors result in immune responses at distant sites (164).
It is increasingly recognized that the systemic antitumor immune response may be used for
prognostic, diagnostic, and therapeutic purposes (165-176). Activation of secondary lymphoid
organs outside of the primary tumor is a necessary component of successful tumor immunotherapy
(177). Lymphoid and myeloid cell lineages in the blood of cancer patients from virtually all tumor
types are significantly different from age-matched healthy controls, with more advanced disease
resulting in more dramatic changes (178-187). It is the current understanding that the mechanisms
underlying these observed systemic immune effects are mediated in part by secreted molecules
from both tumor and immune cells circulating throughout the blood and lymph, leading to
significant immunomodulation at distant organ sites (155). Additionally, tumor cells released into
circulation and antigen-loaded DCs evoke immune responses from immune cells in secondary
lymphoid organs (188). Tumor cells can also secrete signaling molecules that recruit
immunosuppressive myeloid cells to primary tumors to promote growth and metastatic tumor sites
to prepare organotropic tissues for colonization (155, 189-191).

Immunophenotyping
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Immunophenotyping is the process of characterizing immune micro/macro-environments
for diagnostic, prognostic, and therapeutic applications (Figure 3). The data used to construct
immunophenotypes are often generated using immunohistochemistry (IHC), flow cytometry (FC),
or gene expression profiling, and reference expression profiles or matrices are used to extract
pertinent cell population information (192-197). Immunophenotyping has utility across a number
of various pathologies ranging from postoperative recovery to sepsis and diabetes, and has
regained popularity in cancer with the surge of interest in tumor immunotherapies following the
success of checkpoint blockers (discussed below) (198-201).
In practice, a solid or liquid tissue sample is harvested and prepared in a manner that
preserves (or reconstructs, in the setting of gene set enrichment analysis) the expression profile of
individual cell types. In the case of IHC, samples are stained with antibodies recognizing
population-defining immune cell markers and analyzed in their anatomical location using
microscopy (202). For FC and genomics, reference expression profiles are used to classify each
immune cell and assess its relative population distribution. Depending on the choice of
components, expression profiles may be redundant, with multiple arrays often appropriately
describing a certain population. They are also dependent on the context and nature of the research
question being addressed, with further considerations regarding tissue type, species, sex, strain,
and age (195, 203-205). From there, additional structure can be imposed in a hierarchical manner
using non-population defining markers and/or gene signatures to obtain activation status or
whatever else is of interest to the investigator. Currently, the major utilities of immunophenotyping
are to make diagnoses, infer prognosis, and determine candidacy for various immunomodulatory
drugs (193, 197, 202).
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Figure 3. Schematic depicting current utility of creating a tumor immune micro/macro-environment
immunophenotype. A tissue sample, often tumor or blood, is dissociated into single cell suspension and
immunophenotyped, most often through the use of IHC, flow cytometry, or RNA-seq. The resulting data is analyzed
via microscopy (IHC), manual gating or clustering (flow cytometry) or an ever-growing slew of computational
approaches (RNA-seq) and constructed into an immunophenotype that may associate with a particular prognosis.

Osteosarcoma Tumor Immunology

Overview

OS is an orphan disease, and its immunology is not well defined. In contrast to many tumors
of epithelial origin, sarcomas harbor a heterogeneous display of immunophenotypes and do not fit
neatly into immune-excluded, infiltrated-excluded, or infiltrated-inflamed categories described
above. However, there is evidence that the immune system plays an important role in OS
tumorigenesis. Indeed, post-operative infections associate with increased survival in OS patients,
and early lymphocyte recovery following chemotherapy predicts better prognosis in pediatric
patients (206, 207). Futhermore, immune cells harvested from OS patients retain their ability to
react to IFNs, a family of cytokines with potent antitumor activity (208). A recent study using the
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CIBERSORT algorithm to calculate an immune “score” in 83 OS patients showed that those with
a higher immune infiltrate in primary tumors had significantly increased survival (209). Likewise,
metastasis suppression has been associated with the upregulation of genes regulating the immune
response in primary OS tumors (210).
OS tumors are extremely pleomorphic and unlike carcinomas, have few recurrent
clinically-targetable modifications (211). However, the pleomorphism results in a high
nonsynonymous mutation rate, with the highest mutational loads seen in metastatic lesions (212).
Importantly, OS tumors retain MHC class I and MICA expression, which are recognized by
cytotoxic immune cells (213, 214).

When expressed, nonsynonymous mutations create

neoepitopes that can be immunogenic. As such, most of the immune cells found within the OS
immune-genomic landscape participate in CMI, and include NK cells, T lymphocytes, monocytes,
Mφs, and immature MLC cells termed myeloid-derived suppressor cells (MDSCs) (215).
Most of the data available on the OS immunophenotype have come from the tumor immune
microenvironment, and often present an association between immune infiltrate and prognosis. In
general, there is more immune activity in metastatic versus primary lesions, though this increase
in activity is coupled to increased tumor immunosuppressive capacity (214, 215). Schematics
depicting the main components of lymphoid and myeloid lineage OS tumor immunology are
shown in Figures 4 and 5, respectively.

Lymphoid Lineage
Due to the high levels of neoantigens expressed by OS tumors, they protect themselves by
reducing T cell recruitment, downregulating the expression of neoepitope-generating
nonsynonymous mutations, and creating immunosuppressive forces that disrupt the immune
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response (212, 214-216). To block lymphocyte recruitment, OS tumors reduce production of
CXCL12, a potent T cell chemoattractant (217). As they metastasize, however, OS tumors develop
a significantly higher mutational burden which recruits progressively more T cells to the tumor
(212, 215). Tumor cells suppress infiltrated lymphocytes by activating immune checkpoint
receptors like cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and PD-1, recruiting
suppressive myeloid cell populations, and inducing differentiation of regulatory T cells (218-222).
NK cells, which are not antigen restricted, are vital in the control of metastatic tumor cells that
downregulate antigen expression but are decreased in the blood of pediatric OS patients along with
helper and CTLs (223).
Polymorphisms that reduce the capacity of an individual to amount an immunosupportive
helper T cell response have been shown to increase the risk of OS sarcomagensis. IL-12 is a
pleiotropic protein cytokine involved in the induction of antitumor helper T cell responses and
activation of NK cell cytotoxicity (100-102, 224). In OS patients, serum levels of IL-12 and related
cytokine IL-27 are reduced compared to healthy controls, and replenishment of IL-12 via aerosol
gene therapy significantly reduced metastatic rate in preclinical models (225-227); it is
hypothesized that NK cell control of metastatic outgrowth is mediated through the targeting of
tumor-initiating cells in an NKG2D-NKG2DL manner (228). Likewise, activated NK cells are
positively correlated with increased survival in OS patients (229).
Increases in lymphocyte infiltration are coupled with greater immunosuppressive
responses by the tumor, such as the induction of regulatory T cells via the release of exosomes
containing TGF-β, α fetoprotein, and HSPs (230). TGF-β, a critical regulatory T cell-associated
cytokine, is increased in the blood of OS patients with metastases (231). IL-35 is another regulatory
T cell-associated cytokine that is increased in the blood of OS patients and contributes to CTL
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dysfunction in the periphery (232). Within the tumor itself, regulatory T cells expressing galectin9 can suppress the activity of TIM-3+ helper and CTLs and interrupt the antigen presentation
process (233, 234). Blocking regulatory T cells indirectly via TGF-β or directly via cell-targeted
antibody depletion in vivo restores antitumor immunity and reduces metastasis in preclinical OS
mouse models (235, 236). Clinically, patients with high CD8+ cytotoxic to Foxp3+ regulatory T
cell ratios in their primary tumors have significantly better overall survival (237). Interestingly,
antibody blockade of PD-1 has recently been shown to decrease the accumulation of regulatory T
cells within the primary tumor microenvironment (238).
TCE also plays an important role in OS tumor immunology. Helper and cytotoxic T
lymphocytes both within the tumor microenvironment and systemically show an exhausted
phenotype, which increases in intensity with disease progression and metastasis (239-242). OS
tumor cells upregulate PD-L1 expression as disease progresses and suppress PD-1+ T cells (214).
Moreover, high PD-L1 expression within the primary tumor is associated with early-onset
metastasis (243). Both within the primary tumors and systemically, the exhaustion status of T cells
correlates with outcome, and patients with higher percentages of exhausted lymphocytes have
worse outcomes (240, 242-244).
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Figure 4. Schematic depicting major lymphoid OS tumor immunology concepts. 1) Tumor cells upregulate CD80
and CD86 that bind to CTLA-4 on T lymphocytes causing inhibition of effector functions 2) Tumor cells upregulate
PD-L1 that binds to PD-1 receptors on T lymphocytes causing inhibition of effector functions and exacerbation of T
cell exhaustion 3) Galectin-9+ regulatory T cells directly inhibit the effector functions of TIM-3+ helper and cytotoxic
T cells. 4) Tumor cells downregulate the expression of nonsynonymous mutations leading to decreased detection by
lymphocytes 5) Natural killer cells become activated to kill metastatic NKG2DL+ tumor cells via NKG2D receptor
ligation 6) Exosomes secreted by tumor cells induce the differentiation of immunosupportive helper T cells into
regulatory T cells 7) Tumor cells epigenetically downregulate the production of potent T cell chemoattractant CXCL12
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leading to decreased lymphocyte infiltration into the core of the tumor 8) Regulatory T cells secrete cytokines like IL35 and TGF-β that suppress the antitumor immune response

Myeloid lineage
(1) Mφs and other APCs
The most well-studied MLC in OS tumor immunology is the Mφ, though there is
controversy regarding its role in disease progression. The controversy is mostly attributed to the
constantly evolving definition of M1 and M2 polarization in vivo (245). To remove considerable
ambiguity from the literature, the markers used to define M1 and M2 will be explicitly stated
alongside the bias they describe. With this caveat in place, the majority of data suggests that OS
tumors dysregulate polarization of infiltrated Mφs, and that a shift favoring induction of
immunosuppressive Mφ phenotypes is required for disease progression (246).
One of the first studies showing a relationship between Mφs and outcome in OS patients
was published in 2011. In this study, genome-wide gene expression profiling showed that
increased primary intratumoral Mφ density, regardless of M1 (HLA-DRα+) or M2 (CD163+) bias,
correlated with decreased metastatic burden in patients (247). This finding was contrary to most
other cancers, where tumor-associated Mφs are thought to promote metastasis (248); hence, it was
thought that polarization status may be the determining factor. Indeed, a subsequent study found
that patients with high M1 (iNOS+) Mφ bias in primary tumors developed fewer metastases (249).
Still, other studies using similar methods have drawn opposite conclusions; indeed, one study
found no association between M2 (CD163+) Mφs and prognosis, while another observed that the
presence of both tumor-associated Mφs and DCs correlated with worse 5-year event-free survival
(250, 251). The extent of lymphocytic infiltration may provide a reason for these discrepancies, as
high levels of M2 (CD163+) Mφs have been shown to correlate positively with exhausted TIM27

3+PD-1+ T cells; therefore, it is possible that interactions between polarized Mφs and exhausted T
cells determine outcome (239).
Irrespective of M1/M2 nomenclature, it is well established that OS cells and Mφs can
engage in immunosuppressive feedback loops that result in disease progression. Exosomes
released by tumor cells induce M2(CD206, CD163, and arginase-1)-polarization of Mφs, and Mφs
increase OS tumor cell migration via upregulation of cyclooxygenase-2 (COX2) and release
exosomes that activate AKT in tumor cells (252-254). Moreover, the density of tumor-associated
Mφs in metastatic nodules is significantly higher than in primary tumors, and they show a strong
predilection for M2 (CD206+) versus M1 (CD86+) bias (253, 255).
Further support that Mφ polarization plays a key role in OS tumor progression has come
from the Mφ immunomodulatory drug, mifamurtide. Mifamurtide is a synthetic analog of muramyl
dipeptide, a component of the cell wall of Mycobacterium species. Currently, it is approved in
Europe alongside standard of care for patients with resectable, nonmetastatic OS (256). Similar to
LPS, mifamurtide was thought to induce Mφs to adopt immunosupportive phenotypes. Recently,
however, it was shown that mifamurtide induces an intermediate Mφ phenotype, with both
immunosupprotive and suppressive functions; these data highlight the shortcomings of M1/M2
nomenclature and help justify the contradictions seen in the literature (257).

(2) Other Myeloid-Lineage Cells (MLCs)
Outside of Mφs, little work has been done to elucidate the specific roles of other MLCs in
OS tumor immunology. There is, however, evidence to suggest potentially important roles for
neutrophils, monocytes, and myeloid-derived suppressor cells (MDSCs). High neutrophil- and
monocyte-lymphocyte ratios, as well as high overall neutrophil counts in peripheral blood are poor
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prognostic indicators in OS (258-260). Besides blood, neutrophils are also present within tumor
samples and have been shown to induce migration of OS tumor cells (261). Additionally, IL8/CXCL8 (also known as neutrophil chemotactic factor) is increased in the serum of OS patients
and may play a role in mediation of OS lung tropism (262, 263). TIM-3+ monocytes in tumor and
sera secrete high levels of immunosuppressive IL-10, preventing the release of IFN-γ from
galectin-9+ helper T cells (233).
MDCSs are immature myeloid cells that arise in situations of chronic inflammation. In OS
tumor-bearing mice, MDSCs accumulate in spleens and primary tumors following an IL-18 and
CXCL12 gradient (264, 265). They are highly immunosuppressive and have multiple mechanisms
of action, including the induction of regulatory T cells and contact-dependent inhibition of NK and
T cell effector functions (266-269). Another major mechanism by which MDSCs inhibit T cells is
via arginase-1-mediated depletion of L-arginine, which is consumed in large amounts by
proliferating T cells; L-arginine supplementation in the background of PD-L1 blockade increased
survival of OS-tumor-bearing mice (270, 271).
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Figure 5. Schematic depicting major myeloid OS tumor immunology concepts. 1) Tumor cells produce exosomes
that promote the polarization of Mφs to immunosuppressive phenotypes 2) Mifamurtide promotes the polarization of
Mφs to immunosupportive phenotypes 3) MDSCs sequester L-arginine from T lymphocytes thus decreasing their
ability to proliferate 4) TIM-3+ monocytes produce the immunosuppressive cytokine IL-10 that inhibits T cellmediated antitumor immunity 5) CD163+ immunosuppressive Mφs inhibit T cell-mediated antitumor immunity and
exacerbate TCE 6) Exosomes secreted by immunosuppressive Mφs increase the invasiveness of OS tumor cells

Experimental Immunotherapeutics: Checkpoint Blockade
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Under normal physiological circumstances, immune cells express a balance of activating
and inhibitory ligands and receptors. Various stimuli including infection, trauma, autoimmunity,
and neoplasia, tip this balance in one direction or the other and determine the fate of the response.
While there are many molecules that contribute to this delicate balance, a select few have thus far
proven to be important to OS immunotherapy.
Immunological checkpoints are a family of protein checks and balances that, when
expressed, send inhibitory signals to the receiving cell. Checkpoint blockade refers to the use of
drugs—mostly monoclonal antibodies—to disrupt these immunosuppressive receptor-ligand axes
and promote activation through disinhibition (272-274). OS tumor cells themselves, as well as
APCs like Mφs and DCs, express the cell surface checkpoint protein PD-L1. Upon binding of PDL1 to PD-1+ leukocytes, the likelihood of an effective antitumor immune response is reduced (214,
275-276). Clinical trials testing antibodies that block the interaction of PD-1 and PD-L1 (e.g.,
nivolumab and atezolizumab, respectively) have not been successful, and treatment failure has
since been attributed to an escape mechanism involving a compensatory increase of CTLA-4 and
CD80/86 expression on T lymphocytes and tumor cells, respectively (218, 277).
In order to become fully activated, lymphocytes must receive an additional co-stimulatory
signal in the form of CD28 binding to CD80 or 86 on the surface of APCs. CTLA-4 is homologous
to CD28 but with greatly increased binding affinity for CD80/86, effectively out competing CD28
for binding sites (278). Ipilibumab is an α-CTLA-4 monoclonal antibody that, in combination with
α-PD-L1, showed enhanced efficacy against pulmonary metastases versus α-PD-L1 alone in a
preclinical model (218); however, neither ipilibumab as a single agent nor combination checkpoint
blockade therapy with nivolumab has shown efficacy in clinical trials (279).
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Figure 6. Schematic depicting dual
checkpoint blockade of CTLA-4 and
PD-L1. 1) Tumor-expressed CD80/86
binds to CTLA-4 on T cells causing
decreased effector functions 2) Tumorexpressed PD-L1 binds to PD-1 on T
cells causing decreased effector function
3) α-CTLA-4 blocks the ability of T cells
to bind to CD80/86 leading to T cell
activation through disinhibition 4) α-PDL1 blocks the ability of tumor cells to
bind to T cells leading to T cell activation
through disinhibition 5) With CTLA-4
bound by antibody, CD28 can now bind
CD80/86 on APCs and receive the
necessary

co-stimulatory

signals

to

amount an effective antitumor response
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Abstract
Indications for immunotherapies are still unclear, and there is a great need for real-time patient
immune status monitoring. In this study, we confirmed that the local and systemic immune profiles
of an orthotopic osteosarcoma model with or without luciferase transfection were statistically
equivalent. Next, we used flow cytometry to describe systemic immune cell populations influenced
by osteosarcoma disease progression. When compared to vehicle-inoculated sham mice, it was
found that tumor-bearing mice had significant immunophenotype disturbances at approximately
11 weeks post-inoculation (at which time 90% of primary tumor-bearing mice have fulminant
pulmonary metastases). Percent populations of Natural Killer cells and T regulatory cells were
increased in the spleens of tumor-bearing mice (p < 0.0083) compared to shams. Additionally, T
lymphocytes from spleens of tumor-bearing mice showed increased Tim-3/PD-1 exhaustion status
(p < 0.0083). There were also increases in the percent populations of myeloid cells and overall
M1/M2 macrophage marker expression on tumor-bearing mice spleens versus controls (p <
0.00714). Finally, treatment with 20 µg α-PD-L1 decreased T cell exhaustion back to sham status,
with a corresponding increase in CTLA-4 expression on cytotoxic T cells in the majority of mice
tested. Checkpoint inhibition also increased splenic monocyte maturation and returned
macrophage M1/M2 marker expression back to sham status. These data suggest that cancer
induces systemic immune dysregulation, and that these changes may be elucidated and utilized for
treatment purposes by sampling the systemic immune environment via the spleen. In addition,
treatment with the checkpoint inhibitor -PD-L1 may neutralize, but not overcome the systemic
immunological changes induced by a progressing malignancy.
Keywords: immunotherapy; osteosarcoma; tumor microenvironment; PD-L1

53

Introduction
Osteosarcoma is an extremely aggressive tumor of bone, and no new therapeutics have
been implemented clinically in over three decades (1). Its extreme pleomorphism and high
antigenic load (2, 3) make it a seemingly prime candidate for tumor immunotherapies, which can
induce sustainable immunity against cancer cell neoantigens thus providing a viable therapeutic
strategy for overcoming heterogeneity; however, no immunotherapies are currently implicated as
standard of care in the treatment of osteosarcoma. As the malignant process can lead to generalized
immune dysfunction and disease progression (4-6), there has been success across multiple tumor
types with the introduction of various immunotherapies into systemic circulation including
monoclonal antibody checkpoint blockers like those against programmed death-ligand 1 (PD-L1)
and its receptor, programmed cell death protein 1 (PD-1) (7). PD-L1 is expressed on tumor and
antigen presenting cells (APCs), while its receptor PD-1 is expressed on activated T cells; this
interaction suppresses T cell activity and is associated with T cell exhaustion (TCE), a state of
depressed effector function and anergy brought on by chronic antigen exposure and hypoxia (8).
Osteosarcoma tumors are often positive for PD-L1, and its expression has been shown to
upregulate in metastatic versus primary lesions (9). While blockade of this protein interaction has
experienced clinical success in some cancers, there is still confusion surrounding its specific
indications and only a minority show a response (10); preclinical mouse models of metastatic
osteosarcoma have shown resistance to PD-L1/PD-1 blockade (11). Moreover, there is currently
no reliable way of monitoring or predicting patient responses to any immunotherapies including
checkpoint blockers and the search for relevant biomarkers is ongoing (12). Indeed, data of this
nature would potentially allow clinicians to adjust regimens as necessary for maximal efficacy in
real-time, and may uncover reasons as to why tumors like osteosarcoma have remained largely
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unresponsive to immunotherapies despite their high neoantigen load. From the few studies
currently available on osteosarcoma tumor immunology, data have emerged that support the
importance of macrophage M1/M2 polarization and T cell exhaustion and activation in tumor
clearance, although the scope has generally been limited to the primary lesions (11, 13-21). We
suggest that these data warrant further investigation regarding the translation of macrophage-T cell
dynamics systemically and how we might use this information clinically to trigger antitumor
immunity in patients. In the present study, after confirming immunologic equivalency between
two models of osteosarcoma [with or without introduction of a non-viral luciferase reporter vector
for in vivo imaging systems (IVIS) visualization], we further defined the immunological
consequences of osteosarcoma disease progression over time. We also investigated the systemic
effects of monotherapy with checkpoint blockade of PD-L1 using the spleen as a barometer of
immune status. The overarching hypothesis is that the spleen can be used as a barometer to assess
clinically relevant changes in the systemic macrophage-T cell immunophenotype brought on by
osteosarcoma disease progression and immunotherapy.
Materials and Methods
Animals
Female BALB/c mice aged 4-5 weeks and between 20 and 25 grams (mean = 22.5 grams)
in mass were obtained from The Jackson Laboratory (Bar Harbor, ME). Mice were housed
individually in ventilated Allentown cages at ambient temperatures within specific pathogen free
facilities on corncob bedding with 12 hour light/dark cycles, automatic lixit water, and ad libitum
food access. All experiments were approved by the Institutional Animal Care and Use Committee.
Growth and preparation of transfected and wild type K7M2 cells
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K7M2 cells were grown and prepared as previously described (22). Briefly, wild-type (WT) and
genome-stable luciferase-transfected (TF) K7M2 cells were cultured in Dulbecco’s Modified
Eagle’s Medium (DMEM) containing 10% fetal bovine serum (FBS) and 100 units/mL penicillin
and streptomycin (Thermo Fisher Scientific, Waltham, MA). Passage one cells were used for
orthotopic implantation at a density of one million cells in 25 µL of phosphate buffered saline
(PBS) without calcium or magnesium (Corning Inc., Corning, NY).
Osteosarcoma BALB/c K7M2 syngeneic mouse model
K7M2 cells or vehicle were surgically inoculated into the tibias of female BALB/c mice as
previously described (22). Briefly, 25 µL of PBS containing one million TF or WT K7M2 cells
were dispensed into a cortical window made through the center of the tibia at the level of the
proximal tibial flare.
WT and TF tumor-bearing mice were monitored as previously described (22) in accordance
with our institution’s tumor burden scoring system. Tumors were monitored daily using digital
calipers (greatest width x greatest length). Tumor volume was calculated using the formula V =
(length x width2)/2. The health of each animal was assessed using a tumor score ranging from 0 to
60 (0 = healthy animal; 60 = requires euthanasia) based on criteria established by our institution
regarding overall animal health as previously described (22). Once mice reached a tumor score of
60 (approximately 11 weeks post-inoculation), animals were humanely euthanized using carbon
dioxide asphyxiation.
Tumors were harvested as previously described (22). Briefly, animals whose tumors
reached an average of 1.7 cm3 underwent palliative amputation by dissection and hip
disarticulation. Skin edges were closed using 4-0 vicryl suture. Tumors were dissociated and
prepared for flow cytometry analysis as described below. Once tumor scores reached 60
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(approximately 11 weeks post-inoculation), animals were euthanized and their spleens harvested
and prepared for flow cytometry (FC) analysis.
Flow cytometry analysis of tumors and spleens
The excised primary tumor and spleen from each mouse were minced and digested
enzymatically using the MACS Tissue Dissociation Kits (Miltenyi Biotec, Auburn, CA),
according to the manufacturer’s guidelines. After dissociation, each sample was filtered through a
70µM filter (Miltenyi Biotec) and centrifuged at 300 x g for 10 min; the cell pellet was resuspended
in RPMI-1640. Each single cell suspension was split into two. One half of the tumor single cell
suspension was treated with Red Blood Cell Lysis Solution (Miltenyi Biotec), washed twice, and
counted.
Spleen single cell suspensions and the other half of the tumor single cell suspensions were
layered over Ficoll-Paque premium (GE Healthcare Life Sciences, Pittsburgh, PA) and centrifuged
at 400 x g for 40 min at 20 ⁰C to allow density gradient separation of the leukocytes. After Ficoll,
the leukocytes (buffy coat) were harvested, washed twice with PBS, and counted.
Single cell suspensions were stained following standard protocols. Briefly, cells were
washed using FACs buffer (PBS, 2% FBS, and 0.02% sodium azide). Cell pellets were
resuspended, blocked using Rat IgG and Mouse IgG (Jackson ImmunoResearch, West Grove, PA),
washed, and incubated with the appropriate antibodies described below. After incubation, the cells
were washed, fixed in paraformaldehyde, and stored at 4 °C.
Panel 1 antibodies: α-CD45-Phycoerithrin Cyanine5 (BD Biosciences, San Jose, CA), α-CD4BV510 (BD Bioscience), α-Ly6G-V450 (BD Biosciences), α-CD8a-Alexa Fluor 488 (BD
Biosciences), α-NKp46-PE-eFluor 610 (eBioscience, San Diego, CA), α-CD11b-Alexa Fluor 700
(eBioscience), α-Foxp3-Phycoerithrin (eBioscience)
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Panel 2 antibodies: α-CD45-Phycoerithrin Cyanine5 (BD Biosciences), α-PD-L1-Phycoerithrin
Cyanine7 (eBioscience)
Panel 3 antibodies: α-CD45-Phycoerithrin Cyanine5 (BD Bioscience), α-CD4-BV510 (BD
Bioscience), α-CD8a-Alexa Fluor 488 (BD Bioscience), α-Tim-3-PerCP/Cy5.5 (BioLegend, San
Diego, CA), α-PD-1-eFluor 450 (Thermo Fisher Scientific), α-CTLA-4-PE/Cy7 (BioLegend), αFoxp3-Phycoerithrin (eBioscience)
Panel 4 antibodies: α-CD45-Phycoerithrin Cyanine5 (BD Biosciences), α-CD11b-Alexa Fluor 700
(eBioscience), α-Ly6G-V450 (BD Bioscience), α-Ly6C-PerCP/Cy5.5 (eBioscience), α-CXCL9Phycoerithrin (eBioscience), α-NOS2-PE-Cyanine7 (BioLegend), α-Tgm2-Alexa488 (Novus
Biologicals, Littleton, CO), α-Arg1-APC (R&D Systems, Minneapolis, MN)
All cell populations and/or pertinent markers as they are used in this manuscript are defined below
in Table 1.
For Foxp3 staining, after washing cells with FACS buffer, the cells were processed using
Foxp3/Transcription Factor Staining Buffer Set (eBioscience) according to the manufacturer’s
instructions. Briefly, the cell pellet was resuspended and 1.0 mL of diluted (1:3 ratio) Foxp3
Fixation/Permeabilization buffer was added. Samples were vortexed and incubated at 4 °C
overnight. The next day, the cells were washed twice with 1X Foxp3 buffer and incubated with αFoxp3-Phycoerithrin (eBioscience), washed with 1X Foxp3 buffer, and resuspended in FACS
buffer.
Panel 4 included intracellular staining of M1/M2 macrophage markers. For this panel, after
washing cells with FACS buffer, the cells were further processed for intracellular antigens using
the Intracellular Antigen Staining Buffer Set (BioLegend) according to the manufacturer’s
instructions. Briefly, cell pellets were resuspended and 100uL of intracellular-fixation buffer was

58

added. After a pulse vortex, the cells were incubated at 4 ℃ overnight. The next day, the cells
were washed twice with 1X permeabilization buffer, incubated with a master-mix of α- CXCL9Phycoerithrin (eBioscience), α-NOS2 -PE-Cyanine7 (BioLegend), α-Tgm2- Alexa488 (Novus
Biologicals), and α-Arg1-APC (R&D Systems), washed twice with 1X permeabilization buffer,
and resuspended in FACS buffer.
Cells were analyzed and the data were collected on the BD LSRFortessa (BD Biosciences)
using BD FACS Diva version 8.0 software located in the Flow Cytometry & Single Cell Core
Facility. Single stained controls were generated using OneComp beads eBeads (eBiosciences). A
minimum of 50,000 cells were analyzed for each sample. Data analysis was performed using FCS
Express 6 Software (De Novo Software, Glendale, CA).
T cell Exhaustion Status (TCES)
T cells expressing the exhaustion markers PD-1 and/or T cell immunoglobulin and mucindomain containing-3 (Tim-3) exhibit depressed effector functions and an inability to proliferate
(23-25); exhausted Tim-3+ and PD-1+ T cells have been found in osteosarcoma tumor tissues (26).
In order to properly compare expression of these TCE markers on the T cell repertoire across mice
with different cell counts, we normalized for total T cell percent population to yield an overall
exhaustion status we refer to as the TCE status (TCES) calculated by the following equation:
𝑇𝐶𝐸𝑆 =

𝑇𝑜𝑡𝑎𝑙 %𝑃𝐷1 𝑒𝑥𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛𝐶𝑇𝐿,𝑇ℎ + 𝑇𝑜𝑡𝑎𝑙 %𝑇𝑖𝑚3𝐶𝑇𝐿,𝑇ℎ
𝑇𝑜𝑡𝑎𝑙 % 𝐶𝑇𝐿 + 𝑇𝑜𝑡𝑎𝑙 %𝑇ℎ

In words, the TCE status equals the total PD-1 and Tim-3 percent expression on both CD4+ T
helper cells (Th) and CD8+ cytotoxic T cells (CTLs) divided by the total percent population of all
T cells (both CD4+ and CD8+) sampled. This equation yields the ratio of exhaustion-marker
expressing T lymphocytes per total lymphocyte percent population and is driven by peer-reviewed
data showing that PD-1 and Tim-3 expression on T cells correlates with the extent of TCE (23, 2759

29). Normalizing for total T cell percent populations simply allows comparisons to be made across
different samples with varying T cell counts.
α-PD-L1 treatment
Mice were given 20 µg (1 mg/kg) α-PD-L1 (clone MIH5, eBioscience) via intraperitoneal
injection every Monday and Thursday starting when tumors were first palpable and continuing
until euthanasia (approximately 11 weeks following tumor cell inoculation). The standard dosing
used throughout the literature is 200 µg (10 mg/kg); however, 1 mg/kg is the dosage at which
clinical activity in advanced human cancer starts (7), although extended treatment periods with
doses as high as 20 mg/kg have been shown ineffective against metastatic K7M2 tumors [11]. For
this manuscript, which focuses purely on the immunological changes associated with PD-L1
blockade, the minimum dose needed to produce a measurable immune response (1 mg/kg) was
used as there is no known α-PD-L1 dose that produces clinical benefit in osteosarcoma.
Statistical analysis
Statistical significance between groups was assessed using a Student’s T-test with alpha =
0.05 and Bonferroni correction. A minimum of three animals per group were used, which is a
widely used starting number and allows for the determination of potential outliers.
Results and Discussion
The primary FC data for this manuscript can be accessed without restrictions by contacting the
primary author.
SECTION 1: The local and systemic immune environments of BALB/c mice orthotopically
inoculated with luciferase(+) TF or luciferase(-) WT K7M2 cells are statistically equivalent.
Our laboratory previously developed an orthotopic model of metastatic osteosarcoma using
BALB/c syngeneic K7M2 tumor cells transfected with a luciferase reporter for real-time disease
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monitoring using IVIS. This model allows for sensitive visualization and assessment of primary
and metastatic lesions without euthanasia in an immunocompetent mouse. From a clinical
outcomes perspective, both luciferase(+) TF and luciferase(-) WT models were previously shown
to result in statistically equivalent rates of primary lesion formation and pulmonary metastasis
(22). However, as luciferase is a foreign intracellular protein under a constitutively active
promoter, it is presented on MHC class I molecules (30) and has the potential to elicit atypical
immune reactions (31, 32). As this manuscript focuses exclusively on characterizing antitumor
immune responses, we considered it extremely important to first examine whether the luciferase
antigen significantly affected the immune microenvironment. To accomplish this goal, we assessed
the local (tumors harvested at approximately 1.7 cm 3 in volume) and systemic (splenic) immune
microenvironments by flow cytometry. The spleen is a large lymph node-like immune organ with
direct access to blood-borne pathogens and antigens, and thus a good representation of systemic
immune function.
To determine if the local tumor immune microenvironments were influenced by the
presence of the luciferase antigen, we surveyed a variety of key myeloid and lymphoid lineage
immune cells (six populations total) with maximal clinical relevance in both WT tumor-bearing (n
= 11) and TF tumor-bearing (n = 15) mice using Antibody Panel 1. The populations investigated
included CD45+CD8+ CTLs, CD45+CD4+ Ths, CD45+CD4+Foxp3+ T regulatory cells (Tregs),
CD45+NKp46+ Natural Killer (NK) cells, CD45+CD11b+ myeloid lineage cells (MLCs), and
CD45+CD11b+Ly6G+ granulocytes. A sample gating schema is shown in Supplementary Figures
1-3. Using the Bonferroni correction, individual comparisons were made using α = 0.0083 and all
populations were deemed statistically equivalent (p > 0.0083) between the two groups (Table 2).
Additionally, as PD-L1 expression in tumors has been speculated to play an important part in
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osteosarcoma-mediated immune suppression (33, 34) we also examined whether PD-L1
expression differed between groups. We looked for expression of PD-L1 on tumor cells using the
CD45- gate (which identified all non-leukocyte populations within the tumor) in Antibody Panel
2; a sample gating schema is shown in Supplementary Figure 4. No statistical difference (p > 0.05)
was observed in percent PD-L1 expression on tumors generated from both TF tumor-bearing (n =
15) and WT tumor-bearing (n = 11) mice (Table 3).
To further evaluate the immunological equivalence between TF and WT models, we sought
to determine whether the systemic immune microenvironments were influenced by the presence
of luciferase. Previous data had shown that approximately eleven weeks following tumor cell
inoculation, 90% of mice in both TF and WT tumor-bearing groups developed pulmonary
metastases (22). At this time, mice were euthanized and splenocytes were immunophenotyped with
Antibody Panel 1 to determine if splenic immunomodulation in response to late stage disease was
consistent between groups. Using the Bonferroni correction, individual comparisons were made
using α = 0.0083 and, like that for primary tumors, the splenic microenvironments of mice from
both groups were almost uniformly statistically equivalent (p > 0.0083), except for the percentage
of granulocytes (WTgran = 15.27 ± 21.82%: n = 10; TFgran = 52.33 ± 19.02%: n = 9; p = 0.0011).
The statistics for these analyses are shown in Table 4.
Whenever a foreign reporter protein is introduced into in vivo systems, there is the potential
for it to interfere with normal immune processes; however, this aspect of tumor immunology is
often overlooked in the literature even though it has the potential to invalidate conclusions. As the
manuscript focuses on elucidating the antitumor responses, we wanted evidence to support that
introduction of a luciferase reporter did not dramatically alter the antitumor immune response. The
white blood cell (WBC) populations examined in Panel 1 presented a broad overview of key
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mediators of tumor immunology including NK cells, CTLs, Ths, Tregs, and myeloid lineage cells
(MLCs). Overall, out of the 13 comparisons made between TF and WT tumor-bearing models,
only one population (percent CD45+CD11b+Ly6G+ granulocytes in the spleen) was deemed
statistically inequivalent. However, we dismissed it as the probable consequence of a type 1 error
at the 95% confidence interval and concluded that constituent expression of the luciferase reporter
did not significantly affect the local (tumor) or systemic (splenic) immune responses. Therefore,
we continued our study of the systemic immune response to osteosarcoma using only the TF
luciferase(+) model which allows for bioluminescent detection and quantification of disease
burden.
SECTION 2: Using the spleen to identify the baseline systemic immune fingerprint associated
with disease progression and metastasis in the luciferase(+) K7M2 orthotopic BALB/c mouse
model of osteosarcoma.
There is a critical gap in knowledge regarding the effects of malignancy on a patient’s
systemic immune status, especially in the context of tumor immunotherapy. Many
immunotherapies (including monoclonal antibody checkpoint blockers) used in both preclinical
and clinical settings are given systemically via the blood and can modulate interactions between T
and antigen presenting cells (APCs) like macrophages (35-39); however, our understanding of
what systemic immunomodulations underlie tumor clearance (or resistance) is incomplete.
Immunotherapies targeting this axis have shown great antitumor potential and, for the case of
Mifamurtide, come the closest to regular clinical use in osteosarcoma (40). Additionally, there is
currently no reliable way to monitor immune activation changes over time once primary tumors
are removed. Therefore, we sought to establish a baseline systemic immunological profile for the
TF tumor-bearing mouse model that can be used by other investigators to examine tumor and/or
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treatment induced immunomodulation. The spleen was chosen as a marker of systemic immune
status as it is a central hub for circulating immune cells (including mature macrophages) and is the
main filter for blood-borne antigens (including circulating tumor cells and debris). From a
feasibility and clinical translational standpoint, splenic biopsies performed with fine needle
aspirates are an effective cytological monitoring platform with low complication rates in humans
(41).
At 11 weeks post-inoculation (at which time 90% of tumor-bearing mice have fulminant
pulmonary metastases), we used Antibody Panels 3 and 4 to monitor the cellular changes of
lymphoid lineage cells (LLCs) and myeloid lineage cells (MLCs), respectively, occurring
alongside disease progression in the spleens of TF tumor-bearing mice. Antibody Panel 3
examined the following four LLC subsets of WBC populations: CD45 +CD8+ CTLs, CD45+CD4+
Ths, CD45+CD4+Foxp3+ Tregs, and CD45+NKp46+ NK cells (example gating schema seen in
Supplementary Figure 5). We also investigated the exhaustion status of the CD4 + and CD8+ Tlymphocyte populations using the prototypical cell-surface markers PD-1 and Tim-3. T cell
exhaustion (TCE) is a phenomenon characterized by decreased effector cell function first
described in the instance of chronic viral infection that correlates with increases in the expression
levels of PD-1 and Tim-3 (23, 27-29). Indeed, it has been shown that, like viral infections, cancers
can cause similar immunological disruptions in lymphocyte function (42). An additional T cell
surface molecule Cytotoxic T Lymphocyte Associated Protein 4 (CTLA-4) which competes with
CD28 for binding to the B7 molecules CD80 and 86 on APCs inhibiting CTL function can also
play a role in the immunological response to cancer (43). An example gating schema for PD-1,
Tim-3, and CTLA-4 expression on T cells can be seen in Supplementary Figure 6. The expression
profile data for Antibody Panel 3 from the spleens of five mice are shown in the left column of
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Table 5. In summary, NK cell percent population averaged 10.78 ± 4.5%; percent populations of
CTLs, Ths, and Tregs averaged 2.73 ± 1.22%, 6.45 ± 3.08%, and 21.09 ± 5.12%, respectively.
CTLA-4 expression on CTLs and TCES averaged 18.35 ± 10.12% and 18.23 ± 4.58%,
respectively.
Antibody Panel 4 investigated the MLC component of the splenic immunophenotype. The
three cell populations examined included CD45+CD11b+ MLCs, CD45+CD11b+Ly6G-Ly6C+
monocytes/macrophages, and CD45+CD11b+Ly6C-Ly6G+ granulocytes (example gating schema
in Supplementary Figure 7). Additionally, the expression of the following four macrophage
polarization markers transglutaminase 2 (Tgm2), arginase 1 (Arg1), chemokine (C-X-C motif)
ligand 9 (Cxcl9), and nitric oxide synthase 2 (Nos2) was also assessed (example gating schema in
Supplementary Figure 8). Tgm2/Arg1 and Cxcl9/Nos2 are classical M2- and M1-like macrophage
markers typically associated with pro-tumor anti-inflammatory or antitumor pro-inflammatory
properties, respectively. CD45+CD11b+ MLCs were separated into Ly6C+Ly6G- monocytes and
Ly6G+Ly6C- granulocytes. From there, the total percent expression of the following four M1/M2
macrophage markers on Ly6C+Ly6G- monocytes was determined and the expression profile data
for these markers from the spleens of five mice is shown in the left column of Table 6. In summary,
MLC, monocyte/macrophage, and granulocyte percent populations averaged 5.27 ±1.11%, 4.92 ±
1.29%, and 57.49 ± 9.62%, respectively. Percent expression of individual M1/M2 markers Tgm2,
Arg1, Cxcl9, and Nos2 on macrophages was 18.58 ± 5.69%, 0.3 ± 0.56%, 18.28 ± 5.38%, and
97.99 ± 1.62%, respectively.
Here, we have developed two in-depth antibody panels (Panels 3 and 4) that can be used
to assess the splenocyte immune fingerprint. The data gathered can be used as a baseline by which
to assess immunomodulation in response to therapeutic intervention. To date, the splenic lymphoid
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and myeloid immune fingerprints of osteosarcoma tumor-bearing mice at time of pulmonary
metastasis have never been investigated. Note that in this study, macrophages were not classified
overtly as M1 or M2; rather, we report only the percent expression of each individual marker
expressed by the entire macrophage population. As opposed to studies that choose the presence or
absence of a single marker to identify M1/M2 polarization, our paradigm provides a more objective
view of macrophage phenotypes as complex disease processes like cancer influence macrophages
to take on intermediate phenotypes and co-express both M1 and M2 markers (44, 45). Analyzing
the percent expression of each individual marker on the macrophage population allows for the full
spectrum of macrophage phenotypes to be appreciated, compared with using single markers to
incorrectly generalize and simplify a complex population.
SECTION

3:

Osteosarcoma

disease

progression

and

metastasis

induce

systemic

immunomodulation as visualized by splenocyte immunophenotyping.
Evidence suggests that both lymphoid and myeloid lineage activation status in both the
local and systemic immune environments may carry clinically useful information regarding
osteosarcoma disease progression, metastasis, and survival (16, 17, 46). However, once the
primary tumor is removed, it can no longer provide up-to-date information on the evolving
antitumor immune response. Peripheral blood has been used to determine immune status outside
of the primary tumor with promising results in other cancers (47-51); however, the story is
incomplete as mature macrophage data cannot be obtained in this fashion. Therefore, we sought
to determine if the spleen can be used to detect tumor-induced immunomodulation by comparing
the spleens of TF tumor-bearing mice to those undergoing sham (SH) surgery procedures to
examine the extent of systemic splenic immunomodulation induced by malignancy. SH mice
underwent the same surgical procedures and Antibody Panels (3 and 4) as tumor-bearing mice;
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however, they were inoculated with vehicle as opposed to tumor cells. Using the Bonferroni
correction, individual comparisons were made between TF tumor-bearing (n = 5) and SH (n = 4)
mice via the Student’s T-test using α = 0.0083 and α = 0.00714 for Antibody Panels 3 and 4,
respectively, to assess significance at the 95% confidence interval. Between the two panels,
numerous statistically significant differences between TF tumor-bearing and SH mice were
discovered. For Panel 3, NK cell (TFNK = 10.78 ± 4.5%; SHNK = 1.85 ± 0.4%; p = 0.006, Figure
1A) and Treg (TFTreg = 21.09 ± 5.12%; SHTreg = 7.25 ± 0.23%; p = 0.0011, Figure 1B) percentages
were significantly increased in the spleens of TF tumor-bearing versus SH mice. Also, the
exhaustion status was significantly elevated in the spleens of tumor-bearing compared to SH mice
(TFTCES = 18.23 ± 4.58; SHTCES = 0.16 ± 0.054, p = 0.0001, Figure 1C). Interestingly, there was
also an increase in the percentage of CTLA-4+ CTLs in tumor-bearing mice that was trending
toward statistical significance (p = 0.014). Importantly, the overall population percentages of CTLs
and Ths were statistically equivalent (p > 0.0083). For Panel 4, the overall percentage of MLCs
within the tumor-bearing mouse spleens was significantly elevated compared to SH (TFMLC = 5.27
± 1.11%; SHMLC = 1.39 ± 0.4%, p = 0.00031, Figure 2A). However, the percent populations of
both monocytes/macrophages and granulocytes from tumor-bearing mouse spleens versus SH
were decreased and trending toward statistical significance (p = 0.036 and 0.014, respectively),
potentially suggesting a percent increase of immature MLCs exhibiting intermediate phenotypes.
Strikingly, the M1 markers Cxcl9 and Nos2 and M2 marker Tgm2 were significantly upregulated
in the macrophage populations of tumor-bearing mice (p = 0.00052 [Figure 2B], 4.2E-07 [Figure
2C], and 0.0025 [Figure 2D] respectively), displaying no clear transition in terms of polarization.
The M2 marker Arg1 did not stain well in any of the populations examined. The statistics for each
panel are summarized in Tables 5 and 6 for Panels 3 and 4, respectively.
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Out of the thirteen cell populations compared between TF tumor-bearing and SH groups,
seven were found to be statistically significant. On the lymphoid side, we saw significant increases
in both NK cells and Tregs; this increase in splenic Tregs has been observed across multiple tumor
types in preclinical models, correlates with tumor size, and is generally associated with an overall
state of immune suppression (52, 53). The splenic myeloid compartment of tumor-bearing mice
was altered both in terms of myeloid lineage cell pool and macrophage maturation, which reflects
a situation of increased inflammatory monocyte recruitment that may act as a reservoir for fast
deployment to peripheral tissues during disease processes (54). Additionally, it may also represent
an accumulation of immature myeloid cells with immunosuppressive phenotypes, as suggested for
other tumor models (55). The status of macrophage activation was also significantly altered in
tumor-bearing mice. Interestingly, the expression of macrophage M1 markers Nos2/Cxcl9 and M2
marker Tgm2 all increased significantly, with no clear M1/M2 bias. These data support the
evolving hypothesis that macrophages with intermediate phenotypes predominate in
microenvironments associated with complex tumorigenic processes, and that simple M1/M2
classification may lead to gross oversimplifications that lead to incorrect conclusions. Overall,
these data suggest that there is a systemic dysregulation of lymphocyte and myeloid populations
created by malignancy, which can be monitored using these panels we described. The next step in
this process is to more clearly define the specific functions that are associated with the observed
phenotypes and what clinical outcomes they associate with, which may be used to help determine
extent of disease progression and inform prognostics.
SECTION 4: The spleen can be used as a barometer of the systemic immune response to treatment
with monoclonal antibody and immunological checkpoint blocker α-PD-L1.
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In Section 3, we determined that our antibody panels could accurately characterize
malignancy-induced immunomodulations occurring alongside disease progression. As such, if we
are able to assess how the immune system is changing in response to immunotherapeutics in realtime, we may be able to adapt treatment regimens so that the appropriate immune responses are
elicited in the right way at the right time on a patient-by-patient basis. Therefore, if patients’
systemic immune systems are sampled regularly, important tumor immune escape mechanisms
such as these may be exposed and properly accounted for therapeutically. Therefore, we sought to
determine whether the spleen could be used as a systemic immunologic barometer to assess
immunotherapy-induced microenvironment changes. The immunotherapy chosen for this portion
of the study was α-PD-L1, which is used in different cancers with varying success rates (6). As αPD-L1 blockade activity is already well-established in the literature (56, 57) and overall treatment
efficacy was not the desired outcome of study, no isotype controls were deemed necessary.
For these studies, transfected tumor-bearing mice (n = 3) were treated intraperitoneally
with 20 µg of α-PD-L1 antibody in PBS twice a week starting at the first palpable sign of primary
lesion. Primary tumors were removed at approximately 1.7 cm3 and mice were euthanized at
approximately 11 weeks post-inoculation. Harvested spleens were subjected to a modified (mod)
Panel 3 (lacking the NKp46 NK cell identifier) and Panel 4. Using the Bonferroni correction,
individual comparisons to assess significance between α-PD-L1 treated (n = 3) and untreated (n =
5) TF tumor-bearing mice were made via Student’s T-test using α = 0.01 and α = 0.00714 for
Antibody Panels 3 (mod) and 4 at the 95% confidence interval, respectively. Of those populations
investigated in Panel 3 (mod), α-PD-L1 treatment was shown to significantly reduce splenic TCES
(TF(-αPD-L1) = 18.23 ± 4.58; TF(+αPD-L1) = 0.79 ± 0.71, p = 0.00072) as shown in Figure 3A.
Interestingly, however, two out of the three mice that showed decreased TCES in response to α-
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PD-L1 therapy also showed a large increase in the percentage of CTLA-4+ expressed on CTLs
(Figure 3B), perhaps suggestive of a potential escape mechanism by which tumors can depress T
cell activity. α-PD-L1 treatment also greatly increased the percent population of
monocytes/macrophages (Figure 3C: TF(-αPD-L1) = 4.92 ± 1.29%; TF(+αPD-L1) = 12.8 ± 2.92%, p =
0.0016) and decreased the percentage of macrophages expressing Tgm2 (Figure 3D: TF(-αPD-L1) =
18.58 ± 5.69%; TF(+αPD-L1) = 2.1 ± 2.17%, p = 0.0034), Cxcl9 (Figure 3E: TF(-αPD-L1) =18.28 ±
5.38%; TF(+αPD-L1) = 1.52 ± 1.24%, p = 0.002), and Nos2 (Figure 3F: TF(-αPD-L1) = 97.99 ± 1.62%;
TF(+αPD-L1) = 50.89 ± 18.07%, p = 0.00086), essentially normalizing the M1/M2 macrophage
polarization distribution back to SH status. Complete data summaries can be found in Tables 7 and
8 for Panels 3 (mod) and 4, respectively.
Immunotherapies that include PD-1/PD-L1 blockade have shown prolonged clinical
activity against various human malignancies (58-60) excluding osteosarcoma (10, 61), despite the
fact that there is evidence that PD-L1 contributes to osteosarcoma disease progression (33, 34).
Therefore, α-PD-L1 was chosen as our quintessential immunotherapeutic for the dual purposes of
testing the ability of our antibody panels to detect therapy-induced changes in splenic
microenvironment and to potentially shed some light on the immunologic mechanisms behind its
therapeutic shortcomings. Interestingly, we found that while both α-PD-L1-treated and non-treated
mice eventually succumbed to disease, α-PD-L1 monotherapy alone was sufficient to substantially
reverse many immunosuppressive phenomena observed in non-treated tumor-bearing mice.
However, while individual M1 and M2 markers between treated and untreated groups did show
significant changes, the M1:M2 marker ratios were statistically equivalent (p = 0.21). The data
suggest that α-PD-L1 monotherapy alone can stabilize but not induce generalized M1-biased
macrophage polarization that has been associated with decreased metastasis (62). Still, these data
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offer a possible explanation for why combination therapies including α-PD-L1 therapy are more
effective (61), as it appears to neutralize many of the immunological effects induced by
malignancy. Interestingly, two out of three mice treated with α-PD-L1 therapy showed drastically
increased expression of CTLA-4 on CTLs, revealing perhaps a compensatory mechanism by which
tumors can circumnavigate α-PD-L1 monotherapeutic intervention which supports previous
findings (61).
Taken together, these data argue for the use of immunotherapeutic “cocktails” that target
multiple pathways similar to the approach taken for human immunodeficiency virus/acquired
immune deficiency syndrome (HIV/AIDS) therapy. Furthermore, we have provided a reasonable
explanation for why α-PD-L1 monotherapy for osteosarcoma has been less successful in the past.
As such, we propose that the spleen may serve as a barometer for real-time monitoring of disease
progression and patient response to immunotherapy and deserves further investigation.
Conclusions
Introduction of a non-viral luciferase reporter vector into K7M2 osteosarcoma tumor cells
had no significant effect on the local or systemic immune responses to disease progression and
metastasis in an orthotopic murine model of osteosarcoma, confirming its utility for accurately
modeling complex immune microenvironment dynamics despite the luciferase reporter
transfection. Our model can be used to accurately assess both disease burden (via IVIS) and
immune dynamics with confidence that the reporter protein will not cause significant
immunological disturbances. Additionally, it was shown that osteosarcoma disease progression
and metastasis induce systemic dysregulation of immune cell populations including macrophage
maturation and M1/M2 marker expression, TCE, and NK cell percent populations when compared
to disease-free sham controls. These data suggest that osteosarcoma-induced immunomodulation
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is observable in the spleen with the antibody panels described and offer new insight into the
complex role that macrophages play in osteosarcoma disease progression. Indeed, both the
prevalence of tumor-associated macrophages and expression of single macrophage M1/M2
polarization markers have been previously associated with disease events that when taken together
seem contradictory (13, 26, 62, 63).
In this study, we showed that osteosarcoma disease progression induces clear dysregulation
of macrophage activation with increased expression of both M1 and M2 markers, offering further
proof as to why single marker M1/M2 macrophage identifiers do not accurately assess polarization
status in complex malignant settings. Our studies also showed that low-dose α-PD-L1 therapy
alone normalized osteosarcoma-induced systemic immunodysregulation back to that of sham
status without changing clinical outcome; however, a compensatory increase in the
immunosuppressive marker CTLA-4 on CTLs was observed following PD-L1 blockade indicating
a potential tumor escape mechanism. These data suggest that immune escape mechanisms like PDL1/CTLA-4 counter-regulation may be uncovered by immunophenotyping systemic immune
organs like the spleen, which could be extremely useful clinically by adapting therapies to the
immunophenotype that is occurring at a specific time point.
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Figure Legends

Figure 1. Osteosarcoma induces systemic immunomodulation in splenic LLC populations at
11 weeks. The spleens of TF tumor-bearing (n = 5) and SH (n = 4) mice were harvested at time of
metastatic disease (approximately 11 weeks) post-inoculation and analyzed via flow cytometry for
LLC immunophenotyping. The data spread of the following percent populations (A)
CD45+NKp46+ NK cells and (B) CD45+CD4+Foxp3+ Tregs between groups are displayed. (C)
Data spread of TCES (total PD-1 and Tim-3 expression normalized to total percent T-lymphocyte
population) for each group. An asterisk denotes statistical significance (p < 0.0083) between
groups as determined by a two-tailed Student’s T-test with Bonferroni correction and 95%
confidence. LLC = lymphoid lineage cell; TF = transfected; SH = sham; NK = natural killer; Treg
= T regulatory cell; TCES = T cell exhaustion status; PD-1 = programmed cell death protein 1;
Tim-3 = T cell immunoglobulin and mucin-domain containing-3

Figure 2. Osteosarcoma induces systemic immunomodulation in splenic MLC populations at
11 weeks. The spleens of TF tumor-bearing (n = 5) and SH (n = 4) mice were harvested at time of
metastatic disease (approximately 11 weeks) post-inoculation and analyzed via flow cytometry for
MLC immunophenotyping. The data spread of the percent parent populations (A) CD45+CD11b+
MLCs is shown. Also, the spreads of an M2 macrophage polarization marker (B) Tgm2 and two
M1 macrophage polarization markers (C) Cxcl9 and (D) Nos2 on CD45 +CD11b+Ly6C+Ly6Gmonocytes/macrophages are shown. An asterisk denotes statistical signifance with p-values <
0.00714 from a two-tailed Student’s T-test with Bonferroni correction and 95% confidence. MLC
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= myleoid lineage cell; TF = transfected; SH = sham; Tgm2 = transglutaminase 2; Cxcl9 =
chemokine (C-X-C motif) ligand 9; Nos2 = nitric oxide synthase 2

Figure

3.

Treatment

with

α-PD-L1

significantly

reverses

osteosacoma-induced

immunomodulation in LLC and MLC populations in the spleens of tumor-bearing mice.
Spleens were harvested at time of metastatic disease (approximately 11 weeks) post-inoculation
and analyzed via flow cytometry for LLC and MLC immunophenotyping from n = 5 (-) α-PD-L1
and n = 3 (+) α-PD-L1 TF tumor-bearing mice using Antibody Panels 3 (mod) and 4, respectively.
For treated mice, 20 µg of α-PD-L1 was given in phosphate buffered saline via intraperitoneal
injection twice a week (Mondays and Thursdays) starting when tumors were first palpable. The
data spreads of (A) TCES and (B) CTLA-4+ CTLs from Antibody Panel 3 (mod) are shown with
significance being assigned to those populations presenting p-values < 0.01 from a two-tailed
Student’s T-test with Bonferroni correction and 95% confidence as denoted by an asterisk. The
data spreads of (C) monocytes/macrophages, (D)Tgm2+ macrophages, (E) Cxcl9+ macrophages,
and (F) Nos2+ macrophages from Antibody Panel 4 are shown with significance being assigned to
those populations presenting p-values < 0.00714 from a two-tailed Student’s T-test with
Bonferroni correction and 95% confidence as denoted by an asterisk. PD-L1 = programmed deathligand ; LLC = lymhpoid lineage cell; MLC = myleoid lineage cell; TF = transfected; TCES = T
cell exhaustion status; CTLA-4 = cytotoxic T lymphocyte associated protein 4; CTL = cytotoxic
T lymphocyte; Tgm2 = transglutaminase 2; Cxcl9 = chemokine (C-X-C motif) ligand 9; Nos2 =
nitric oxide synthase 2
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Supplementary

Figure

1.

Example

gating

schema

for

myeloid

lineage

cells,

monocytes/macrophages, and granulocytes from Antibody Panel 1. Cells were gated into
CD45+ and CD45- groups; from there, CD4-CD8-CD11b+ cells myeloid lineage cells were gated
into Ly6C+Ly6G- macrophages/monocytes and Ly6G+Ly6C- granulocytes.

Supplementary Figure 2. Example gating schema for T helper cells, cytotoxic T cells, and T
regulatory cells from Antibody Panel 1. Cells were gated into CD45+ and CD45- groups; from
there, cells were gated into CD4+ T helper cells and CD8+ cytotoxic T cells. CD4+ cells were further
gated using Foxp3+ as a defining marker of T regulatory cells.

Supplementary Figure 3. Example gating schema for Natural Killer cells from Antibody
Panel 1. Cells were gated into CD45+ and CD45- groups; from there, CD45+ cells were gated into
NKp46+ Natural Killer cells.

Supplementary Figure 4. Example gating schema for PD-L1 positive non-white blood cell
tumor cells from Antibody Panel 2. Tumor cells were gated into CD45+ and CD45- groups; from
there, CD45- non-white blood cell tumor cells were assessed for programmed death-ligand 1 (PDL1) positivity. Note that, although the figure displays staining for CD95 positivity, this marker
was not included in the analysis for PD-L1 expression in the manuscript.

Supplementary Figure 5. Example gating schema for cytotoxic T cells, T helper cells, Natural
Killer cells, and T regulatory cells from Antibody Panel 3. Cells were gated into CD45+ and
CD45- groups; from there, CD45+ cells were gated into NKp46+ Natural Killer cells, CD45+CD8+
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cytotoxic T cells, and CD45+CD4+ T helper cells. CD45+CD4+ T cells were further gated for
Foxp3 positivity to define CD45+CD4+Foxp3+ T regulatory cells.

Supplementary Figure 6. Example gating schema for T cell exhaustion and functional status
from Antibody Panel 3. CD4+ T helper cells and CD8+ cytotoxic T cells were assessed for
expression of the T cell exhaustion markers programmed cell death protein 1 (PD-1) and T cell
immunoglobulin and mucin-domain containing-3 (Tim-3). CD8+ T cells were also separately
assessed for expression of inhibitory molecule cytotoxic T lymphocyte-associated protein 4
(CTLA-4).

Supplementary

Figure

7.

Example

gating

schema

for

myeloid

lineage

cells,

monocytes/macrophages, and granulocytes from Antibody Panel 4. Cells were gated into
CD45+CD11b+ myeloid lineage cells; from the CD45+CD11b+ quadrant, cells were further gated
into Ly6C+Ly6G- macrophages/monocytes and Ly6G+Ly6C- granulocytes.

Supplementary Figure 8. Example gating scheme for markers of macrophage M1/M2
polarization from Antibody Panel 4. CD11b+Ly6C+ monocytes/macrophages were assessed for
expression of M1 activation markers chemokine (C-X-C motif) ligand 9 (Cxcl9), and nitric oxide
synthase 2 (Nos2) and M2 activation markers transglutaminase 2 (Tgm2) and arginase 1 (Arg1).
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Table 1. Specific cell populations discussed and their corresponding defining markers.
Cell Population
Defining Markers
Tumor cells and stroma
CD45-PD-L1±
Cytotoxic T-lymphocyte
CD45+CD8+
T helper lymphocyte
CD45+CD4+
Myeloid lineage cell
CD45+CD11b+
Granulocyte
CD45+CD11b+Ly6G+Ly6CMonocyte/macrophage
CD45+CD11b+Ly6C+Ly6GExhausted cytotoxic T-lymphocyte
CD45+CD8+ PD-1±Tim-3±
Exhausted T helper lymphocyte
CD45+CD4+PD-1±Tim-3±
CTLA-4-expressing cytotoxic T-lymphocyte
CD45+CD8+CTLA-4+
M1-like macrophage
Cxcl9±Nos2±
M2-like macrophage
Arg1±Tgm2±
PD-L1 = programmed death-ligand 1; PD-1 = programmed cell death protein 1; Tim-3 = T cell
immunoglobulin and mucin-domain containing-3; CTLA-4+ = cytotoxic T-lymphocyte-associated
protein 4; Cxcl9 = chemokine (C-X-C) motif ligand 9; Nos2 = nitric oxide synthase 2; Arg1 =
arginase 1; Tgm2 = transglutaminase 2
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Table 2. Population distribution comparisons of WBCs isolated from primary tumors of BALB/c
mice inoculated with TF (n = 15) or WT (n = 11) K7M2 cells. The statistics for each group are
summarized accordingly with significance being assigned to those populations presenting p-values
< 0.0083 from a two-tailed Student’s T-test with Bonferroni correction and 95% confidence as
denoted by an asterisk.
Population
WT % Expression
TF % Expression p
NK cells
19.76 ± 4.76%
20.94 ± 12.67%
0.77
CTLs
5.45 ± 3.09%
6.07 ± 7.55%
0.8
Ths
6.96 ± 1.69%
5.42 ± 3.39%
0.18
Tregs
16.95 ± 10.44%
24.02 ± 15.37%
0.2
MLCs
36.5 ± 23.12%
34.74 ± 17.53%
0.95
Granulocytes 35.8 ± 18.32%
36.59 ± 16.38%
0.91
WBC = white blood cell; TF = transfected; WT = wild type; NK = natural killer; CTL = cytotoxic
T-lymphocyte; Th = T helper cell; Treg = T regulatory cell; MLC = myeloid lineage cell
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Table 3. Non-WBC cell PD-L1 expression of primary tumors isolated from BALB/c mice
inoculated with TF (n = 15) or WT (n = 11) K7M2 cells. Statistical significance was assessed using
a two–tailed Student’s T-test and 95% confidence.
Marker WT % Expression TF % Expression p
PD-L1
1.96 ± 0.77%
1.91 ± 1.28%
0.9
WBC = white blood cell; PD-L1 = programmed death-ligand 1; TF = transfected; WT = wild type
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Table 4. Population distribution comparison of WBCs isolated from the spleens of BALB/c mice
inoculated with TF (n = 9) or WT (n = 10) K7M2 cells. The statistics for each group are
summarized accordingly with significance being assigned to those populations presenting p-values
< 0.0083 from a two-tailed Student’s T-test with Bonferroni correction and 95% confidence as
denoted by an asterisk.
Population
WT % Expression
TF % Expression
p
NK cells
5.35 ± 4.58%
7.55 ± 5%
0.33
CTLs
7.23 ± 2.41%
5.03 ± 2.64%
0.08
Ths
18 ± 13.61%
11.71 ± 12.95%
0.32
Tregs
12.68 ± 6.01%
16.19 ± 8.43%
0.31
MLCs
5.2 ± 11.41%
9.76 ± 10.76%
0.38
Granulocytes 15.27 ± 21.82%
52.33 ± 19.02%
0.0011*
WBC = white blood cell; TF = transfected; WT = wild type; NK = natural killer; CTL = cytotoxic
T-lymphocyte; Th = T helper cell; Treg = T regulatory cell; MLC = myeloid lineage cell
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Table 5. Population distribution comparison of LLCs isolated from the spleens of mice from TF
tumor-bearing (n = 5) and SH (n = 4) groups. The statistics for each group are summarized
accordingly with significance being assigned to those populations presenting p-values < 0.0083
from a two-tailed Student’s T-test with Bonferroni correction and 95% confidence as denoted by
an asterisk.
Population
TF % Expression/TCES
SH % Expression/TCES p
NK cells
10.78 ± 4.5%
1.85 ± 0.4%
0.006*
CTLs
2.73 ± 1.22%
3.72 ± 0.86%
0.21
Ths
6.45 ± 3.08%
7.72 ± 1.1%
0.46
Tregs
21.09 ± 5.12%
7.25 ± 0.23%
0.0011*
CTLA-4+ CTLs
18.35 ± 10.12%
1.72 ± 0.42%
0.014
TCES
18.23 ± 4.58
0.16 ± 0.054
0.0001*
LLC = lymphoid lineage cell; TF = transfected; NK = natural killer; CTL = cytotoxic Tlymphocyte; Th = T helper cell; Treg = T regulatory cell; CTLA-4+ CTL = cytotoxic Tlymphocyte-associated protein 4 positive cytotoxic T-lymphocyte; TCES = T cell exhaustion
status
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Table 6. Population distribution comparison of MLCs isolated from the spleens of mice from TF
tumor-bearing (n = 5) and SH (n = 4) groups. The statistics for each group are summarized
accordingly with significance being assigned to those populations presenting p-values < 0.00714
from a two-tailed Student’s T-test with Bonferroni correction and 95% confidence as denoted by
an asterisk.
Population
TF % Expression SH % Expression
p
MLCs
5.27 ± 1.11%
1.39 ± 0.4%
0.00031*
Monocytes/Macrophages 4.92 ± 1.29%
7.49 ± 1.7%
0.036
Granulocytes
57.49 ± 9.62%
74.69 ± 4.55
0.014
Tgm2+ macrophages
18.58 ± 5.69%
4.22 ± 2.66%
0.0025*
Arg1+ macrophages
0.3 ± 0.56%
0 ± 0%
0.32
Cxcl9+ macrophages
18.28 ± 5.38%
1.44 ± 1.23%
0.00052*
Nos2+ macrophages
97.99 ± 1.62%
16.56 ± 10.19%
4.2E-07*
MLC = myeloid lineage cell; TF = transfected; Tgm2 = transglutaminase 2; Arg1 = arginase 1;
Cxcl9 = chemokine (C-X-C) motif ligand 9; Nos2 = nitric oxide synthase 2
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Table 7. Treatment with α-PD-L1 significantly reduces TCES but does not affect parent
populations of LLCs in the spleens of TF tumor-bearing mice. Spleens were harvested at
approximately 11 weeks post-inoculation and the tissue was subjected to Panel 3 (mod) for
immune cell population analysis from n = 5 (-) α-PD-L1 and n = 3 (+) α-PD-L1 tf tumor-bearing
mice. For treated mice, 20 µg of α-PD-L1 was given in PBS via intraperitoneal injection twice a
week starting when tumors were first palpable. The statistics for each group are summarized
accordingly with signifiance being assigned to those populations presenting p-values < 0.01 from
a two-tailed Student’s T-test with Bonferroni correction and 95% confidence as denoted by an
asterisk.
Population
TF (-) α-PD-L1 % Expression/TCES TF (+) α-PD-L1 % Expression/TCES p
CTLs
2.73 ± 1.22%
2.85 ± 1.13%
0.9
Ths
6.45 ± 3.08%
5.14 ± 3.74%
0.61
Tregs
21.09 ± 5.12%
26.63 ± 7.02%
0.24
CTLA-4+ CTLs 18.35 ± 10.12%
44.95 ± 37.19%
0.16
TCES
18.23 ± 4.58
0.79 ± 0.71
0.00072*
PD-L1 = Programmed death-ligand 1; TF = transfected; LLC: lymphoid lineage cell; CTL =
cytotoxic T-lymphocyte; Th = T helper cell; Treg = T regulatory cell; CTLA-4+ CTL = cytotoxic
T-lymphocyte-associated protein 4 positive cytotoxic T-lymphocyte; TCES = T cell exhaustion
status
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Table 8. Treatment with α-PD-L1 dramatically affects macrophage maturation and M1/M2
polarization in the spleens of TF tumor-bearing mice. Spleens were harvested at approximately 11
weeks post-inoculation and the tissue was subjected to Panel 4 for immune cell population analysis
from n = 5 (-) α-PD-L1 and n = 3 (+) α-PD-L1 tf tumor-bearing mice. For treated mice, 20 ug of
α-PD-L1 was given in PBS via intraperitoneal injection twice a week starting when tumors were
first palpable. The statistics for each group are summarized accordingly with significance being
assigned to those populations presenting p-values < 0.00714 from a two-tailed Student’s T-test
with Bonferroni correction and 95% confidence as denoted by an asterisk.
Population
TF (-) α-PD-L1 % Expression TF (+) α-PD-L1 % Expression p
MLCs
5.27 ± 1.11%
5.73 ± 1.68%
0.65
Monocytes/Macrophages 4.92 ± 1.29%
12.8 ± 2.92%
0.0016*
Granulocytes
57.49 ± 9.62%
51.37 ± 9.11%
0.41
Tgm2+ macrophages
18.58 ± 5.69%
2.1 ± 2.17%
0.0034*
Arg1+ macrophages
0.3 ± 0.56%
0.23 ± 0.17%
0.84
Cxcl9+ macrophages
18.28 ± 5.38%
1.52 ± 1.24%
0.002*
Nos2+ macrophages
97.99 ± 1.62%
50.89 ± 18.07%
0.00086*
PD-L1 = Programmed death-ligand 1; TF = transfected; MLC = myeloid lineage cell; Tgm2 =
transglutaminase 2; Arg1 = arginase 1; Cxcl9 = chemokine (C-X-C) motif ligand 9; Nos2 = nitric
oxide synthase 2
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Chapter 3
Systems-Wide Immunophenotyping Defines Distinct Malignancy-Induced Immunological
Changes in an Immunocompetent K7M2 Orthotopic Murine Model of Osteosarcoma
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Systems-Wide Immunophenotyping Defines Distinct Malignancy-Induced Immunological
Changes in an Immunocompetent K7M2 Orthotopic Murine Model of Osteosarcoma
Justin E. Markel1, Ryan A. Lacinski*, Amanda B. Stewart*, Justin Vaida*, Hillary G. Pratt*, Ryan
M. Reinbeau*, Alan D. Mizener*2, Brock A. Lindsey*3

Abstract: Osteosarcoma (OS) is the most common primary tumor of bone and largely affects
children and young adults. When metastatic, survival rates are extremely poor. While the primary
tumor immune microenvironment has been extensively studied, immunotherapies (IMTs) have not
yet been effective for patients with systemic disease. Metastatic OS tumors harbor high mutation
rates and contain infiltrated leukocytes; however, little is known about the immune response
beyond the tumor border. Real-time tracking of the systemic antitumor immune response may
allow for the creation of personalized IMT regimens that regress metastatic lesions. Here, we
report systems-wide immunological disturbances that occur alongside disease progression in an
orthotopic model of metastatic OS. We have identified three populations of tumor-sensitive
immune cells, including Natural Killer (NK) cells, T helper (T H) cells, and cytotoxic T (TC) cells,
with systemic NK cell depletion being specific to advancing disease. Additionally, an innovative
metric of OS disease burden was generated using co-expression percentages of programmed deathligand 1 (PD-L1) and major histocompatibility complex II (MHC-II) on monocytic-myeloidderived suppressor cells (M-MDSCs) to produce the PD-L1+/MHC-II+ (P[1]/M[II]) ratio. In blood,
this ratio showed a significant linear association with tumor burden, increased in magnitude with
advancing disease, and provided insight into the immunophenotype of the lung. The ratio was also
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increased in the lungs and bone marrow (BM) of mice with advanced disease compared to sham
controls. Moreover, all malignancy-induced immunological disturbances appeared to normalize
following disease clearance. Thus, we present the first ever placement of systemic OS-induced
immune disturbances within the context of disease progression which may ultimately lead to
successful IMT for metastatic OS.

Keywords: osteosarcoma, immunophenotype, myeloid-derived suppressor cell, PD-L1, MHC-II
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Introduction

Despite the presence of nonsynonymous mutations and immune infiltrates, metastatic OS tumors
have not responded to immunotherapies (IMTs) [1, 2]. The IMTs tested thus far have been
generated largely in response to data from primary tumors; however, primary and metastatic tumor
microenvironments are immunophenotypically distinct [3-8]. There is also no meaningful way to
assess immune status after the primary tumor is removed, and clinically actionable malignancyinduced immune deficits may be missed.
Unlike the primary tumor immune microenvironment, the systemic immune system can be
sampled continuously. Our group has shown previously that the systemic immune system can
serve as a surrogate marker of OS disease progression; however, only one tissue (spleen) and time
point (end-stage disease) were assessed [8]. Therefore, the objective of this study was to extend
our analysis of the systemic anti-OS immune response to include other tissues across multiple time
points. As such, herein we describe the utility of systems-wide immunophenotyping for placing
malignancy-induced immunomodulation within the context of OS disease progression.
Using an orthotopic tumor model, we have quantified disease burden over time using luciferasetransfected K7M2 (luc-K7M2) tumor cells and In Vivo Imaging Systems (IVIS). At intervals
described in Fig. 1, we conducted systems-wide flow cytometry (FC) surveys on blood, spleen,
lung, and bone marrow (BM). The survey included pertinent components of the OS immuno105

genomic landscape that may be targeted therapeutically, including the mononuclear phagocyte
system (monocytes, myeloid-derived suppressor cells [MDSCs], and macrophages), T cells, and
Natural Killer (NK) cells [9-16].
FC antibody panels (one focusing on lymphoid- [panel L] and one myeloid- [panel M] lineage cell
populations) used in this study were optimized using the markers shown in supplementary Table
S1 but are focused on CD45+NKp46+ NK cells, CD45+CD4+ T helper (TH) cells, CD45+CD8+
cytotoxic

T

(TC)

cells,

CD45+CD11b+Ly6C+Ly6G-

monocytic(M)-MDSCs,

and

CD45+CD11b+Ly6Clo/-Ly6G+ polymorphonuclear(PMN)-MDSCs, which showed sensitivity to
tumor burden. Hence, herein we describe a distinct combination of OS-induced immune events
within the context of disease progression; these events occur consistently across multiple tissue
types and may be followed in real-time for clinical benefit.

Materials and Methods

Mice
Male and female BALB/c mice aged 4-5 weeks (Stock Number: 000651) were obtained from The
Jackson Laboratory and housed individually in ventilated Allentown cages within specific
pathogen-free facilities on corncob bedding with 12 hour light/dark cycles, automatic lixit water,
and ad libitum food access. All experiments were approved by the Institutional Animal Care and
Use Committee (IACUC).

OS BALB/c K7M2 Syngeneic Mouse Model with Time Point Blood and Spleen Collection
Inoculation of luc-K7M2 cells or vehicle into the proximal tibia (INOC, week 0) (Fig. 1A)
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K7M2 murine OS tumor cells (ATCC CRL-2836, ATCC) were kindly donated by Dr. Kurt Weiss,
MD (University of Pittsburgh Medical Center, Pittsburgh, PA) in April 2014 and transfected with
the luc2 reporter as previously described [17]. Luc-K7M2 cells were Mycoplasma free and their
identity confirmed in 2018 via IDEXX BioResearch Case #6926-2018 (ID 3). For inoculations,
luc-K7M2 cells (1 x 106) suspended in DMEM or vehicle (media alone) were administered
intratibially as previously described [17]. An initial cohort of n = 10 (five male and five female)
BALB/c mice were randomized into tumor-bearing (TUMOR) and age- and sex-matched sham
(SHAM) groups prior to inoculation with tumor cells or media only, respectively. Due to high
mortality rate, additional mice were added to achieve an n of 5 for each group per time point. To
further correct for fluctuation in tumor growth rates, each TUMOR mouse was matched with a
same-sex SHAM that underwent surgical procedures at the same intervals. As a result, the analyses
herein were conducted using n = 14 TUMOR (six male and eight female) and n = 11 SHAM (four
male and seven female) BALB/c mice
Primary tumor amputation (AMP, weeks 4-7) (Fig. 1B)
TUMOR mice were monitored as previously described [17] in accordance with our institution’s
tumor burden scoring system (supplementary Table S2). Primary tumor size was measured on both
longitudinal (length) and transverse (width) axes. Between four and seven weeks when tumor
volumes measured > 1.5 cm3 (Vtumor = length x width)2/2), TUMOR mice were imaged via IVIS
before undergoing cheek bleed, leg amputation, and spleen biopsy procedures within 24 hours.
Cheek bleeds were performed by piercing the facial vein plexus with a 4mm Goldenrod Animal
Lancet (Braintree Scientific) to collect 100 µL whole blood; the tumor-bearing limb was removed
as previously described [17]. To obtain the spleen biopsy, a small (5 mm) incision was made in
the skin and peritoneum over the left upper abdominal quadrant. The specimen (23.3 ± 10.4 mg
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tissue) was excised from the anterior extremity of the diaphragmatic surface parallel to the
segmental vessels [18, 19]. Care was taken to ensure that the splenic artery was not severed to
preserve tissue viability [20-25]. SHAM mice underwent identical blood draw and surgical
procedures as their tumor-bearing mouse counterparts. Despite our efforts, the surgical insult of
repeated splenic biopsy caused tissue death and cell loss that disrupted its natural immune
response; for clarity, these data are not included in this manuscript but can be made available upon
request.
Post-Amputation Time Points 1 (T1) and 2 (T2) (Fig. 1C, D)
Four (T1) and six (T2) weeks following AMP, TUMOR mice were imaged via IVIS. The next
day, TUMOR and SHAM mice underwent a second (T1) and third (T2) cheek bleed and spleen
biopsy procedure.
Euthanasia (EUTH) (Fig. 1E)
Eight weeks following AMP, TUMOR mice were imaged via IVIS. The next day, both TUMOR
and SHAM mice underwent a third and final cheek bleed before euthanasia and tissue (BM, spleen,
and lung) harvest. In this manuscript, local recurrence was defined as any extra-pulmonary disease
burden but was mainly confined to the peritoneum within the ipsilateral abdominal quadrant from
which the affected limb was removed; metastasis was defined by pulmonary nodules via IVIS or
gross inspection.

There were two special scenarios that arose defined as early euthanasia (EE) and unplanned death
(UD). In the case of EE, animals with advanced (post-AMP) disease that met mandatory euthanasia
criteria (tumor burden score > 30 [supplementary Table S2]) must be prematurely euthanized; in
this instance, an immediate EUTH time point surgery was scheduled so that all tissues could be
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harvested. Accordingly, all EE blood, spleen, lung, and BM tissue data for said mouse were then
moved to the EUTH time point for group average purposes. An UD resulted when a mouse died
from tumor burden before its scheduled time point was reached (early or otherwise) and no viable
tissue was collected; in this instance, data collected at the previous time point were moved to
EUTH for group average purposes. These adjustments were made to account for differences in
tumor burden between animals over time and ensure that EUTH data points were assembled from
time points when each mouse was at its most advanced stage of disease progression. Of the nonUD mice surviving to a terminal time point, 87.5% were macrometastatic disease positive (via
IVIS imaging and/or gross inspection).

In vivo imaging system (IVIS) imaging of tumor burden
Animals were IVIS-imaged 24 hours prior to each time point (AMP, T1, T2, and EUTH) using the
IVIS Spectrum CT imaging system (PerkinElmer Life Sciences) with Living Image version 4.5
Software to monitor disease burden. To visualize disease burden, mice received 150 mg/kg
intraperitoneal (i.p.) D-luciferin (Caliper Life Sciences); to visualize metastatic disease in the lung
(time points T1-EUTH), mice received an additional 15 mg/kg of intranasal (i.n.) D-luciferin
(approximately 30 µL). Images were captured using auto-exposure within the predetermined
interval of maximum bioluminescence.

Solid tissue single-cell preparation
Solid tissues were disassociated using a gentleMACS Dissociator and mouse Tumor
Disassociation Kit (Miltenyi Biotec, Auburn, CA) or Lung Dissociation Kit (Miltenyi Biotec),
respectively. Cell suspensions from lung tissue were enriched for CD45+ leukocytes using CD45
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MicroBeads and autoMACS Pro Separator per manufacturer’s recommendations (Miltenyi
Biotec). Red blood cells were lysed with Red Blood Cell (RBC) Lysis Solution (Miltenyi Biotec).

Flow cytometry (FC)
Single cell suspensions were split and incubated with either the lymphoid (L) or myeloid (M) panel
antibody panels (supplementary Table S1), according to the manufacturer’s instructions; a
minimum of 1 x 104 events were analyzed per sample. Sample gating strategies can be found in
supplementary Figs. S1 and S2. The average CD45+ percentage of cells harvested from all tumorbearing and sham animal tissues was statistically equivalent across all time points measured
(supplementary Fig. S3).

Statistical Analysis
For all parameters measured, combined male/female group (TUMOR versus SHAM) averages
were calculated for each tissue and time point and the standard deviations (SD) calculated. Power
analyses based upon a range of markers that vary significantly in expression between TUMOR
and SHAM mice determined that the minimum required sample size to achieve at least 90% power
was n = 8 per time point (supplementary Table S3). Statistical significance between TUMOR and
SHAM group immunophenotypes was determined with Student unpaired two-tailed t test and the
strength of associations was evaluated using Pearson’s correlation test. Although there was a high
drop in n over time due to surgical insult and/or tumor burden, all statistics were performed with
n ≥ 5 mice per group. For comparisons across multiple time points, a preliminary Fisher’s least
significant differences determined that test variables “TUMOR versus SHAM” and “time” differed
significantly (p < 0.05).
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Results

OS disease progression induces accelerated lymphocyte depletion in blood
NKp46+ NK, CD4+CD8- TH, and CD8+CD4- TC cells exhibited distinct downward trajectories in
TUMOR mice as disease progressed (Fig. 2A-B and 2D-F, respectively). Across these three cell
populations, a pattern of statistical significance was achieved where differences between TUMOR
and SHAM mice were greatest at times of highest mean tumor bioluminescence (AMP,
Supplementary Fig. S4G) and point of furthest disease progression/highest tumor burden score
(EUTH, supplementary Table S2). NK cell percentages in TUMOR mice were also significantly
lower than those of SHAM at T1 (Fig. 2B). From a longitudinal perspective, NK cells were the
only lymphocyte population that changed significantly in TUMOR but not SHAM mice across
AMP and EUTH time points (Fig. 2C), suggesting that NK cell depletion in blood was specific to
OS disease progression. The overall change in TH cells across AMP and EUTH time points was
significant for both TUMOR and SHAM animals (Fig. 2G), while the change in T C was not
significant in either group (Fig. 2H).

The differences in circulating lymphocyte populations between TUMOR and SHAM mice over
time became magnified when comparing individual time- and sex-matched pairs. IVIS-reported
disease burden of TUMOR mice for three exemplary matched pairs (supplementary Fig. S5A,
S5H, and S5O) is shown alongside blood NK, TH, and TC cell trajectories in supplementary Fig.
S5B-D, S5I-K, and S5P-R, respectively. Note that Male Tumor 1 mouse (supplementary Fig. S5AG) had local recurrence and pulmonary metastasis on necropsy prior to tissue processing while
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Male Tumor 2 mouse (supplementary Fig. S5H-N) had local recurrence only. Importantly, Female
Tumor 1 mouse (supplementary Fig. S5O-U) was disease-free following the removal of its primary
lesion at AMP; strikingly, its lymphocyte populations returned roughly to that of the matched-pair
sham for subsequent time points.

OS disease progression induces changes in PMN- and M-MDSC populations in blood
While lymphocyte percentages of TUMOR mice were significantly decreased compared to SHAM
at AMP and EUTH time points, immunosuppressive CD11b+Ly6Clo/-Ly6G+ PMN-MDSCs were
significantly increased (Fig. 2I, J). Unlike the progressive depletion of circulating lymphocytes,
PMN-MDSCs remained consistently elevated across time points with no clear trend (Fig. 2J).
Conversely, TUMOR mice M-MDSCs were significantly elevated at AMP only and decreased
over time (Fig. 2I, K). Neither PMN- nor M-MDSC populations changed significantly across AMP
and EUTH time points in TUMOR or SHAM mice groups (Fig. 2L and 2M, respectively). The
IVIS-reported disease burden of TUMOR mice for three exemplary matched pairs (supplementary
Fig. S5A, S5H, and S5O) is shown alongside blood PMN-MDSC and M-MDSC trajectories in
supplementary Fig. S5E and S5F, S5L and S5M, and S5S and S5T, respectively.

The PD-L1/MHC-II ratio on blood M-MDSCs correlates with increasing tumor burden and
is a specific marker of OS disease progression
Expression of Human Leukocyte Antigen DR isotype (HLA-DR), an immunostimulatory
molecule and member of the major histocompatibility complex II (MHC-II) family that presents
foreign peptides to TH cells [26], is lost on monocytes in pediatric patients with aggressive
sarcomas and postulated to be one of the first steps in the transition of monocytes to M-MDSCs
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[27, 28]. As decreased MHC-II expression is linked to increased PD-L1 expression and
immunosuppression [29, 30], we investigated their co-expression levels on CD11b+Ly6C+Ly6GM-MDSCs over time. Indeed, as disease progressed, M-MDSCs in TUMOR mice gained
expression of PD-L1 and lost expression of MHC-II as shown by the representative histograms in
Fig. 3A and B, respectively. We then considered whether increasing tumor burden was associated
with increasing %PD-L1 to %MHC-II (P[1]/M[II]) ratio on M-MDSCs. Note that luciferinmediated tumor bioluminescence can paradoxically decrease with increasing tumor size in cases
where rapid growth prompts central necrosis [31, 32]. Supplementary Fig. S4A shows a
representative TUMOR mouse with central necrosis of a local recurrence between time points T2
and EUTH, as indicated by the loss of bioluminescent signal coupled with increasing tumor
diameter (Fig. S4B and S4C, respectively). In contrast, the animal in Supplementary Fig. S4D
displayed concurrent increases in both tumor bioluminescence and diameter (Fig. S4E and S4F,
respectively). To account for this imaging limitation, associations were assessed using data points
from mice with corresponding increases in both tumor bioluminescence and radius only. In doing
so, it was found that the ratio of %PD-L1 to %MHC-II (P[1]/M[II]) expression on blood MMDSCs correlated strongly and positively with tumor bioluminescence over time (Fig. 3C: R =
0.96; p = 0.0006), while %PD-L1 and %MHC-II alone (Fig. 3D and 3E, respectively) did not.

When the average P[1]/M[II] ratios were plotted over time, they increased in TUMOR mice only
and showed greatest divergence from SHAM mice at EUTH (Fig. 3F), the time point at which
disease was most advanced. Longitudinally, the M-MDSC P[1]/M[II] ratio was significantly
increased across AMP and EUTH time points in TUMOR but not SHAM mice (Fig. 3G),
suggesting that its change was specific to disease progression. Following amputation of its tumor-
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bearing limb, Female Tumor 1 mouse remained disease-free throughout the remainder of the study
and its ratio returned to that of the matched-pair sham by T2 (supplementary Fig. S5U).
Conversely, the ratios of Male Tumor 1 and 2 mice with relapses increased rapidly (supplementary
Fig. S5G and S5N, respectively).

Decreased lymphocytic infiltration and abnormal myeloid activation in lung and BM reflect
disease status
At EUTH, lungs and BM were collected (in addition to blood and spleen) and analyzed for diseasespecific changes in immune composition. NKp46+ NK and CD8+ TC cells were significantly
decreased in the lungs and BM of TUMOR versus SHAM mice (Fig. 4A-B and 4C-D),
respectively. Conversely, the M-MDSC P[1]/M[II] ratio was increased in the lungs and BM of
TUMOR versus SHAM mice (Fig. 4G-H), which was significant in lung. Interestingly, while there
were no statistical differences in percent populations of CD4+ TH cells or CD11b+Ly6Clo/-Ly6G+
PMN-MDSCs in lung and BM (Fig. 4C-D and 4E-F respectively), CD11b+Ly6C+Ly6G- MMDSCs were increased in lungs and significantly decreased in the BM of TUMOR versus SHAM
mice (Fig. 4E-F). For reference, the average immunophenotype of the primary tumors is shown in
supplementary Fig. S6.

Blood and BM M-MDSC P[1]/M[II] ratios correlate with lung M-MDSC P[1]/M[II] ratios
in TUMOR mice only
Lung metastasis is the leading cause of death in OS patients [33], and as M-MDSCs are a vital
component of the metastatic niche [34], we investigated the utility of the M-MDSC P[1]/M[II]
ratio as a diagnostic and/or prognostic tool. In primary tumors, the P[1]/M[II] ratio at AMP did
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not correlate with the M-MDSC P[1]/M[II] ratio in lung (Fig. 5A: R = 0.15; p = 0.81). However,
there was a strong positive correlation between the M-MDSC P[1]/M[II] ratios of blood at EUTH
and lung in TUMOR mice (Fig. 5B: R = 0.972; p = 0.0056). The correlation between BM and lung
ratios, while not significant, showed a similar effect in TUMOR mice (Fig. 5B: R = 0.849; p =
0.069). Importantly, these correlations were nonexistent in the blood (Fig. 5B: R = 0.255; p = 0.58)
and BM (Fig. 5B: R = 0.267; p = 0.56) of SHAM mice, suggesting disease specificity.

Discussion

Primary tumor data is often used to direct immunotherapeutic approaches despite the fact that they
are not representative of systemic immune status [3-8]. Additionally, the primary tumor provides
no further information once it is removed. While some studies have investigated OS serum
biomarkers, most have focused on highly variable, non-cellular entities [35]. Herein, we described
the systemic immune response to disease burden and evaluated the potential of its cellular
components as real-time immune biomarkers. In doing so, we have identified several diseaseresponsive lymphoid and myeloid immune cell populations that warrant further investigation.

It has been shown that pediatric OS patients have decreased numbers of circulating lymphocytes
versus healthy age-matched controls [36]. Our data support this conclusion, as all three lymphocyte
populations studied (NK, TH, and TC cells) were significantly decreased in TUMOR versus SHAM
mice blood at AMP (i.e., the time point analogous to when patients would present in clinic). Our
data suggest that circulating lymphocyte percentages continue to decline at an accelerated rate as
disease progresses. From a longitudinal perspective, the depletion of circulating NK cells was
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significant and specific to advancing disease (Fig. 2A-C). Not surprisingly, NK cells were also
significantly decreased in the lungs of TUMOR versus SHAM mice (Fig. 4A-B), of which 87.5%
had macrometastatic pulmonary disease. Clinically, it has been shown that increased circulating
percentages of NK cells in pediatric OS patients correlate with better outcomes [37]. Our data
suggest that NK cell percentages will continue to fluctuate in direct response to tumor burden and
therefore may serve as a useful biomarker of disease progression. Average T H and TC cell
percentages in the lungs of TUMOR mice, while decreased versus SHAM, were more variable and
did not achieve statistical significance; it is possible that suppressive myeloid cells within the lung
parenchyma sufficiently inhibit T lymphocytes responses regardless of their tumor-infiltrating
capacity [16].

Very little is known about the myeloid component of systemic immune responses to OS. Here, we
have shown that circulating PMN- and M-MDSC percent populations are significantly elevated in
TUMOR mice at AMP and variable throughout the remaining course of disease (Fig. 2I-K), with
neither population showing disease-specific outcomes (Fig. 2L-M). Interestingly, PMN-MDSC
percentages were significantly increased in blood (Fig. 2I-J) but not lungs of TUMOR versus
SHAM mice (Fig. 4E-F). Conversely, M-MDSC percentages were decreased in BM and increased
in lungs of TUMOR versus SHAM mice (Fig. 4E-F); together, these data suggest that M-MDSCs
may play a more direct role in supporting OS metastases than PMN-MDSCs.

The P[1]/M[II] ratio, a novel immune biomarker of OS disease progression, not only allowed for
magnification of effect size for each observation, but also correlated significantly with increasing
tumor burden (Fig. 3E) and progressively increased in magnitude over time (Fig. 3F) in a disease-
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specific manner (Fig. 3G). It is possible that this ratio could be partially describing the monocyteto-M-MDSC dedifferentiation phenomenon seen in pediatric patients with aggressive sarcomas,
where monocytes lose MHC-II and gain PD-L1 expression [27-30]. In contrast to SHAM, the
P[1]/M[II] ratio of blood and BM from TUMOR mice showed strong correlations with that of lung
(Fig. 5B), suggesting that 1) increases in ratio magnitude are specific to disease process, and 2)
systemic tissue sampling (i.e., via a blood draw) may provide insight into the immunophenotype of
the lung. The ability to infer immunological information about lung from blood is clinically
relevant, as it would otherwise require biopsy. Primary tumors had no predictive value regarding
the P[1]/M[II] status in the lung at EUTH. Also, the 12.5% of non-UD mice with local recurrences
but without confirmed macrometastases had similar changes in their systemic immunophenotypes,
suggesting that the presence of tumor produces similar immunologic disturbances regardless of
location.

In conclusion, primary tumors are not always good indicators of systemic disease burden as they
provide only a snapshot of disease and exclude the systemic impact of the progressing malignancy.
Our data suggest that there is clinically useful information that can be extrapolated from blood,
which unlike primary and metastatic tumors, can be sampled continually and non-invasively.
Therefore, we suggest that, aside from its diagnostic and prognostic application potential, systemswide immunophenotyping may greatly increase the success rate of all IMTs currently in use and
allow for the creation of individualized immunotherapeutic regimens tailored to the specific needs
of each patient. Also, these data suggest that IMTs specifically targeting monocyte-to-M-MDSC
dedifferentiation may be effective against metastatic OS.
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Figure Legends

Fig. 1 Experimental design for systems-wide immunophenotyping in an orthotopic murine
model of metastatic OS. (A) Inoculation: at week 0, male and female BALB/c mice received
inoculums in the proximal tibia comprised of either 1 x 106 luc-K7M2 tumor cells in media
(TUMOR) or media only (SHAM). (B) Amputation/AMP: primary tumors reached an average
volume > 1.5 cm3 within 4-7 weeks. The day preceding amputation, TUMOR mice were given 150
mg/kg D-luciferin intraperitoneal (i.p.) and IVIS-imaged for bioluminescence intensity. The
following day, TUMOR and SHAM mice were cheek bled for 100 µL whole blood followed by
leg amputation and splenic biopsy. Blood, spleen, and tumor samples were stained with lymphoid
and myeloid antibody panels for immunophenotyping via flow cytometry (FC). Four (C) and six
(D) weeks following limb amputation (time points 1 [T1] and 2 [T2], respectively), TUMOR and
SHAM mice underwent additional cheek bleeds and spleen biopsies; samples were stained and
immunophenotyped. The day preceding each time point, TUMOR mice were given 150 mg/kg Dluciferin i.p. plus an additional 15 mg/kg intranasal (i.n.) and IVIS-imaged for bioluminescence
intensity. (E) Eight weeks following amputation, TUMOR and SHAM mice were cheek bled one
final time before euthanasia (EUTH) and tissue harvest; all tissues (blood, spleen, lung, and bone
marrow [BM]) were stained and immunophenotyped. The day preceding the EUTH time point,
TUMOR mice were given 150 mg/kg D-luciferin i.p. plus an additional 15 mg/kg i.n. and IVISimaged for bioluminescence intensity.

Fig. 2 OS disease progression induces changes in percentages of circulating lymphocytes,
PMN-MDSCs, and M-MDSCs. Mice were inoculated intratibially with luc-K7M2 tumor cells
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(TUMOR) or vehicle (SHAM) and followed over 12 weeks with time point tissue sampling.
Representative flow cytometry (FC) plots of select peripheral blood cell populations for TUMOR
and SHAM animals at each time point are shown for (A) NKp46+ NK cells, (D) CD4+ TH and
CD8+ TC cells, and (I) CD11b+Ly6Clo/-Ly6G+ PMN-MDSCs and CD11b+Ly6C+Ly6G- MMDSCs. Average (mean ± SD) percent of peripheral blood CD45+ leukocytes in TUMOR versus
SHAM mice are shown for NKp46+ NK cells (B) along the entire course of disease and (C) across
AMP and EUTH time points only, CD4+ TH cells (E) along the entire course of disease and (G)
across AMP and EUTH time points only, CD8+ TC cells (F) along the entire course of disease and
(H) across AMP and EUTH time points only, CD11b+Ly6Clo/-Ly6G+ PMN-MDSCs (J) along the
entire course of disease and (L) across AMP and EUTH time points only, and CD11b+Ly6C+Ly6GM-MDSCs (K) along the entire course of disease and (M) across AMP and EUTH time points
only. Trendlines represent linear curves of best fit for tumor-bearing mice. *, p < 0.05; **, p <
0.01; ***, p < 0.001 by an unpaired two-tailed t test (TUMOR versus SHAM). N.S. = not
significant. Data are representative of n  5 mice (male/female combined) per time point.

Fig. 3 The ratio of PD-L1/MHC-II (P[1]/M[II) expression on the surface of systemically
circulating M-MDSCs correlates with increasing tumor burden and is specific to disease
progression. Mice were inoculated intratibially with luc-K7M2 tumor cells (TUMOR) or vehicle
(SHAM) and followed over 12 weeks with time point tissue sampling. (A) Representative flow
cytometry (FC) plot showing the percent expression of PD-L1 on the surface of peripheral blood
M-MDSCs in TUMOR (red) and SHAM (black) mice. (B) Representative FC plot showing the
percent expression of MHC-II on the surface of blood M-MDSCs in TUMOR (red) and SHAM
(black) mice. (C-E) IVIS-reported increases in tumor bioluminescence were used to test for
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associations with (C) peripheral blood M-MDSC surface PD-L1 expression alone (n = 9), (D)
peripheral blood M-MDSC surface MHC-II expression alone (n = 9), and (E) peripheral blood MMDSC P[1]/M[II] ratio (n = 9) using Pearson’s correlation test. Trendlines were centered at the
origin and translated to begin at x = 0 using the means of each group. (F) Average (mean ± SD)
magnitude of the M-MDSC P[1]/M[II] ratio in TUMOR versus SHAM mice along the entire
course of disease and (G) across AMP and EUTH time points only. The trendline represents the
linear curve of best fit for TUMOR mice. *, p < 0.05; **, p < 0.01; ***, p < 0.001 by an unpaired
two-tailed t test (TUMOR versus SHAM). N.S. = not significant. In (F) and (G), the data are
representative of n  5 mice (male/female combined) per time point.

Fig. 4 Decreased lymphocytic infiltration and abnormal myeloid activation in lung and bone
marrow reflect disease status and mirror systemic changes in blood. Mice were inoculated
intratibially with luc-K7M2 tumor cells (TUMOR) or vehicle (SHAM) and followed over 12
weeks with time point tissue sampling. Representative flow cytometry (FC) plots of select lung
and bone marrow (BM) cell populations for TUMOR and SHAM animals at euthanasia (EUTH)
are shown for (A) NKp46+ NK cells, (C) CD4+ TH and CD8+ TC cells, and (E) CD11b+Ly6Clo/Ly6G+ PMN-MDSCs and CD11b+Ly6C+Ly6G- M-MDSCs. Boxplots of (B) NKp46+ NK cells,
(D) CD4+ TH and CD8+ TC cells, and (F) CD11b+Ly6Clo/-Ly6G+ PMN-MDSCs and
CD11b+Ly6C+Ly6G- M-MDSCs are shown as a percent of total CD45+ leukocytes in lungs and
BM of TUMOR versus SHAM mice. (G) Exemplary FC plot showing the percent expression of
PD-L1 and MHC-II on the surface of lung and BM M-MDSCs in TUMOR (red) and SHAM
(black) mice. (H) Boxplots of the M-MDSC P[1]/M[II] ratio are shown for lungs and BM of
TUMOR versus SHAM mice. *, p < 0.05; **, p < 0.01; ***, p < 0.001 by an unpaired two-tailed
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t test (TUMOR versus SHAM). Data are representative of n  5 mice (male/female combined) per
time point.

Fig. 5 The M-MDSC P[1]/M[II] ratio is a specific and systemic marker of OS disease. Mice
were inoculated intratibially with luc-K7M2 tumor cells (TUMOR) or vehicle (SHAM) and
followed over 12 weeks with time point tissue sampling. (A) Pearson correlation in TUMOR mice
between the M-MDSC P[1]/M[II] ratios of primary tumors harvested at amputation (AMP) versus
the M-MDSC P[1]/M[II] ratios of lung tissue collected at euthanasia (EUTH) (n = 5). (B) Pearson
correlation in TUMOR (triangles) and SHAM (squares) mice between the M-MDSC P[1]/M[II]
ratios of blood (left: TUMOR n = 5; SHAM n = 7) and BM (right: TUMOR n = 5, SHAM n = 7)
at EUTH and the M-MDSC P[1]/M[II] ratio of lung.

Supplementary Fig. S1 Sample gating strategy for NK cells, T H cells, and TC cells from
antibody panel L. Intact cells were separated from debris using SSC-A versus FSC-A (A), which
were then gated to exclude doublets using FSC-A versus FSC-W (B). CD45+LIVE/DEAD- live
white blood cells (C) were then gated into (D) NKp46+ NK cells and (E) CD4+ TH and CD8+ TC
cells using a univariate and bivariate plots, respectively.

Supplementary Fig. S2 Sample gating strategy for PMN- and M-MDSCs from antibody
panel M. Intact cells were separated from debris using SSC-A versus FSC-A (A), which were then
gated to include only CD45+ white blood cells (B). CD45+ white blood cells were further gated
into CD11b+ myeloid lineage cells (C), which were separated into (D) Ly6C+Ly6G- M-MDSCs
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and Ly6Clo/-Ly6G+ PMN-MDSCs with a bivariate plot. Percent expression of PD-L1 and MHC-II
on M-MDSCs was then determined using univariate histograms (E).

Supplementary Fig. S3 CD45+ percent of total cells harvested from tumor, lung, BM, and
blood tissues. Mice were inoculated intratibially with luc-K7M2 tumor cells (TUMOR) or vehicle
(SHAM) and followed over 12 weeks with time point tissue sampling. Blood and spleen samples
were collected from TUMOR and SHAM mice at amputation (AMP) and again at four (T1), six
(T2), and eight (EUTH) weeks post-AMP. Lung and BM were harvested in addition to blood and
spleen at the EUTH time point and all tissues were stained with lymphoid- and myeloid-specific
antibody panels and immunophenotyped via flow cytometry (FC). (A) CD45+ percent of total cells
harvested from primary tumors at AMP from TUMOR mice and lung and BM harvested at EUTH
from TUMOR and SHAM mice. (B) CD45+ percent of total cells harvested from blood of TUMOR
and SHAM mice at AMP, T1, T2, and EUTH time points. Data are representative of n  5 mice
(male/female combined) for each time point and/or tissue.

Supplementary Fig. S4 Luciferin-mediated tumor bioluminescence can paradoxically
decrease with increasing tumor size in cases where rapid growth promotes central necrosis.
Mice were inoculated intratibially with luc-K7M2 tumor cells (TUMOR) or vehicle (SHAM) and
followed over 12 weeks with time point tissue sampling. The day preceding each time point,
TUMOR mice were IVIS-imaged for bioluminescence intensity. IVIS images of representative
TUMOR mice with (A) and without (D) central tumor necrosis are shown across four time points.
IVIS-reported tumor bioluminescence in average radians ([p/s]/[cm2/sr]) is shown at each time
point for representative TUMOR mice with (B) and without (E) central tumor necrosis. Magnified
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IVIS images of select time points showing representative TUMOR mice with (C) and without (F)
central tumor necrosis highlighting the relationship between tumor radius (red dotted circle and
arrows) and signal intensity. (G) Average (mean ± SD) tumor burden bioluminescence in average
radians ([p/s]/[cm2/sr]) across each time point as measured by IVIS imaging.

Supplementary Fig. S5 Individual matched-pair comparisons highlight the temporal
relationship cellular immune biomarkers in blood and OS disease burden. Mice were
inoculated intratibially with luc-K7M2 tumor cells (TUMOR) or vehicle (SHAM) and followed
over 12 weeks with time point tissue sampling. Blood samples were collected from TUMOR and
SHAM mice at amputation (AMP) and again at four (T1), six (T2), and eight (EUTH) weeks postAMP and stained with both lymphoid- and myeloid-specific antibody panels for
immunophenotyping via flow cytometry (FC). The day preceding each time point, TUMOR mice
were IVIS-imaged for bioluminescence intensity. (A) Top panel: Male Tumor 1 mouse with a
primary lesion of the left lower extremity leading to local recurrence and peritoneal infiltration at
T2 (Day 70) and widespread disease with pulmonary metastasis (upon visual inspection of lung)
at EUTH (Day 84). Bottom panel: Male Tumor 1 mouse IVIS-reported tumor burden in average
radians ([p/s]/[cm2/sr]) at each time point. From the lymphoid antibody panel, populations of (B)
NKp46+ NK, (C) CD4+ TH, and (D) CD8+ TC cells as a percent of total CD45+ leukocytes in the
blood of Male Tumor 1 mouse (triangle) versus a matched-pair sham (square). From the myeloid
antibody

panel,

populations

of

(E)

CD11b+Ly6Clo/-Ly6G+

PMN-MDSCs

and

(F)

CD11b+Ly6C+Ly6G- M-MDSCs as a percent of total CD45+ leukocytes blood of Male Tumor 1
mouse versus a matched-pair sham. (G) Male Tumor 1 mouse blood M-MDSC P[1]/M[II] ratio
versus matched-pair sham. (H) Top panel: Male Tumor 2 mouse with a primary lesion of the right

127

lower extremity leading to local recurrence and peritoneal infiltration at T1 (Day 70) and
widespread disease with pulmonary metastasis at T2 (Day 84). As this mouse reached euthanasia
criteria early (early euthanasia = EE), it was euthanized at its T2 time point. Bottom panel: Male
Tumor 2 mouse IVIS-reported tumor burden in average radians at each time point. From the
lymphoid antibody panel, populations of (I) NKp46+ NK, (J) CD4+ TH, and (K) CD8+ TC cells as
a percent of total CD45+ leukocytes in the blood of Male Tumor 2 mouse versus a matched-pair
sham. From the myeloid antibody panel, populations of (L) CD11b+Ly6Clo/-Ly6G+ PMN-MDSCs
and (M) CD11b+Ly6C+Ly6G- M-MDSCs as a percent of total CD45+ leukocytes in blood of Male
Tumor 1 mouse versus a matched-pair sham. (N) Male Tumor 2 mouse blood M-MDSC P[1]/M[II]
versus matched-pair sham. (O) Top panel: Female Tumor 1 mouse with a primary lesion of the
right lower extremity which was cured at AMP (Day 77) and endured no further disease burden
all the way to its EUTH time point (Day 105). Bottom panel: Female Tumor 1 mouse IVISreported tumor burden in average radians at each time point. From the lymphoid antibody panel,
populations of (P) NKp46+ NK, (Q) CD4+ TH, and (R) TC CD8+ cells as a percent of total CD45+
leukocytes in the blood of Female Tumor 1 mouse versus matched-pair sham. From the myeloid
antibody

panel,

populations

of

(S)

CD11b+Ly6Clo/-Ly6G+

PMN-MDSCs

and

(T)

CD11b+Ly6C+Ly6G- M-MDSCs as a percent of total CD45+ leukocytes in the blood of Female
Tumor 1 mouse versus matched-pair sham. (U) Female Tumor 1 mouse M-MDSC P[1]/M[II] ratio
versus matched-pair sham.

Supplementary Fig. S6 Immunophenotype of primary tumors removed at time point AMP.
Mice were inoculated intratibially with luc-K7M2 tumor cells (TUMOR) or vehicle (SHAM) and
followed over 12 weeks with time point tissue sampling. Lymphoid (A) and myeloid (B) lineage
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immune cell populations as a percent of total CD45+ leukocytes in primary tumors harvested from
TUMOR mice at time point AMP. (C) The M-MDSC P[1]/M[II] ratio of primary tumors harvested
from tumor-bearing mice at time point AMP. Data (mean + SD) are representative of n  5 mice
(male/female combined).
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Supplementary Table S1: Markers used to describe the Lymphoid (L) and Myeloid (M)
Antibody Panels
ANTIGEN/DYE
LIVE/DEAD

PANEL
Lymphoid

CLONE

FLUOROCHROME
Far red

CD45
CD45
CD4
CD8
CD335 (NKP46)
CD152 (CTLA-4)
CD279 (PD-1)
FOXP3
GALECTIN-9
KI67
CD69
CD366 (TIM-3)
CD11B
LY6C
LY6G
CD124 (IL4R-A)

Lymphoid
Myeloid
Lymphoid
Lymphoid
Lymphoid
Lymphoid
Lymphoid
Lymphoid
Lymphoid
Lymphoid
Lymphoid
Lymphoid
Myeloid
Myeloid
Myeloid
Myeloid

AF405
BV605
PE-Cy5
APC-Cy5.5
APC-eFLuor 780
DyLight 488
PE-CF594
PE
AF 594
PE-Vio 770
Brilliant Violet 510
BB700
PE-CF594
AF700
PE-Cy5
Fluoroscein (FAM)

CD206
(MANNOSE
RECEPTOR)
CD119 (IFN-ΓR1)
TLR2
MHC CLASS II
CD274 (PD-L1)
CD38
F4/80

Myeloid

MEM-45
30-11
RM4-5
53-6.7
29A1.4
1B8
J43
MF23
108A2
REA183
H1.2F3
5D12
M1/70
HK1.4
RB6-8C5
Polyclonal goat
IgG
MR5D3

MANUFACTURER
Life Technologies, Fisher
Scientific
Novus
BD Biosciences
BD Biosciences
Southern Biotech
Invitrogen
Novus
BD Biosciences
BD Biosciences
BioLegend
Miltenyi Biotec
BioLegend
BD Biosciences
BD Biosciences
BioLegend
Invitrogen
RnD Systems

AF647

Bio-Rad

Myeloid
Myeloid
Myeloid
Myeloid
Myeloid
Myeloid

RM0093-7K23
203325
114.15.2
10F9G2
09.4
BM8

DyLight 550
AF594
APC-eFluor 780
PE-Cy7
VioBlue
PerCP-Cy5.5

Novus
RnD Systems
Invitrogen
BioLegend
Miltenyi Biotec
BioLegend
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Supplementary Table S2: OLAR Tumor Burden Scoring System
PARAMETER
GENERAL
APPEARANCE

BODY CONDITION

TUMOR
APPEARANCE

RESPIRATION

OBSERVATION
Normal
(e.g. appropriate body condition ; healthy appearing fur; pink
mucus membranes, bright, alert, responsive)
Mild abnormal
(e.g. rough/scruffy fur, slightly decrease activity and grooming,
pale mucus membranes)
Moderately abnormal
(e.g. hunched posture, squinted eyes, reluctant to move, cachectic
body condition, white mucus membranes)
Severely compromised
(e.g. minimally to non-responsive, closed eyes)
Normal to Overweight body condition
Thin – obvious dorsal vertebrae
Severe Cachexia – prominent dorsal vertebrae and skeleton
Non-ulcerated
Not limiting normal mobility
Not limiting ability to eat or breathe
[One or more listed below]
Non-ulcerated wound associated with tumor-intact healing or
scab present
Limiting normal mobility
Limiting ability to reach food and/or water
[One or more listed below]
Ulcerated or actively bleeding
Preventing mobility, or so cannot eat or drink
Limiting ability to breathe, or any combination thereof
Normal rate and effort for species/strain
Increased rate and/or effort for species/strain
Severe respiratory distress or gasping (agonal) breathing
pattern
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SCORE
0

10

20

30
0

0

20

30

0
30
60

Supplementary Table S3
POPULATION
NK CELLS
T REGULATORY CELLS
T CELL EXHAUSTION SCORE
MYELOID LINEAGE CELLS
GRANULOCYTES
TGM2+ MACROPHAGES
CXCL9+ MACROPHAGES
NOS2+ MACROPHAGES

α
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05

σ
2.5
2.6
2.5
0.75
1.5
4
3.5
6

δ
9
14
18
3.88
2.57
14
15
60

NUMBER
8
8
8
8
8
8
8
8

POWER
1.0000
1.0000
1.0000
0.9786
0.9994
1.0000
1.0000
1.0000

TGM2 = transglutaminase 2; CXCL9 = C-X-C motif chemokine ligand 9; NOS2 = nitric oxide synthase 2
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Chapter 4
IL-12-loaded Poly(lactic-co-glycolic) acid (PLGA) Nanospheres Reduce Metastasis and
Increase Cure Rate in a NK cell-dependent Fashion in an Immunocompetent K7M2
Orthotopic Murine Model of Osteosarcoma

Unpublished data
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Abstract
Interleukin(IL)-12 is a protein cytokine that greatly increases the ability of Natural Killer
(NK) cells to attack tumors, and IL-12-based immunotherapies have shown activity against
osteosarcoma (OS) in preclinical models. The antitumor effects of recombinant IL-12 are greatest
when administered systemically; however, intravenous delivery of large bolus doses of IL-12 is
associated with severe side effects. Encapsulating IL-12 within biodegradable nanoscale
poly(lactic-co-glycolic) acid (PLGA) vectors (nIL-12) may allow for enhanced biodistribution
while minimizing side effects. In this study, we first established that high doses of intravenously
administered recombinant mouse(rm)IL-12 produced immunologic consequences similar to that
seen in humans, including NK cell depletion, T cell exhaustion (TCE), and polymorphonuclearmyeloid-derived suppressor cell (PMN-MDSC) myelocytosis in healthy BALB/c mice. Next, we
evaluated the survival benefits of nIL-12 on the luciferase-transfected K7M2 (luc-K7M2) mouse
model of metastatic OS while monitoring the systemic immunophenotype. It was observed that
luc-K7M2 tumor-bearing mice treated with nIL-12 had a 35.3% reduction in pulmonary metastases
(p = 0.007), as well as a 27.1% increase in disease-free rate (p = 0.008) at 12 weeks compared to
34 untreated mice from previous experiments utilizing the same model. The immunophenotypes
of nIL-12-treated tumor-bearing mice on a per-dose group basis followed the same trajectories
across all seven time points assessed, suggesting that dose-dependent nIL-12-mediated IL-12
immunotoxicity was unlikely. Importantly, the nIL-12-treated mice with residual disease at 12
weeks had lower NK cell percentages in their peripheral blood at primary tumor amputation versus
disease-free mice; upon stratifying nIL-12-treated mice around the median blood NK cell
percentage at primary tumor amputation, it was found that mice with NK cell percentages above
the median (8.21%) value developed significantly fewer metastases than those below (p = 0.038).
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While more controls are needed to flesh out the details of nIL-12 therapy for OS, these data support
the fact that immunophenotyping may be used alongside immunotherapy to increase efficacy and
assess immunotoxicity and thus warrant further investigation.

Introduction

While rare, osteosarcoma (OS) is the most common primary malignancy of bone and is
most prevalent in children and young adults (1). When metastatic, patients have extremely low
survival rates and no new therapies have been introduced since MAP (methotrexate, doxorubicin,
and cisplatin) combination chemotherapy several decades ago (1, 2). OS tumors are extremely
heterogeneous; the spectrum of mutations comprising individual tumors has been likened to that
of “fingerprints,” where each patient presents with a unique constellation of mutations driving
sarcomagenesis (3, 4). As such, there are few genomic alterations of which direct targeting has
yielded clinical benefits, and a new treatment perspective is warranted.
High genomic instability in OS tumors leads to extensive nonsynonymous mutation rates,
with the highest density of neoantigens expressed in metastatic lesions. Increased neoantigen
production

is

associated

with

increased

tumor-infiltrating

leukocytes

and

tumor

immunosuppressive forces (5). Although the immunogenicity of metastases is greater than that of
primary tumors, advancing disease brings systemic malignancy-induced immunosuppression in
the form of stepwise depletion of circulating lymphyoctes and the accumulation of suppressive
myeloid cells (5-7).
Natural killer (NK) cells are cytotoxic lymphocytes of the innate immune system that are
depleted in the peripheral circulation of OS patients at diagnosis and continue to decrease as
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disease progresses (6, 8). They are a subset of innate lymphoid cells (ILC) that kill infected and/or
malignant-transformed cells by recognizing nonspecific cellular stress proteins. NK cells are an
important player in tumor immunosurveillance as they prevent metastatic outgrowth by
disseminated tumor cells (9, 10). Various preclinical studies have confirmed the importance of NK
cells in the eradication of metastatic tumors, and they have been shown to kill OS tumor-iniating
cells (11-13).
Interleukin(IL)-12 is a heterodimeric protein cytokine that promotes cell-mediated immune
responses against microorganisms and cancers (15). It is mainly released by activated antigen
presenting cells (APCs) to assist in the priming of naïve helper T cells (16). In an IL-12-rich
environment, helper T cells polarize into type 1 (TH1) subsets and NK cells become activated and
proliferate. The highly antitumorigenic cytokine interferon(IFN)-γ is released by activated T and
NK cells and is an important mediator of IL-12 immunostimulation (17-20). Exogeneous
administration of recombinant IL-12 has shown efficacy against a variety of murine tumors and
infections, though the development of standardized dosing regimens has been complicated by
extensive side effect profiles in human patients (21-25).
Recombinant IL-12 induces its most powerful immune responses when given systemically,
allowing for more direct activation of immune cells in secondary lymphoid organs (26, 27).
However, systemic administration of recombinant protein requires high loading doses to achieve
adequate biodistribution and may lead to systemic toxicities associated with T cell exhaustion
(TCE), depletion of circulating lymphocytes, and neutrophilia (24-29). To overcome these
limitations, IL-12 can be encapsulated within poly(lactic-co-glyolic) acid (PLGA) nanospheres
(nIL-12). Nanoencapsulation results in entrapment of the encapsulated protein within a PLGA
polymer web, which may allow for therapeutic doses of IL-12 to reach tissues while mitigating
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side effects. Indeed, in contrast to bolus administration of free cytokine, nanosphere encapsulation
decreases the amount of bioavailable IL-12 per unit time as it is released more slowly pending
polymer hydrolysis (30-32).
Previous studies from our group have shown that systemic NK cell depletion is a specific
malignancy-induced immune deficit that worsens with increasing disease burden; as IL-12 has
both mitogenic and activating influences on NK cells, we tested the utility of systemic nIL-12
therapy alongside systemic immunophenotyping to correct malignancy-induced immune deficits
and inhibit metastasis formation in OS tumor-bearing mice (9, 18).

Materials and Methods

Mice
Male and female BALB/c mice aged 4-5 weeks (Stock Number: 000651) were obtained
from The Jackson Laboratory and housed individually in ventilated Allentown cages within
specific pathogen-free facilities on corncob bedding with 12 hour light/dark cycles, automatic lixit
water, and ad libitum food access. All experiments were approved by the Institutional Animal Care
and Use Committee (IACUC).

In vivo induction of free IL-12 toxicity in healthy mice
Two groups of four BALB/c mice (two female and two male per group) were cheek bled
by piercing the facial venous plexus with a sterile 4mm Goldenrod Animal Lancet (Braintree
Scientific, Braintree, MA) to gather 100 µL whole blood for baseline immunophenotyping.
Immediately following cheek bleeds, each group was given a retro-orbital (r.o.) injection of either
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a low (100 ng) or high (100 µg) dose of free recombinant mouse (rm)IL-12 (eBiolegend, San
Diego, CA) with 0.1% mouse serum albumin (MSA, Sigma, St. Louis, MO) in 150 µL DPBS. At
24 and 48 hours following r.o. injections, mice underwent additional cheek bleeds for
immunophenotyping.

nIL-12 synthesis
nIL-12 nanospheres were prepared using the double emulsion solvent evaporation
technique (33). Briefly, 150 µL of 83.3 mg/mL recombinant mouse IL-12 (rmIL-12, (eBiolegend,
San Diego, CA) with 10% mouse serum albumin (MSA, Sigma, St. Louis, MO) in DPBS was
added to 250 mg PLGA resomer RG 503H (Sigma) dissolved in 1.51 mL dicholoromethane
(Sigma) with 14% w/w Span 60 (Sigma); the resulting emulsion was sonicated at 50W for 10
seconds on ice before being added to 5 mL of 1% w/v polyvinyl alcohol (PVA, Sigma) with 4%
w/v Tween 80 (Sigma) and sonicated again on ice at the same parameters. The resulting mixture
was stirred for three hours at room temperature and washed four times; particles were stored at 80 °C until usage. Representative rmIL-12 drug elution profiles and scanning electron microscopy
(SEM) nIL-12 images are displayed in supplementary Figure S1A and S1B, respectively.

K7M2 syngeneic orthotopic BALB/c mouse model of metastatic OS
K7M2 murine OS tumor cells (ATCC CRL-2836, ATCC) were kindly donated by Dr. Kurt
Weiss, MD (University of Pittsburgh Medical Center, Pittsburgh, PA) in April 2014 and
transfected non-virally with the Promega luc2 reporter vector (luc-K7M2) as previously described
(34). Luc-K7M2 cells were Mycoplasma free and their identity confirmed in 2018 via IDEXX
BioResearch Case #6926-2018 (ID 3). For the orthotopic inoculation, luc-K7M2 cells (1 x 106)
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suspended in DMEM media were injected intratibially into 30 mice as previously described (34).
Four weeks later, 12 mice with the smallest and most similarly-sized IVIS-confirmed primary
tumors were randomized into three log-scale dose treatment groups 1) low dose (0.1 mg nIL-12),
2) medium dose (1 mg nIL-12), and 3) high dose (10 mg nIL-12). One week following IVISconfirmation of primary tumors, mice underwent amputation of their tumor-bearing limbs as
previously described (34). At 12 weeks post-inoculation, mice were euthanized. A schematic of
the full experimental design can be seen in Figure 1. The dose group and disease status for each
nIL-12 treated mouse are shown in supplementary Table S1.

Time point cheek bleeds in OS tumor-bearing mice
Prior to inoculation with tumor cells (week 0), all 30 male BALB/c mice were cheek bled
to collect 100 µL whole blood for baseline immunophenotyping. Cheek bleeds were repeated at
first sign of palpable primary tumor (week 4), prior to amputation of the affected limb (week five),
and again at weeks 6 (T1), 8 (T2), 10 (T3), and 12 (euthanasia/EUTH), as shown in Figure 1.

nIL-12 treatment of OS tumor-bearing mice
Twelve tumor-bearing mice were randomized into three n = 4 dose groups; 0.1 (low), 1
(medium), or 10 mg (high) of nIL-12 were suspended in 0.1% MSA in sterile DPBS. Mice received
their first dose of nIL-12 following IVIS confirmation of palpable primary tumors, and then at
weekly time points thereafter for a total of eight doses, as shown in Figure 1. Each nIL-12 dose
was administered intraperitoneal (i.p.) in a total volume of 500 µL.

In vivo imaging system (IVIS) imaging of OS tumor-bearing mice
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Animals were IVIS-imaged from the first sign of palpable primary tumor and at weekly
intervals thereafter using the IVIS Spectrum CT imaging system (PerkinElmer Life Sciences,
Waltham, MA) with Living Image version 4.5 Software to monitor disease burden. At each
session, mice received 150 mg/kg i.p. D-luciferin (Caliper Life Sciences, Hopkinton, MA); to
visualize metastatic disease in the lung, mice received an additional 15 mg/kg of intranasal Dluciferin (approximately 30 µL). Images were captured using auto-exposure within the
predetermined interval of maximum bioluminescence.

Flow cytometry (FC)
Red blood cells were lysed with Red Blood Cell (RBC) Lysis Solution (Miltenyi Biotec,
Auburn, CA). Single cell suspensions were split and incubated with optimized lymphoid (L) and
myeloid (M) antibody panels (supplementary Table S2) according to the manufacturer’s
instructions; a minimum of 1 x 104 events were analyzed for each sample.

Histology
Histology was performed on the lungs of all nIL-12-treated mice that did not have IVISpositive pulmonary metastases at euthanasia; the metastatic rate of the untreated control group was
assessed via a combination of histology and IVIS positivity. Lungs of nIL-12-treated mice were
immediately harvested en bloc following euthanasia, placed in neutral buffered formalin, and
mounted on a microtome; 50 µm sections were obtained every 250 µm and stained with
hematoxylin and eosin, and specimens were analyzed for the presence or absence of metastases by
a board-certified pathologist.
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Statistical Analysis
To determine significance between categorical clinical data (metastatic and disease-free
rates), two-sided chi-squared tests were used. To compare the NK percent populations in
peripheral blood between healthy and diseased nIL-12-treated mice, average values for both
groups were determined at each time point and the standard deviations (SD) calculated; statistical
significance was determined via unpaired two-tailed t tests.

Results

Both low and high doses of free rmIL-12 induce TCE and PMN-MDSC myelocytosis while
high doses induce additional NK cell depletion in peripheral blood of healthy BALB/c mice
at 48 hours
In mice, the specific toxicities associated with recombinant IL-12 therapy are strain
dependent (35). Therefore, we first tested the ability of rmIL-12 to induce immunotoxic events in
BALB/c mice to provide a reference for monitoring nIL-12-associated toxicities. It was observed
that both low (100 ng) and high (100 µg) doses induced significant increases in TCE at 48 hours
in all three T cell populations surveyed, including CD45+CD8-CD4+ helper T cells, CD45+CD4CD8+ cytotoxic T cells, and CD45+CD8-CD4+Foxp3+CD25+/- regulatory T cells (Figure 2).
Furthermore, both doses induced strong PMN-MDSC myelocytosis at 48 hours, with low and high
doses producing an average increase of 43.6% and 62.54%, respectively (Figure 3); however, only
high dose rmIL-12 induced significant NK cell depletion (Figure 4). Helper and cytotoxic T cells
were also decreased in response to both low and high dosages; however, smaller effect sizes and
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substantial variability decreased the statistical power, and a larger n will be needed to determine
significance (data not shown).

nIL-12 treatment reduces metastatic disease and increases disease-free rate in OS tumorbearing mice at 12 weeks
Between all three nIL-12 dose groups, the immunophenotypes assessed across all seven
time points were surprisingly uniform (supplementary Figure S1A-H). Therefore, we conducted
further analyses on combined (n = 12) data to assess the nIL-12 response irrespective of dose. As
such, we compared the metastatic and cure rates of the 12 nIL-12-treated OS tumor-bearing mice
to 34 untreated tumor-bearing mice from previous experiments. It was observed that treated mice
had a combined 35.3% reduction in metastatic disease at 12 weeks, which was significant (p =
0.007). Further, the percentage of disease-free “healthy” (i.e., metastasis and local-recurrence
negative) mice in the nIL-12 treated group was 33% versus 5.9% in the untreated group, which
was also significant (p = 0.008); these data are displayed in Table 1.

Peripheral blood NK cell percentages above 8.21% at primary tumor amputation separate
non-metastatic from metastatic mice at 12 weeks
Of the 12 tumor-bearing mice that received nIL-12, it was observed that four were
completely healthy and eight had residual disease at 12 weeks. As there can be considerable NK
cell heterogeneity within mice of the same strain (36), we investigated whether differences in the
NK cell immunophenotype could provide insight into whether nIL-12-treated mice achieve
complete (i.e., “healthy” mice) or incomplete/no responses (i.e., “diseased” mice). Indeed,
significant differences in NK cell percentages were found between healthy and diseased mice at
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both amputation and T3 time points (Figure 5A). Following the first dose of nIL-12 at palpable
primary tumor (PT), healthy mice had steady-state NK cell percentages in blood for the duration
of the study, whereas the NK cell percentages of diseased mice dropped significantly at time point
T3 and remained low at euthanasia. Importantly, diseased mice showed a significant decrease in
NK cell percentages at amputation (AMP), a time point that proceeds the development of
metastases in the majority of OS patients (2). We also investigated whether there existed an NK
cell “threshold” at amputation, below which nIL-12-treated mice have worse outcomes. To do this,
the median NK cell percentage in peripheral blood was determined for nIL-12-treated mice at
amputation. Next, mice were stratified into two groups based upon whether their NK cell
percentages fell above or below the median; remarkably, mice with NK cell percentages above the
median had a significantly lower metastatic rate than those with NK cell percentages below the
median (16.67% versus 66.67%, respectively; p = 0.038, Figure 5B).

Discussion

While immunotherapies are currently being used to treat a variety of different tumors, there
is extreme heterogeneity amongst patient responses (37). Even within inbred laboratory mouse
strains, immunological variables are pervasive; indeed, immune-related gene polymorphisms, Tcell repertoire diversity, gut microbiome diversity, variations in interactions with investigators
(e.g., surgeries), and unique allelelic variations contribute to immune heterogeneity (38-42).
Obviously, immune variability amongst humans is astronomically greater; therefore, it is essential
to perform longitudinal real-time asessments of immune status to continually match the most
effective therapeutic to the patient.
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The current method for monitoring immunotherapy efficacy is limited to evaluating disease
burden, which is restricted by instrument detection limits and often misleading (e.g.,
pseudoprogression and hyperprogression) (43-45). Previous studies from our group have
highlighted both the feasibility and clinical utility of using real-time systemic immunophenotyping
to uncover tumor immune escape mechanisms and identify targetable malignancy-induced
immune deficits (8). As such, this manuscript describes our preliminary in vivo investigation of
the efficacy of nIL-12 therapy against metastatic OS while simultaneously conducting real-time
immunophenotyping to assess systemic immune responses.
It was observed that nIL-12-treated mice, irrespective of dose, showed significantly better
outcomes than untreated mice. Further, the decrease in metastatic rates was linked to increased
NK cell percentages in peripheral blood at amputation. The observation that a particular
component of the blood immunophenotype (NK cell percentage > 8.21%) could potentially
distinguish between complete and non-responders at such an early clinical time point (amputation)
has obvious clinical implications. It is possible that the observed treatment effects are mediated by
IL-12-dependent NK cell activation and repletion, although more data will be needed to test this
hypothesis (1, 15). However, as NK cells play an integral role in tumor immunosurveillance, it is
reasonable to assume that immediate correction of NK cell deficits and/or increased activation may
lead to regression of metastatic disease in OS patients (6, 8, 11-13, 46).
Although the current study does not offer conclusive evidence regarding immunemonitoring of drug-related toxicites, we have provided a solid foundation for well-informed
hypothesis generation. Indeed, the free rmIL-12 toxicity study highlighted IL-12-induced toxicities
specific to BALB/c mice that could be surveyed alongside nIL-12 treatment, namely TCE status,
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PMN-MDSC myelocytosis, and NK cell depletion; these changes are similar to those seen in IL12-treated humans and nonhuman primates (24-28).
Interestingly, the TCE status of nIL-12-treated tumor-bearing mice progressed similarly
across the three dose goups for all three T cell popululations assessed. Further, PMN-MDSC
myelocytosis and NK cell percentages were similar across all dose groups and time points; these
data may indicate that the study is underpowered to detect dose-dependent differences in
immunophenotype. However, it is also possible that, due to immune heterogeneity, each response
must be assessed and treated as a separate entity (i.e., using pre-treatment immunophenotype data
as baseline and making subsequent assessments relative). It is also possible that the proposed
antibody panels were not sensitive enough to determine dose-related differences in
immunomodulation, and other immune populations or activation/deactivation markers may need
to be considered. Overall, more data will be needed to make robust conclusions about using
systemic immunophenotyping to assess for nIL-12-related immunotoxicity and ultimately define
the upper threshold of the therapeutic window (i.e., immunotoxic threshold); no direct comparisons
can be made between the free and nanoencapsulated IL-12 studies included in this manuscript, as
healthy and tumor-bearing mice have significantly different background immunophenotypes (8,
47).
While the study described herein is preliminary, we have clearly established that free rmIL12 induces distinguishable changes in the BALB/c systemic imunopheneotype. Further, we have
observed that nIL-12 therapy is efficacious against metastatic OS tumors and decreases the chances
of disease relapse. Additionally, we have found that monitoring the NK cell percentages in
peripheral blood may provide important information about response to nIL-12 and outcome.
However, more controls will be needed to determine the therapeutic contributions of IL-12 and
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PLGA individually, and the exact amounts of IL-12 delivered per mg nIL-12 will need to be
calculated. Further, nIL-12 will need to be tested in female OS tumor-bearing mice to evaluate for
sex-induced differences in response rates. Regardless, we

conclude that systemic

immunophenotyping may be used alongside immunotherapy for clinical benefit, and its utility for
monitoring drug-related immunotoxicities warrants further investigation; these data support the
fact that systemic immunophenotyping and experimntal immunotherapies may be used hand-inhand to generate efficacious immunotherapeutic regimens for metastatic OS.
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Figure Legends

Figure 1 Schematic depicting experimental design. Thirty male BALB/c mice were cheek bled
(red arrows) for 100 µL whole blood before being inoculated intratibially with 1 x 10 6 luc-K7M2
OS tumor cells. The first 12 mice to establish primary tumors were cheek bled again and
subsequently randomized into three n = 4 nIL-12 dosing groups (low dose: 0.1 mg, medium dose:
1 mg, or high dose: 10 mg). The first dose of nIL-12 (blue arrows) was given via intraperitoneal
(i.p.) injection following IVIS-confirmation of primary tumors. Mice were imaged via IVIS and
dosed at weekly intervals thereafter, and successive cheek bleeds were performed at weeks 5, 6, 8,
10, and 12. Immediately following the week 12 cheek bleed, mice were euthanized. At week 5,
the tumor-bearing limbs were amputated.

Figure 2 rmIL-12-induced T cell exhaustion of helper, cytotoxic, and regulatory T
lymphocyte subsets in peripheral blood. Twelve BALB/c mice were cheek bled for 100 µL
whole blood (baseline) before being dosed with either 100 ng (L: low dose) or 100 µg (H: high
dose) of recombinant mouse(rm)IL-12 via retro-orbital (r.o.) injection. Mice were cheek bled again
at 24 and 48 hours (48h), and blood samples were immunophenotyped via flow cytometry. CD8CD4+ helper T cells (left, white), CD4-CD8+ cytotoxic T cells (middle, gray), and CD8CD4+FOXP3+CD25+/- regulatory T cells (right, black) were assessed for the extent of PD1+TIM3+ positivity, which is indicative of exhaustion. Shown here are T cell data from baseline and 48h
time points. Individual bars (top half) represent group averages + SD. The table (bottom half)
shows the group averages ± SD for each treatment group and T cell subset. Baseline blood samples
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(n = 4; 2 male and 2 female per group) were compared to 48h samples using unpaired two-tailed t
tests. * p < 0.05, ** p < 0.01, *** p < 0.001.

Figure 3 rmIL-12-induced polymorphonuclear-myeloid-derived suppressor cell (PMNMDSC) myelocytosis in peripheral blood. Twelve BALB/c mice were cheek bled for 100 µL
whole blood (baseline) before being dosed with either 100 ng (L: low dose) or 100 µg (H: high
dose) of recombinant mouse(rm)IL-12 via retro-orbital (r.o.) injection. Mice were cheek bled again
at 24 and 48 hours (48h), and blood samples were immunophenotyped via flow cytometry. Shown
here are PMN-MDSC data from baseline and 48h time points. Individual bars (top half) represent
group averages + SD. The table (bottom half) shows the group averages ± SD for each treatment
group. Baseline blood samples (n = 4; 2 male and 2 female per group) were compared to 48h
samples using unpaired two-tailed t tests. * p < 0.05, ** p < 0.01, *** p < 0.001.

Figure 4 IL-12-induced decrease of circulating Natural Killer (NK) cells. Twelve BALB/c
mice were cheek bled for 100 µL whole blood (baseline) before being dosed with either 100 ng
(L: low dose) or 100 µg (H: high dose) of recombinant mouse(rm)IL-12 via retro-orbital (r.o.)
injection. Mice were cheek bled again at 24 and 48 hours (48h), and blood samples were
immunophenotyped via flow cytometry. Invidual bars (top half) represent group averages + S.D.
The table (bottom half) shows the group averages ± SD for each treatment group. Baseline blood
samples (n = 4; 2 male and 2 female per group) were compared to 48h samples using unpaired
two-tailed t tests. * p < 0.05, ** p < 0.01, *** p < 0.001.
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Figure 5 Blood NK cell percentages above 8.21% at amputation separate non-metastatic
from metastatic mice at 12 weeks. nIL-12-treated OS tumor-bearing mice were separated into
two groups based upon disease status at 12 weeks including n = 8 diseased (metastasis and/or local
recurrence positive) and n = 4 healthy (both metastasis and local recurrence negative) mice. (A)
Average (± SD) percentage of NKp46+ Natural Killer (NK) cells in the peripheral blood of healthy
(tumor burden negative at 12 weeks, green circles) versus diseased (tumor burden positive at 12
weeks, red triangles) compared across seven time points for 12 weeks. *, p < 0.05; **, p < 0.01;
***, p < 0.001 using unpaired two-tailed t tests. (B) Mice were stratified based upon their NK cell
percentages in peripheral blood at amputation. Each bar represents the extent to which that
individual mouse’s NK cell percentage deviated from the median value (8.21%). The metastatic
rate of mice above the median was compared to that of those below using a one-sided chi-squared
test; pmet = p value for the metastatic rate between groups with NK cell percentages above and
below the median at amputation.

Supplementary Figure S1 rmIL-12 elution profile and morphology of nIL-12. (A)
Representative in vitro nIL-12 elution profile over the course of 15 days. 100 billion particles
suspended in 0.5 mL of protein release buffer (10% heat-inactivated fetal bovine serum in DPBS)
were incubated at 37 °C with vigorous agitation over 15 days. Every 24 hours, the supernatant was
sampled by pelleting, aspiration, and buffer replacement; protein concentrations were determined
via ELISA. (B) Representative scanning electron micrograph of nIL-12 particles showing the
characteristic spherical morphology and submicron diameter.
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Supplementary Figure S2 Pertinent lymphoid and myeloid lineage immunophenotypes for
nIL-12-treated OS tumor-bearing mice by dose group. At the first sign of palpable primary
tumors, 12 OS tumor-bearing male BALB/c mice were randomized into three groups of n = four
and treated with i.p. nIL-12 at weekly intervals. Each group received the same dose (0.1 mg
[low/orange square], 1 mg [medium/purple triangle], or 10 mg [high/blue circle]) for a total of
eight doses across 12 weeks. Mice were cheek bled for 100 µL whole blood at seven time points
throughout the study for immunophenotyping purposes. Shown here are eight pertinent
components of the systemic (peripheral blood) immunophenotype for each dose group, including
(A) NKp46 NK cells, (B) CD8-CD4+ helper T lymphocytes, (C) CD4-CD8+ cytotoxic T
lymphocytes, (D) CD8-CD4+Foxp3+ regulatory T lymphocytes, (E) PD-1+TIM-3+ helper T
lymphocytes, (F) PD-1+TIM-3+ cytotoxic T lymphocytes, (G) PD-1+TIM-3+ regulatory T
lymphocytes, and (H) CD11b+Ly6Clo/-Ly6G+ PMN-MDSCs. Individual data points represent the
group average ± SD across all seven time points for each immune constituent. INOC = inoculation
(week 0), PT = IVIS-confirmed primary tumor (week 4), AMP = amputation of tumor-bearing
limb (week 5), T1 = post-amputation time point 1 (week 6), T2 = post-amputation time point 2
(week 8), T3 = post-amputation time point 3 (week 10), EUTH = euthanasia (week 12).
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Table 1: nIL-12 treatment reduces metastatic disease and increases cure rates in OS
tumor-bearing mice at 12 weeks.
Group
Untreated (n = 34)
nIL-12 (n = 12)
p

Proportion Metastatic Proportion Disease-free
0.853

0.059

0.5

0.33

0.007

0.008
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Supplementary Table S1: Disease (local and systemic) status of nIL-12 treated mice by dose
at 12 weeks.
Mouse ID number

Dose

Pulmonary MT Local RC

2

Medium (1 mg)

Positive

Negative

3

High (10 mg)

Negative

Positive

4

High (10 mg)

Negative

Positive

5

Medium (1 mg)

Negative

Negative

6

Low (0.1 mg)

Negative

Negative

11

Medium (1 mg)

Positive

Positive

15

High (10 mg)

Positive

Positive

18

Low (0.1 mg)

Positive

Positive

19

High (10 mg)

Positive

Negative

22

Low (0.1 mg)

Negative

Negative

25

Low (0.1 mg)

Negative

Negative

28

Medium (1 mg)

Positive

Positive

MT = metastasis; RC = recurrence
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Supplementary Table S2: Lymphoid (L) and myeloid (M) lineage antibody panels
ANTIGEN/DYE
LIVE/DEAD
CD4
CD8
CD335 (NKP46)
CD279 (PD-1)
FOXP3
CD366 (TIM-3)
CD25
CD11B
LY6C
LY6G
MHC CLASS II
CD274 (PD-L1)

PANEL
Lymphoid
Myeloid
Lymphoid
Lymphoid
Lymphoid
Lymphoid
Lymphoid
Lymphoid
Lymphoid
Myeloid
Myeloid
Myeloid
Myeloid
Myeloid

CLONE

FLUOROCHROME
Far red

RM4-5
53-6.7
29A1.4
J43
MF23
5D12
3C7
M1/70
HK1.4
RB6-8C5
114.15.2
10F9G2

PE-Cy5
APC-Cy5.5
APC-eFLuor 780
PE-CF594
PE
BB700
BV510
PE-CF594
AF700
PE-Cy5
APC-eFluor 780
PE-Cy7
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MANUFACTURER
Life Technologies, Fisher
Scientific
BD Biosciences
Southern Biotech
Invitrogen
BD Biosciences
BD Biosciences
BD Biosciences
BD Biosciences
BD Biosciences
BioLegend
Invitrogen
Invitrogen
BioLegend
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Overall Conclusions
The immune microenvironment of primary OS tumors has been extensively related to
prognosis in multiple contexts. Additionally, it has been documented that certain systemic immune
deficits can be associated with the development of OS tumors (1-9). However, these data have not
led to increases in survival for metastatic OS patients (10, 11). Our work has built upon these
foundations

by

developing

protocols

for

measuring

the

evolving

tumor

immune

macroenvironment of metastatic individuals in real-time. We have identified that OS immune
deficits are propagated throughout the course of disease progression. Furthermore, by determining
that the immune system changes in direct response to increasing tumor burden, we have identified
therapeutic targets that may present opportunities for therapeutic intervention.
We have developed an immunocompetent mouse model that closely resembles the clinical
course of disease in patients. With the introduction of luciferase into the tumor cells, this model
allows for real-time tracking and quantification of pulmonary metastatic disease burden to a high
degree of sensitivity while preserving the integrity of the antitumor immune response.
Investigators can now test experimental immunotherapeutics in vivo while monitoring and
adjusting therapy to meet disease burden in real-time.
We have also developed antibody panels that allow for monitoring of the tumor immune
microenvironment across multiple tissues along the entire course of disease progression. It was
found that the outstretched arm of malignant immunomodulation extends far beyond the primary
tumor and throughout the entire organism. Also, similar to that described for primary tumors, data
from the spleens of tumor-bearing mice provide evidence that the M1/M2 convention alone is not
appropriate to describe systemic Mφ polarization in OS. Furthermore, we have determined that
immunotherapy can be used to directly affect malignancy-induced immunomodulation, which can
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be measured using specific antibody panels. Lastly, we present exciting data from blood showing
that NK cell percent population and the M-MDSC P[1]/M[II] ratio change in direct response to
disease burden and can be easily measured from a peripheral venous blood draw. It is possible that
these parameters may have clinical utility in OS for diagnostic, prognostic, and therapeutic
purposes.

Future Directions
The next steps to be taken are two-fold. First, it is obvious that the panels described in this
manuscript must be translated to humans. Very few immunophenotypes translate directly between
humans and mice on a one-to-one basis (12). Therefore, it is imperative that these findings be
validated in human patients with the proper panels. Moreover, it will likely be essential to develop
and maintain large data sets, as many patients, time points, and tissues will be included in the
analyses. Such data sets may be filed on a per-patient basis and include demographics, diagnosis,
treatment, co-morbidities, as well as any clinical components that change along the course of
disease. We hope to use these large datasets to discover trends that describe the real-time capacity
of the antitumor immune response to control disease progression. Not only would this data have
prognostic and diagnostic utility, it may act as a guide to identify what specific immune deficits
could be corrected with therapy. Therefore, the second step is to evaluate and test the malignancydefining immunophenotypes described herein for their ability to respond dynamically to
immunotherapy. One such preliminary experiment is described in Chapter 4, where NK cells are
used to define a treatment threshold for nanoscale IL-12 therapy.
The long-term goal of this project is described in Figure 7, which combines endogenous
(tumorigenic and exogenous (immunotherapeutics) immunomodulation in a single hypothetical
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clinical scenario. Here, a patient presents to the clinic with a primary tumor and is diagnosed with
OS. An initial blood immunophenotype is taken, and an individualized immunotherapeutic
treatment plan is constructed. The initial immunophenotype analysis identifies a deficit in a certain
immune parameter “X,” and immunotherapy is started (box 1, red arrow) to correct it. At a followup appointment (box 2), a second immunophenotype is taken and parameter “X” is shown to have
increased to within the therapeutic window (previously determined to be the range in which most
patients develop an effective antitumor immune response). At the third (box 3) follow-up
appointment, immunophenotyping shows that the parameter has dropped to the lower threshold of
the therapeutic window, and the patient is given a second dose of the immunotherapeutic (red
arrow). However, at the next appointment, immune parameter “X” is shown to be approaching the
upper limit of the therapeutic window, above which has associations with higher morbidity due to
increased risk of TCE. No immunotherapy is given at this time point. Finally, the patient presents
at a follow-up appointment with the parameter at the center of the therapeutic window and no
additional dose is delivered.
Over 100 years ago, Dr. Coley recognized the importance of the antitumor immune
response and used a crude mixture of microbial products to promote inflammation (13). Now, a
multitude of technologies exist for the creation of detailed immunophenotypes from any tissue in
the body (14-18). As demonstrated throughout this manuscript, once the immune components that
vary predictably and in direct response to relevant immunomodulatory forces are determined,
systemic immunophenotypes may be created that allow clinicians to monitor disease progression
and adjust therapeutic regimens in real-time. From the data presented in this manuscript, NK cells
and the [P1]/[MII] M-MDSC ratio appear to be the most promising candidates to include when
immunophenotyping OS patients; however, as both of these cell types play important roles in many
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cancers, it is possible that these concepts translate to other malignancies (19-24). Indeed, while
each specific tumor type and patient come with their own unique sets of immunological variables,
the prognostic significance of strong cell-mediated antitumor immune responses and
immunosupportive Mφ polarizations are common themes throughout all immunogenic tumor
types; therefore, we hypothesize that once systemic immunophenotyping comes of age, it may be
used across multiple cancer types to assess the extent of disease progression, identify targetable
immune deficits allowing for treatment adjustments in real-time, and even determine the
therapeutic windows for strong immunostimulatory agents like IL-12 whose benefits have thus far
been offset by toxic side effect profiles.
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Figure 7. Schematic depicting a hypothetical clinical scenario describing the long-term goal of the project. 1)
Patient presents to clinic with tumor and is diagnosed with OS; preliminary immunophenotyping identifies a
potentially correctable immune deficit in some immune parameter “X” and the appropriate immunotherapy is given
(red arrow) 2) At first follow-up, parameter “X” has responded to therapy and is now within the therapeutic window;
patient is on track for a good overall prognosis 3) At second follow-up, parameter “X” has dropped to the lower
threshold of the therapeutic window and is in danger of tumor immune escape; patient is given a second dose of
appropriate immunotherapeutic 4) At third follow-up, parameter “X” has rebounded and is now at the upper level of
the therapeutic window; patient is in danger of immune stimulation and is not given a dose at this time 5) At fourth
follow-up, parameter “X” has returned to a safe value within the therapeutic window and is not given a dose at this
time.
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ABSTRACT
Osteosarcoma (OS) is the most common primary malignancy of bone and patients with metastatic disease
or recurrences continue to have very poor outcomes. Unfortunately, little prognostic improvement has
been generated from the last 20 years of research and a new perspective is warranted. OS is extremely
heterogeneous in both its origins and manifestations. Although multiple associations have been made
between the development of osteosarcoma and race, gender, age, various genomic alterations, and
exposure situations among others, the etiology remains unclear and controversial. Noninvasive diagnostic
methods include serum markers like alkaline phosphatase and a growing variety of imaging techniques
192

including X-ray, computed tomography, magnetic resonance imaging, and positron emission as well as
combinations thereof. Still, biopsy and microscopic examination are required to confirm the diagnosis and
carry additional prognostic implications such as subtype classification and histological response to
neoadjuvant chemotherapy. The current standard of care combines surgical and chemotherapeutic
techniques, with a multitude of experimental biologics and small molecules currently in development and
some in clinical trial phases. In this review, in addition to summarizing the current understanding of OS
etiology, diagnostic methods, and the current standard of care, our group describes various experimental
therapeutics and provides evidence to encourage a potential paradigm shift toward the introduction of
immunomodulation, which may offer a more comprehensive approach to battling cancer pleomorphism.

Key Words: osteosarcoma; metastatic osteosarcoma; bone sarcoma; treatment for sarcoma; bone cancer

Compliance with Ethics Guidelines: This article is based on previously conducted studies and does not
involve any new studies of human or animal subjects performed by any of the authors.
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INTRODUCTION

Osteosarcoma (OS) is an osteoid-producing malignancy of mesenchymal origins. This high-grade tumor
is the most common primary malignancy of bone and is often fatal in both children and adults. While
primary bone cancers represent less than 0.2% of all cancers (1), according to the National Cancer
Institute SEER (Surveillance, Epidemiology, and End Results) program, their frequency has been
increasing by 0.3% per year over the last decade (2). While OS occurs most frequently in patients
between five years of age and early adulthood, incidence peaks again in the older (>65) populations and
has been associated with pre-existing Paget’s disease and prior radiation therapy (3-7). Collectively, the
metaphysis of the lower long bones, specifically the distal femur and proximal tibia, are the most
commonly involved primary sites, with patients over 25 displaying a greater variety of bony locations (3).

Metastatic disease is classified by location as either pulmonary or extrapulmonary and is the major cause
of OS-related death (8-10). While bony metastases are associated with poorer prognoses (with reports of
13% survival at five years [11]), the lung is involved in approximately 80% of cases (12) and subsequent
respiratory compromise is responsible for most of the death toll (13). Compared with a potential cure rate
of over 60% in patients presenting with nonmetastatic disease (12,14), those with detectable metastases at
the time of diagnosis (approximately 15-20% [15,16]) have the poorest overall prognoses (17-22), with
reports of five-year survival rates as low as 19% (17,23). Moreover, even in the subset of patients free of
primary metastases, 40% will go on to eventually develop a secondary metastasis (12); in one study,
survival rates of patients with nonmetastatic high-grade OS with subsequent metastases were 23% at five
years and 0% at four years for pulmonary and bony metastases, respectively (24).

In contrast to distant pulmonary and extrapulmonary metastases, skip lesions (also known as skip
metastases or synchronous regional bone metastases) are local and yet potentially more serious metastatic
complications. These small, anatomically isolated cancerous foci are distinct from the primary tumor and
194

located either within the same bone or transarticular to it (25,26). Classically, they are associated with
extensive metastatic dissemination, robust therapeutic resistance, and particularly poor prognoses (27-29).

Similar to those with metastatic OS, patients with recurrent disease have comparably dismal five-year
post-relapse-overall-survival (PROS) rates (18). In addition, features such as axial tumor site (30,31),
male sex (30), and advancing age (31) have all shown correlation with inferior patient outcomes. Notably,
the pre-operative histologic response to neoadjuvant chemotherapy, as judged by the extent of tumor
necrosis, offers some of the most important predictive value regarding overall patient survival (30, 3234).

ETIOLOGY AND GENOMICS

OS etiology is complex and not well understood. The molecular pathogeneses and genetics of OS are vast
and extremely heterogeneous (35), with discrepancies in the literature regarding its demographic and
environmental influences further complicating the story. Most cases are sporadic; however, increased risk
has been associated with multiple germline mutation disorders including hereditary retinoblastoma (36,
37), Rothmund-Thomson syndrome (38, 39), Li Fraumeni syndrome (40), and Bloom syndrome (41)
among others.

Classically, alterations in the Retinoblastoma (Rb) gene have been strongly associated with a
predisposition for developing OS (43-44) and loss of heterozygosity has been reported to occur in up in
40-70% of cases (45-49). Additionally, altered p53 loci, which have been reported to occur in
approximately 10-39% of cases (49-59), display synergistic tumorigenic properties (50,60-62). Whole
genome sequencing studies have attempted to elucidate recurrent chromosomal structural patterns, most
recently with loci at 6p21.3 and 2p25.2 displaying potentially genome wide significance (63,64).
However, despite these and countless other genetic similarities discovered across cell lines, OS continues
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rapidly modifying its genotype thus making potential targeted molecular therapeutics increasingly
impractical. To date, no single genetic target has proven therapeutically successful and this wealth of
information has yet to lead to a significant decrease in mortality (35).

As per the central dogma, this genotypic heterogeneity has translated into a wide variety of
macromolecular biomarker expression profiles with potentially useful clinical implications. Indeed,
phenotypic trends have been found and characterized across various OS cell lines. Multiple studies have
identified characteristic protein and mRNA expression profiles showcasing anomalous levels of ErbB-2
(65,66), cathepsin D (67), FBXW7 (68), miR-421 (69), and HMGB1 (70) among others. It has also been
suggested that matrix-Gla protein expression may play a role in facilitating tumor spread to the lungs
(71). However, as of yet, the true diagnostic, etiologic, and clinical significance of these biomarkers is
ongoing and controversial.

Apart from genetic mutations and expression profiles, studies have also discovered correlations between
poor prognosis (or increased incidence) and various demographics such as male gender (72), old age
(73,74), height (75), and African American descent (76). Others have suggested an association between
bone growth and incidence rates (77-81), but the relative strength and importance of this relationship have
been challenged (82). Environmental factors that have been associated with increased risk of future OS
development include exposure to radiation (6,7), teriparatide usage (83), and consumption of fluorinated
drinking water in childhood (84,85); however, more recent studies have disputed the latter two
relationships (86-89).

DIAGNOSIS AND PATHOLOGY

Due to the complex nature of primary bone malignancies, diagnosis of OS is best accomplished via a
comprehensive multidisciplinary approach (90). Often, the first sign of potential bone malignancy is
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intermittent pain around the affected area with or without a palpable mass (91). When involving areas
around the knee joint, pain exacerbated by weight bearing may manifest as a limp; occasionally, patients
will present with a recent bout of bone trauma (92). As previously mentioned, any older adult with a
history of Paget’s disease has an increased risk of developing OS, most notably of the pelvis (93), and this
transformation is associated with a poor prognosis (94).

Various serum markers have been investigated for their utility in diagnosing and tracking progression and
recurrence. Alkaline phosphatase (ALP) and lactose dehydrogenase (LDH) are useful serum biomarkers,
with ALP carrying the most diagnostic value in OS (95,96). ALP has also been shown to correlate
positively with tumor volume, which carries additional useful prognostic implications (95-97). LDH has
also been shown to correlate with tumor volume; however, the correlation is weaker than for ALP and is
mainly a result of nonspecific metabolic demand (96). If disease is suspected, the first step is to gather
plain radiographs of the involved bone and adjacent joint. Any abnormal films then warrant further
radiological investigation of soft tissue involvement and possible primary lung metastasis via magnetic
resonance imaging (MRI) and computed tomography (CT), respectively (98). Bone scintigraphy (BS) is
often used in conjunction with CT to identify metastases and the presence or absence of metastatic disease
remains one of the most important predictors of patient outcome (98, 99). For a more detailed, flow-chart
style approach to patient work-up, please refer to the guidelines put forth by the National Comprehensive
Cancer Network (NCCN) for bone cancer, Version 2.2017 (100).

Although they have not yet taken the place of BS in OS diagnosis, various experimental test procedures
such as positron emission tomography (PET) scans are currently being investigated for their potentially
superior ability to diagnose and track the progression of bone cancers. In 2009, Costelloe et al.
demonstrated that combined PET/CT could be used to reliably predict the progression-free survival
(PFS), overall survival, and extent of tumor necrosis in OS (101). Studies have also suggested enhanced
sensitivity with the use of fludeoxyglucose- (18F-FDG)-PET-CT over BS for detecting metastases (102).
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Hyung-Jun Im et al. (2016) used a similar technique to show that initial baseline metabolic tumor volume
and total lesion glycolysis have independent prognostic value in determining survival in pediatric
osteosarcoma populations (103). Importantly, combined PET/CT scanning has been shown to accurately
determine the extent of histological osteonecrosis and may offer a less invasive alternative to the typical
biopsy-requiring Huvos grading system (104), as previously described (105). Please refer to Table 1 for a
list of test properties, including sensitivity, specificity, and a brief note on diagnostic application (as
indicated by the study from which those numbers were derived). Note, however, that despite the
promising aspects of these non-invasive techniques, a biopsy is always required to confirm the diagnosis
(106). As such, proper disease management mandates tissue collection with the correct identification of
the specific histologic subtype (107). While many subtypes exist and correlate specifically to
corresponding chemotherapeutic responses (108), the unifying histological feature is the presence of
osteoid-producing malignant cells (106).

Incisional or core needle biopsy is the final step in the diagnostic process (98) and the tumor is staged
using the Musculoskeletal Tumor Society staging scheme (109) or the American Joint Commission on
Cancer (AJCC) system. In the AJCC system, the tumor is described based on four important factors
represented by letters (110): T (primary tumor size), N (spread to regional lymph nodes), M (metastasis),
and G (grade). Each letter is then assigned a particular number (e.g., T1) that describes the tumor’s
pathologic extent (T, N, and M) and histological appearance (G). Once assigned its corresponding
TxNxMxGx code, the tumor can then be grouped into its corresponding stage, with Stage 1A being the
most localized and Stage IVB the most invasive. This information can be used to determine prognosis,
assess response to therapy, and monitor disease progression (111).

Osteosarcoma subtypes include osteoblastic, chondroblastic, fibroblastic, small cell, telangietactic, highgrade surface, extra-skeletal, and other lower grade forms including periosteal and parosteal (112). Based
upon their histological appearances, OS subtypes can be grouped into three categories: high-grade,
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intermediate-grade, and low-grade. Parosteal OS is a low-grade subtype that is fibroblastic in appearance
and limited to the bone surface; however, with time, it may progress to involve deeper structures. For this
and other low-grade subtypes, treatment involves surgery alone and carries a favorable prognosis.
Periosteal OS is chondroblastic on histology and is the only subtype that falls into the intermediate-grade
category. Depending on extent of invasion, treatment for intermediate-grade OS often includes systemic
chemotherapy. High-grade OS, which includes the classic osteoblastic subtype, is the fastest growing and
most aggressive group. The majority of OS subtypes fall under this category and include osteoblastic,
chondroblastic, fibroblastic, small cell, telangiectatic, high-grade surface, and extra-skeletal.
Telangiectatic OS is notable for its profuse vascularity and scant osteoid production, which often
complicates tissue biopsy and radiographic identification, respectively (113). Telangiectatic OS also
carries with it an anatomical predilection to the epiphyseal region of the bone. All high-grade OS should
be considered micrometastatic at diagnosis and treated with surgery and systemic chemotherapy.
TREATMENT

The current standard for osteosarcoma treatment employs neoadjuvant chemotherapy, surgery, and then
post-operative adjuvant chemotherapy. Multiple different chemotherapy regimens containing anywhere
from two to seven drugs have been used (98,114,115). The four drugs that have shown consistent activity
are cisplatin, doxorubicin, high-dose methotrexate with leucovorin rescue, and isofosfamide with or
without etoposide. A recent meta-analysis showed that patients who were treated with three drugs had a
superior outcome to those that received two drugs. However, there was no benefit in using four drugs
compared to three drugs (116). Indeed, adding standard or high-dose ifosfamide significantly increased
toxicity while having negligible effects on outcome (117, 118) which was recently confirmed by an
international trial which showed that there was no benefit in adding high-dose ifosphamide plus etoposide
to the cisplatin, doxorubicin, methotrexate combination (MAP) (119). Therefore, MAP multi-agent
chemotherapy is the first-line treatment and the standard of care at the present time. For a more thorough
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investigation of OS chemotherapeutics, please refer to the meta-analysis conducted in 2011 by Anninga et
al. (116).

Neoadjuvant (pre-operative) chemotherapy greatly increases relapse-free survival (RFS) of patients with
non-metastatic disease (120, 121). Furthermore, it allows for tumor categorization into histological
response subgroups, which has significant prognostic and clinical value and provides the opportunity to
alter the post-operative treatment strategies (122). The goal for a positive treatment with neoadjuvant
chemotherapy is to achieve at least 90% necrosis on the surgically resected tumor (122). If the percent
necrosis is below 90% at resection after neoadjuvant treatment then the post-resection adjuvant
chemotherapy regimen can be altered. However, changing the chemotherapy regimen post-operatively
based on response has not been shown to have a positive impact on patient outcome (119); indeed,
another finding from the EURAMOS-1 randomized control trial series has reported increased toxicity and
secondary malignancies from intensifying chemotherapy regimens (adding both ifosfamide and etoposide
to MAP therapy, i.e., MAPIE) for poor responders (123). For full treatment guidelines with detailed
workup flow charts, please refer to the NCCN guidelines for bone cancer, Version 2.2017 (100).

SURGERY AND RADIATION THERAPY

Surgical excision usually involves tumor resection with negative margins, as multiple studies have linked
positive margins with an increased risk of local recurrence (LR) and inferior survival (124). Classically,
Enneking et al. described four different types of surgical margins: intralesional, marginal, wide, and
radical (125). An intralesional margin, as the name suggests, is obtained when the specimen is taken from
within the tumor itself. Although these margins have little therapeutic utility, they are often used for
biopsies and have diagnostic purposes. Marginal and wide margins remove the lesion en bloc, with wide
leaving a substantial border of normal tissue. This border of normal tissue surrounding the tumor is
absolutely paramount in the treatment of OS. Despite these definitions, however, the proper margin to
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obtain on a case-by-case basis has been continually met with controversy; to date, no general consensus
has been born out of the literature. In 2012, a retrospective cohort of 47 patients found no significant
difference in LR between groups with close (tumor < 5mm from resection margin) and wide (tumor >
5mm from resection margin) margins (126). The following year, Jeon et al. suggested that negative tumor
margins correlate with significantly lower risks of LR in bone and perineurovascular resection planes
while having little influence on LR in soft tissue (127). Furthermore, there is also evidence to support that
the risk of LR is higher in patients treated with closer margins (113). In either case, when adequate
margins cannot be achieved, amputation should be considered (128). Naturally, limb-salvage is greatly
preferred over amputation; over 85% of patients are candidates for this type of procedure (129-132).

In patients with disseminated disease, the complete resection of pulmonary metastases is vital when
possible (133, 134), as lung metastectomy has been shown to significantly prolong survival in this
population (135, 136). Patients with recurrent unresectable metastases usually have poorer prognoses,
even when treated aggressively with pre-operative chemotherapy (137). For recurrent or refractory
disease, some studies have suggested that incorporating etoposide into the chemotherapy treatment
regimen may be beneficial (138); however, these data are controversial and associated with severe
toxicities (139). Whenever possible, surgical resection of recurrent disease is first-line over systemic
therapy, which is less effective and reserved for unresectable cases (20). Radiation therapy may also be
used to help clear microscopic or minimal residual disease when substantial surgical resection is not
possible (140); however, for a majority of cases, radiation is not used.

NEW THERAPEUTIC APPROACHES

Effective new OS therapies have plateaued over the last several decades; this lack of new treatment
strategies is reflected by unchanging survival rates (3,141). As OS cells tend to exhibit extreme genetic
pleomorphism, therapeutic attempts to target specific cell receptors and intracellular signaling molecules
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have not significantly increased survival. In addition, and likely as a result of its pleomorphism, OS cells
exhibit strong chemotherapy resistance, most notably in the 15-20% of patients initially presenting with
detectable metastases at the time of diagnosis (15), and who consequently have the poorest prognoses (1722). Therefore, MAP adjuvant treatment strategies have had minimal beneficial effects on this subset of
patients (142); as such, a number of alternative therapeutic modalities have been investigated.

Various biologics and small molecules have been used to target cell surface receptors and downstream
signaling pathways involved in OS pathogenesis. For example, as HER2 is often expressed in a subset of
OS cell lines and has been associated with poorer prognoses (143), a phase II trial was conducted using
trastuzumab to target HER2-positive OS; however, despite minimal drug reactions and additional
toxicity, no significant difference in groups was observed (144). Pappo et al. (2014) conducted a similar
phase II trial targeting another receptor commonly expressed by malignant cells, IGF-1R (145); again,
clinical responses were underwhelming (146). The PI3K/mTOR pathway (147, 148) and mitogenactivated protein kinases (148, 149) have also recently been recognized as potential targets and their
therapeutic significance is currently under investigation.

Over the past few decades, increasing evidence has suggested that platelets and other mesenchymal cells,
notably the PDGFR-alpha-R for OS (150), can assist tumor cell pathogenesis (151). Indeed, Labelle et al.
(2011) showed that platelet-tumor cell interactions, mediated by activation of transforming growth factor
(TGF)-beta/SMAD (small mothers against decapentaplegic) and nuclear factor (NF)-kappa-B, could
promote metastasis by inducing an epithelial-mesenchymal-like transition (152). As such, Takagi et al.
(2014) was able to significantly inhibit platelet-induced OS cell proliferation by blocking Akt-mediated
downstream signaling using sunitinib (153). Likewise, sunitinib has since been shown to reduce tumor
burden and lung metastasis in mice (154); however, the clinical significance of these initial data is yet to
be determined.
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Elucidating the mechanisms of OS’s robust chemoresistance has yielded other potentially promising
therapeutic targets. Recently, it has been shown that HMGB1-induced autophagy contributes to OS
chemotherapy resistance (155); hence, this and other chemoresistance-promoting pathways provide the
means for new therapeutic approaches and their inhibitors deserve further investigation. Other potential
therapeutics currently under investigation include zoledronic acid (156) and even the natural phenolic
compound, curcumin (157).

Due to the vast heterogeneity of OS molecular profiles (35-40, 63, 64), the future of OS treatment may be
moving away from targeted anti-oncogenic paradigms and toward more generalized
immunomodulatory/immunoeditory approaches (158). Cancer immunotherapy, although still in its
infancy, attempts to enhance tumor immunogenicity and stimulate tumorocidal activity, thereby
reallocating the burden of disease clearance back to the patient’s own body. Nonspecific immunogens,
cytokines, adoptive T-cells, vaccines, oncolytic virotherapies, and checkpoint blockades have all shown
potential therapeutic promise (159). If deemed clinically advantageous, these new immunotherapeutics
will likely be administered as adjuvants and integrated into the current standard of care.

Muramyl tripetide (MTP), which has been shown to activate NF-kB (160) and increase circulating levels
of TNF alpha and interleukin-6 (IL-6) in patients with OS (161), can be packaged within liposomes (162)
and injected (163, 164). This liposomal product (Mifamurtide) allows for particle ingestion by monocytes
and macrophages and the subsequent activation of their cytotoxic function against tumor cells (165).
Tumor-associated macrophages, although mostly thought of as being pro-tumorigenic (166), have been
found to play a potentially significant role in preventing metastasis in high-grade OS (167). In patients
with no clinically detectable metastases and in those with resectable disease, the addition of Mifamurtide
to multi-agent chemotherapy has been shown to significantly increase event-free survival (EFS) and
overall survival with a 29% reduction in the mortality rate at eight years (168). The addition of
Mifamurtide also improved the outcomes of patients who presented with metastases at the time of
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diagnosis (169). A therapeutic synergism of MTP with zoledronic acid on primary tumor progression has
also been suggested (170).

There have also been attempts to target immunotherapy directly to the lungs via the use of aerosols, which
have the potential benefit of lowering systemic toxicity by being delivered directly to the site of action
(171). OS relapse most commonly occurs as pulmonary metastasis (106), with patient survival often
being below 30% (172, 173) and as low as 14% (20) in these cases. Granulocyte-macrophage colony
stimulating factor (GM-CSF), a molecule with multiple roles in immune regulation and phagocyte
maturation (174), was recently used in a phase II trial of post-relapse OS patients to investigate its effect
on disease-free survival (DFS). However, despite the ability to reach adequately high doses with minimal
side effects, no significant improvement in survival was seen (175). While these results are
disappointing, they may indicate that the immunomodulatory effects of GM-CSF alone were not enough
to influence a tumorocidal environment. Unfortunately there was no investigation of whether GM-CSF
treatment resulted in any biologic effect on the lung tumor nodules. Therefore, it is hard to assess
whether this therapy resulted in the desired effect in terms of activating an immune response in the lung.
Thus, the possibility remains that the lack of therapeutic effect was secondary to the inability of GM-CSF
to stimulate an immune response in the lung. Indeed, there is growing evidence to support that the
chemical profile of tumor microenvironments comprises an astonishingly complex constellation of
signaling molecules in various distributions (176, 177) and it is highly possible that further manipulation
may be necessary to achieve an effective tumorocidal environment (178). As such, Zeidner et al. (2014)
and Wang et al. (2001) have showed that combinations of GM-CSF with interferon (IFN) and IL-12
therapy improved outcomes for chronic myeloid leukemia patients (179) and increased antitumor effects
against murine hepatocellular carcinoma (180), respectively. Another more recent immunotherapeutic
attempt at combatting OS pulmonary metastasis with combination immunotherapy included aerosol IL-2
with adjuvant natural killer (NK) cell infusions, which has shown enhanced efficacy compared to IL-2 or
NK cell infusions alone (181). Other cytokines, including IL-15 and IL-12, have been shown to increase
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natural killer cell-mediated lysis of chemotherapy-resistant OS cells (182) and suppress pulmonary
metastasis formation (183), respectively.

IFN immunotherapy has also shown promise in the treatment of OS. IFN-α, while initially recognized for
its ability to inhibit viral replication, is now used in the treatment of a variety of different solid and
hematological cancers (184). In OS, it has been shown to suppress tumor invasion as well as enhance the
cytotoxic effects of cisplatin (185). In 2015, Bielack et al. conducted an international randomized,
controlled trial comparing the efficacy of MAP therapy alone versus MAP plus pegylated interferon
alpha-2b in 2260 registered patients; however, the results were complicated by insufficient patient
adherence and no statistical difference in outcome was found (186). In 2015, Gao et al. revealed that IFNlambda1, a relatively new member of the interferon family (187), inhibits the invasive properties of MG63 human osteosarcoma cell lines in vitro (188). Another in vitro study showed that INF-gamma can
enhance the ability of γδ T cells to target and kill HOS and U2OS OS cell lines (189).

As it is now widely accepted that tumors often promote suppression of the immune system in order to
facilitate their pathogenesis (190), many immunotherapies have shown promise by targeting
immunoregulatory cell surface markers. Programmed death ligand 1 (PD-L1) and cytotoxic Tlymphocyte-associated protein 4 (CTLA-4) are surface receptors involved in down-regulating the
cytotoxic T cell response (191-193) and their blockade has been implicated in the treatment of a variety of
cancers (194). Interestingly, combined blockade of PD-L1 and CTLA-4 has been shown not only to
completely eliminate metastatic osteosarcoma in murine models, but also to induce immunity to further
inoculation (195, 196).

CONCLUSIONS
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Over the past 25 years, altering or intensifying the chemotherapy regimens for newly diagnosed
osteosarcoma patients has failed to improve the 65-70% long-term survival. The only success in
improving patient outcomes was the addition of Mifamurtide to the three-drug or four-drug regimen.
Combining Mifamurtide with chemotherapy increased long-term survival from 70-78% at eight years
(168) and improved the outcome of patients who presented with metastases at diagnosis (169). This
improvement shows that immunotherapy is effective against this cancer. As OS therapies move forward
over the next five years, it is likely that both immunostimulation and suppression blockade
immunotherapies will play emerging roles. The genetic heterogeneity and morphological adaptability of
OS necessitates a more comprehensive treatment approach, as the disease’s molecular repertoire is too
vast to be treated successfully by targeted therapies alone. Successful treatment will almost certainly
require a combination of these different techniques to best achieve an effective tumorocidal environment;
the key will lie in recognizing what specific role each immune cell plays and how best to assist its
function.
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Table 1: OS serological and radiological test properties with diagnostic applications.

Test
Serum ALP (96)

Sensitivity
0.78

Specificity
0.94

Application
-Correlation (r = 0.5) with tumor
volume
-Most descriptive for osteoblastic
subtype

Serum LDH (96)

0.82

0.97

-Correlation (r = 0.4) with tumor
volume
-Describes tumor metabolic
demand

Spiral CT (197)
FDG-PET (197)

0.75
0.5

1.00
0.98

PET/CT (198)

0.95

0.98

Pulmonary metastases
Pulmonary metastases;
confirmation of CT abnormality
Bony metastases (examinationbased analysis)

BS (198)

0.76

0.97

Bony metastases (examinationbased analysis)

PET/CT + BS
(198)

1.00

0.96

Bony metastases (examinationbased analysis)

FDG-PET/CT
(199)

0.947

Not reported

Initial staging or assessment of
recurrent disease
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Abstract
Osteosarcoma is rare and little improvement in survival rates has occurred in the last 25 years
despite modern chemotherapeutic treatment. Bioluminescent cell lines for the modeling of
osteosarcoma have shown success in tracking metastases in vivo, but commonly use adenoviral
vectors to transfect the native cell line with bioluminescent reporters. The purpose of this study
was to develop an orthotopic model for metastatic osteosarcoma capable of in vivo monitoring of
metastatic and primary tumor burden in an immunocompetent mouse and compare that model to
its wild type pathogenesis. K7M2 cells were transfected using a plasmid vector and were stable
after 12 weeks. Thirty-four female BALB/c mice aged four to five weeks underwent orthotopic
implantation of either wild type (n=12) or transfected (n=22) K7M2 cells in the proximal tibia.
Mice were monitored for tumor growth and weekly In Vivo Imaging System (IVIS) imaging was
performed to monitor for pulmonary metastasis. Although tumors developed sooner in the wild
type group, no significant differences were seen compared to Transfected Group 1 in rate of
inoculation, growth rates after first detection, metastatic rate, and time between inoculation and
death. This study establishes a new murine model for metastatic osteosarcoma using the K7M2wt cell line transfected with a non-viral plasmid luciferase vector. The benefits of this preclinical
model include an intact immune system and orthotopically driven metastatic disease; this model
appears comparable to its wild type counterpart. In the future, the model may be used to examine
promising immunomodulatory therapies using bioluminescence in vivo.
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Introduction
Primary osteosarcoma is rare and has an incidence of 800 new cases diagnosed yearly, with half
of cases diagnosed in children.1 Five-year survival rate for localized disease is 60-80% and a
dismal 15% with a metastatic presentation.2 Complete surgical resection with reconstruction in
combination with neo-adjuvant and adjuvant chemotherapy is the mainstay of treatment. However,
with the addition of modern chemotherapeutic agents, little progress has been made in patient
survival rates in the past 25 years.

Multiple factors contribute to the difficulty of developing new therapies, including a low incidence
of disease and rapid clinical course with the onset of metastasis. However, because of the poor
survival outcomes, new treatment modalities are crucial. Immunotherapy is an innovative
approach to treating osteosarcoma. Spurred by the observation that patients who develop postoperative infections have increased survivorship, the goal of immunotherapy is to harness the
beneficial effects of a pro-inflammatory response while limiting destructive side effects.3-5 Most
current murine models of osteosarcoma are insufficient to examine immunomodulation because
the models use immunodeficient animals.6-10 In an attempt to study tumor burden and metastatic
progression in vivo, a model of metastatic osteosarcoma in immunocompromised mice using the
luciferase vector and bioluminescent imaging was recently established.11,12. However, the use of
an orthotopic driven metastatic model in an immunocompetent model is needed.

Metastatic disease is of particular interest in osteosarcoma; the ability to monitor such progression
is paramount in determining the efficacy of novel treatments. Methodologies that are currently
available to detect disease in vivo include the use of micro computed tomography (micro CT) and
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magnetic resonance imaging (MRI). These modalities have high sensitivity to detect metastasis in
murine models, with the lowest detection limits of 600 um in the lungs.13 However, drawbacks
include need for prolonged anesthesia to complete the scan partly because images are obtained
between respirations to produce the best resolution. Further, machine capacity often allows for
only one animal to be imaged at a time.

In osteosarcoma research, bioluminescent imaging has recently emerged as an important method
for tracking both primary tumor burden and metastatic spread. It has the advantage of in vivo
monitoring in live animals, precluding the need for euthanasia to survey metastasis and tumor
burden. Its primary benefit is reduction in the number of animals required for in vivo studies.12,14,15
The in vivo imaging system (IVIS) quantifies flux produced by a reaction in which the luciferin
substrate is oxidized by the luciferase enzyme. The gene for this enzyme can be transfected into
the cancerous cell using plasmid vectors or viruses.

The purpose of this study was to develop an orthotopic model for metastatic osteosarcoma capable
of in vivo monitoring of metastatic and primary tumor burden in an immunocompetent mouse and
compare that model to its wild type pathogenesis. Most murine models consist of xenotransplants
and have limited utility in examining the interactions among the host, the microenvironment, and
the cancerous cells.16-19 In this syngeneic model, we used the highly metastatic K7M2-wt murine
cell line transfected with the luciferase gene and applied cells orthotopically to the tibiae of
BALB/c mice. We followed the progression of the tumor and metastasis using IVIS and performed
palliative amputations of the affected extremity; at euthanasia, metastatic tumor size was
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quantified and cross referenced with IVIS detection. These data were also compared to the wild
type model to determine differences in inoculation rates, tumor growth rates, and metastatic rates.

Methods
Growth and preparation of transfected and wild type K7M2 cells
The K7M2 murine osteosarcoma cell line (ATCC CRL-2836, ATCC, Manassas, VA) was kindly
donated by Dr. Kurt Weiss, MD (University of Pittsburgh Medical Center, Pittsburgh, PA) in April
2014. Mycoplasma testing is not routinely performed in our lab. The K7M2 cell line is derived by
harvesting pulmonary metastases of the K7 murine osteosarcoma cell line, reimplanting the
metastatic cells orthotopically and repeating the harvest of a pulmonary metastatic lesion. The cell
line is considered highly aggressive with a reported pulmonary metastatic rate of over 90% in
mice.

Wild Type (WT) K7M2 osteosarcoma cells were cultured in Dulbecco's Modified Eagle's Medium
(DMEM) containing 10% fetal bovine serum and 1% penicillin and streptomycin (Life
Technologies, Carlsbad, CA) to obtain 75% confluency. The cells were washed with phosphate
buffered saline (PBS) without calcium and magnesium (Corning Inc., Corning, NY) and harvested
with Trypsin (0.25% Trypsin, 0.1% EDTA in HBSS w/o Calcium, Magnesium and Sodium
Bicarbonate, Corning Inc.). The cell density was adjusted to one million cells (1.0 x 106) in 25 µL
of PBS for inoculating mice. Passage one cells were used for orthotopic implantation.

Transfected K7M2 osteosarcoma cells were prepared by adding 1.0 ml (approximately 3.0x10 5)
WT cells into each well of a six-well plate containing 1.0 ml of DMEM containing 10% fetal
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bovine serum and 1% penicillin and streptomycin. Cells were incubated at 37oC for 24 hours to
obtain 75% confluency. A 3:1 transfection ratio complex was created using ViaFect Transfection
reagent (Promega, Madison, WI) and pGL4.51 [luc2/CMV/Neo] plasmid vector (Promega)
prepared per the manufacturer’s specifications and incubated with K7M2 cells for 24 hours. The
cells were washed once with PBS, 2.0 ml of DMEM media was added to each well, and the cells
were incubated for 48 hours at 37oC. The selective drug Geneticin-418 (Life Technologies) was
then added to kill non-transfected cells. After further propagation, the cell density was adjusted to
one million cells (1.0 x 106) in 25 µL of PBS for inoculating mice. Passage one transfected cells
were used for orthotopic implantation.

Stability of transfected cell line
To assess if the luciferase reporter vector was stably passed to future generations, in vitro
bioluminescence imaging was performed for 12 weeks. For this verification, 4.5 x 105 transfected
K7M2 cells were seeded in a 12-well plate, covered with media and incubated for 24 hours which
created a final concentration of 5.0 x 105 cells per well. The media was removed just prior to
imaging and 1.0 ml of 0.5 mM luciferin was added to each well. The cells were imaged using the
In Vivo Imaging System (IVIS) Lumina II with Living Image Software (PerkinElmer, Waltham,
MA). Bioluminescent imaging was set to medium binning with an exposure time of five minutes.

Surgical implantation of K7M2 cells
All animal procedures were conducted in accordance with the Institutional Animal Care and Use
Committee (IACUC). Thirty-four female BALB/c mice age four to five weeks were purchased
from Jackson Laboratories (Bar Harbor, ME) and maintained in pathogen free animal housing
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facilities. A twelve-hour light/dark cycle was used, the animals were fed autoclaved chow, and had
access to sterile water ad-libitum.

The Wild Type (WT) group (n = 12) underwent inoculation with wild type K7M2 cells.
Transfected Group 1 (n = 10), Transfected Group 2 (n = 10), and Transfected Group 3 (n = 2) were
all inoculated with luciferase transfected K7M2 cells. Transfected Group 1 received intraperitoneal
injection of luciferin only for tumor detection. Transfected Groups 2 and 3 received both
intraperitoneal and intranasal luciferin for tumor detection, along with shaving of the operative
limb and chest prior to imaging.

The animal was weighed on a calibrated scale and placed into an anesthesia induction chamber.
General anesthesia was induced using isofluorane (Piramal Enterprises Limited, Andhra Pradesh,
India) with 100% oxygen at a rate of 2.5 liters/min until loss of the righting reflex occurred. The
animal was then transferred to a heated operating stage, placed supine, and maintained under
general anesthesia using a nasal cone at a rate of 2.5 L/min. Opthalamic lubricant was placed in
both eyes and 0.02 ml of 1 mg/ml buprenorphine SR (Wildlife Pharmaceuticals, Windsor, CO)
was injected subcutaneously using a 25 gauge needle.

The animal’s operative hind limb was prepped using betadine solution and sterilely draped. Using
sterile technique, a small incision was made over the anterolateral leg under an operating
microscope. Dissection was carried sharply to the tibia and directed proximally until the
metaphyseal flair was identified. An 18 gauge needle was then used to create a small bore hole in
the center of the tibia at the level of the proximal tibial flare. As soon as a small pilot hole was
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created, the needle was angled approximately 45° in the sagittal plane and advanced until the
cortex was penetrated. The needle was twisted gently which caused the anterior flare/cortex to
separate from the intact tibia, creating a cortical window. The posterior cortex remained intact to
avoid a bicortical fracture. Twenty-five microliters of PBS containing one million K7M2 cells was
then injected into the defect. The muscle was pulled back over the bone and the skin was closed in
a running fashion using a 4-0 vicryl suture. Animals were awakened and recovered in the usual
fashion.

Clinical monitoring of mice
Mice were monitored weekly until a visible tumor was appreciated after which they were measured
daily using digital calipers (greatest width x by greatest length). Tumor volume was calculated
using the formula V=(length x width2)/2. The mice were graded using our institution’s tumor
burden scoring system weekly. This scoring system ranges from 0 to 60 (0 = healthy animal; 60
= requires euthanasia) and is based on general appearance (fur, mucus membranes, response to
stimuli), body condition (well nourished, thin, cachectic), neurologic status (head tilt, bulging eyes,
depression, self-mutilation, limb paralysis, seizures), tumor appearance (ulcerated, limits ability to
ambulate, bleeding), and respiratory rate (normal, increased rate/effort, severe distress). After the
elevation of any scoring variable, the animals were monitored daily and veterinary staff was
consulted to ensure humane treatment and minimization of pain.

IVIS imaging
IVIS imaging uses a charge-coupled device camera that is able to detect light emitted from the
luciferin-luciferase reaction within the tumor bed. Once a visibly detectable tumor was identified,
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animals were imaged weekly using the IVIS Lumina II with Living Image Software to monitor
metastatic burden. After isoflurane induction, the animal was injected with luciferin (150 mg/kg)
in the intraperitoneal cavity and placed onto the imaging platform, dorsal side up. Exposure varied
between one and five minutes and bioluminescence binning was set to medium. Images were taken
approximately five minutes post luciferin injection. After the first set of images was performed,
the lower extremity (if present, see Tissue harvest below) was shielded for the second set of images.
This method improves sensitivity for small lung tumors that are below the low threshold intensity
obtained when a tumor is present in the limb (Figures 1a and 1b).

Intranasal luciferin
Ten BALB/c mice (Transfected Group 2) aged four to five weeks underwent inoculation with one
million K7M2 cells according to the same protocol as mentioned above. These mice received 30
microliters of intranasal luciferin (150 mg/kg) in addition to the intraperitoneal luciferin as
mentioned above. The operative extremity and chest of these mice were shaved prior to imaging.
Otherwise, IVIS imaging settings, exposures, and images were taken in accordance with the
protocol mentioned above. The purpose of this transfected group was to show improved IVIS
sensitivity and earlier detection of pulmonary metastatic disease using intranasal luciferin.

Tumor luminescence over time
Two BALB/c mice (Transfected Group 3) aged four to five weeks underwent inoculation with one
million K7M2 cells according to the same protocol as mentioned above. These mice received both
intranasal and intraperitoneal luciferin according to the protocol mentioned above. The operative
extremity of these mice was shaved prior to imaging. IVIS imaging settings, exposures, and images
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were taken in accordance with the above protocol. The purpose of this transfected group was to
monitor luminescence and primary tumor size over time. Mice were imaged twice weekly until the
tumor score reached 60, at which time the mice were euthanized.

Tissue harvest
Once the tumor reached sufficient volume (around 1.7 cm3), a palliative amputation of the affected
hind limb was performed. The mouse was anesthetized and analgesic was provided as described
previously. After prepping with betadine and sterile draping, a longitudinal incision was made on
the medial third of the tumor bed. The tumor was dissected away from the peritoneum, taking care
not to violate the peritoneal cavity. The femoral vessels were identified along the medial tumor
and traced toward the pelvis. Using 4-0 vicryl suture, the vessels were ligated just distal to the
inguinal ligament. The hip was disarticulated from the pelvis by sharply incising the capsule,
exposing the femoral head and dislocating it from the acetabulum with the tip of the scalpel. The
limb was amputated by circumferentially dividing any remaining soft tissue attachments in line
with the original incision. The skin edges were approximated and closed using a 4-0 vicryl suture
in a running fashion. The animal was then awakened and recovered in the usual fashion.

Weekly IVIS imaging was continued (per above) until the tumor score reached 60 or at 16 weeks
post-inoculation. At this time, the mice were euthanized using carbon dioxide asphyxiation. The
lungs were harvested en bloc and placed into a conical tube containing 10% neutral buffered
formalin (NBF). The specimens were delivered to the Pathology Laboratory for Translational
Medicine, processed, and embedded per their protocol. The paraffin blocks were mounted on a
microtome and 5 µm sections were obtained every 25 µm of sectioning until the entire specimen
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was exhausted. The slides were stained with hematoxylin and eosin. Slides were analyzed by one
author (BG) as well as a board certified pathologist to confirm the presence of metastatic disease.
The number of metastatic lesions was counted as well as the dimensions of the single largest tumor
identified in the specimen.

Results
Stability of transfected cell line
There were no significant differences in radiance of the transfected cells at baseline and at 12
weeks (3.93x106 p/sec/cm2 versus 9.71x106 p/sec/cm 2). Linear regression modeling did not reveal
significant differences in radiance of the transfected cells over time (R2=0.019, p=0.65).

Inoculation data of the wild type group
Twelve mice were inoculated (6 left limbs, 6 right limbs) with wild type K7M2 cells. The average
mouse weight was 18.73 g (range 17.5 – 21.0) at time of inoculation. Eleven of twelve mice grew
primary tumors at an average of 16.82 days (range 15 – 26) after cell implantation. One mouse
died 15 days after the inoculation; no tumor growth was noted in this mouse. Eight mice underwent
palliative amputation of their limb at an average of 12 days (range 10 - 16) after first tumor
sighting. Seven of eight survived the palliative amputation; one mouse died due to uncontrollable
hemorrhage from the femoral vessels. Three mice did not undergo palliative amputation of their
hind limb; these mice were euthanized at the time of primary tumor harvest. Average mouse weight
was 23.58 g (range 21.0 – 26.5) at time of amputation or early euthanasia and average tumor
weight was 2.72 g (range 1.90 – 4.53). A primary recurrence of the tumor was noted in six of the
eight mice. Five mice were euthanized at an average of 74 days (range 68 - 89) after inoculation
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for tumor scores of 60. All five of these mice had noted recurrent primary disease. Two mice were
euthanized at 16 weeks post-inoculation in accordance with the study protocol; neither mouse
demonstrated primary recurrence and both had a tumor score of 0 at time of euthanasia. Three
mice were euthanized at an average of 10.3 days (range 10 – 12) after first tumor sighting. At the
time of euthanasia, lung specimens were collected on 10 mice (all eight that underwent palliative
amputation and two mice euthanized at the time of primary tumor harvest) and processed for
metastatic evaluation (see below).

Inoculation data for Transfected Group 1
Ten mice were inoculated (5 left limbs, 5 right limbs) with the luciferase transfected K7M2 cells.
The average mouse weight was 18.46 g (range 16.5 - 20.8) at the time of inoculation. Nine of the
ten mice grew a primary tumor at an average of 35 days (range 27 – 55) after cell implantation.
One mouse failed to develop a tumor; this mouse was euthanized eight weeks after inoculation.
Six mice underwent palliative amputation of the affected hind limb an average of 11 days (range
9 – 18) after first tumor sighting. All mice survived the palliative amputation. Three mice did not
undergo a palliative amputation of their affected limb; one mouse died during IVIS imaging prior
to the procedure and two mice were euthanized at the time of primary tumor harvest rather than
undergoing an amputation. The average mouse weight at time of amputation or early euthanasia
was 25.2 g (range 23.5 – 26.5) and the average tumor weight was 3.06 g (range 2.06 – 4.34). Four
of the six mice that underwent palliative amputation demonstrated a recurrence of tumor growth
at the amputation site. Four mice were euthanized at an average of 87 days (range 77 – 132) after
inoculation due to a tumor score of 60. One mouse was euthanized at 16 weeks post-inoculation
in accordance with the study protocol and one mouse died in the IVIS system 91 days after
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inoculation (41 days after palliative amputation). The lungs of seven mice (all six that underwent
palliative amputation and the one mouse that did not develop a primary tumor) were harvested at
the time of euthanasia for histological analysis (see below).

Inoculation data for Transfected Group 2
Ten mice were inoculated (5 left limbs, 5 right limbs) with the luciferase transfected K7M2 cells
to study IVIS sensitivity and detection of pulmonary metastasis using intranasal luciferin. The
average mouse weight was 18.6 g (range 17.0 - 20.0) at the time of inoculation. Eight of the ten
mice grew a primary tumor at an average of 23 days (range 21 – 26) after cell implantation. Two
mice failed to develop a tumor; these mice were euthanized sixteen weeks after inoculation. Eight
mice underwent palliative amputation of the affected hind limb an average of 12 days (range 8 –
16) after first tumor sighting. Seven mice survived the palliative amputation; one mouse died due
to uncontrollable hemorrhage from the femoral vessels. The average mouse weight at time of
amputation was 23.0 g (range 20.0 – 24.0) and the average tumor weight was 2.13 g (range 1.13
– 3.0). Seven mice were euthanized at an average of 57 days (range 48 - 79) after inoculation due
to a tumor score of 60. Two mice were euthanized at 16 weeks post-inoculation in accordance with
the study protocol and one mouse died during palliative amputation. The lungs of seven mice (all
seven that survived palliative amputation) were harvested at the time of euthanasia for histological
analysis (see below).

Inoculation data of Transfected Group 3
Two mice were inoculated (1 left limb, 1 right limb) with the luciferase transfected K7M2 cells to
monitor luminescence and primary tumor size over time. The average mouse weight was 17.0 g at
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the time of inoculation. Both mice grew a primary tumor at an average of 11 days after cell
implantation. These mice were imaged twice weekly until reaching a tumor score of 60, at which
time the mice were euthanized. The lungs were not harvested for histological analysis.

Analysis
There were no significant differences between the WT and Transfected Group 1 with regard to
inoculation rate, time from tumor detection to removal, tumor weight, mouse weight at death, or
time from inoculation to time of death (any cause). There was a significant difference between
the time of inoculation to time of tumor growth and weight of the mouse at time of primary
tumor harvest, however. On average, it took 17.85 days longer for a primary tumor to develop in
the transfected mice compared to the wild type strain (p<0.0001) and the transfected mice
weighed 1.63 g more (p = 0.0175) (Table 1).

There were no significant differences between Transfected Group 1 and Transfected Group 2
with regard to inoculation rate, time from tumor detection to removal, time from inoculation to
death (days), metastatic rate, or IVIS positivity in histologically-confirmed metastasis. There was
a significant difference noted between the time from inoculation to primary tumor detection,
mouse weight at time of tumor harvest, and average primary tumor weight. On average, it took
12.2 days longer for a primary tumor to develop in Transfected Group 1 compared to Group 2 (p
= 0.0032). Tumors for Transfected Group 1 weighed 0.87 g more than tumors for Group 2(p =
0.0269) (Table 2).

Histology results
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Lungs were collected on ten of the twelve WT specimens. Lungs were not collected on one mouse
that died prior to developing a primary tumor and one mouse euthanized at the time of primary
tumor harvest. Nine of ten specimens showed evidence of metastatic disease when analyzed
microscopically. The number and size of metastatic nodules varied per mouse with a range of 1
to >10 lesions measuring 0.1 mm to 5.8 mm.

Lungs were collected on seven of ten Transfected Group 1 mice. Lungs were not collected on one
mouse that died during IVIS imaging (prior to palliative amputation) and two mice euthanized at
the time of primary tumor collection. Six of seven mice showed evidence of metastatic disease by
microscopy. Again, size and number of lesions ranged from 1 to >10 and measured 1.3 mm to 20
mm in greatest single dimension. One mouse (T17) showed nearly complete obliteration of native
lung tissue with tumor; tumor was seen within the lymph nodes as well as invading the diaphragm
(Figures 2a-c).

Lungs were collected on seven of ten Transfected Group 2 mice. Lungs were not collected on one
mouse that died during palliative amputation and two mice that failed to develop a primary tumor.
Six of seven mice showed evidence of metastatic disease by microscopy. Size and number of
lesions ranged from 1 to >10 and measured 0.1 mm to 4.0 mm in greatest single dimension. Lungs
were not collected for Transfected Group 3 mice.

Histologically, specimens revealed confluent sheets of poorly differentiated cells. There was a
spectrum of cells from those with a spindle shaped appearance, prominent chromatin, and
eosinophilic cytoplasm to those with a purely anaplastic appearance. High numbers of mitotic
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figures were appreciated. There was no statistical difference between the rate of metastasis
between the WT and Transfected Group 1 (90% WT versus 86% transfected p=1.0000).

IVIS data
Seven of ten mice in Transfected Group 1 were imaged routinely by IVIS. All primary tumors
were confirmed by presence of a bioluminescent signal from the leg region that was inoculated.
Three mice showed evidence of a pulmonary metastatic lesion by IVIS. These lesions were seen
on average 85.3 days (range 51 - 128) after inoculation with tumor cells. The smallest pulmonary
lesion that was IVIS positive measured 5.3 mm microscopically. This mouse did not show a
pulmonary lesion until 128 days after inoculation and was euthanized four days later (Figures 3a
and 3b). The largest non-IVIS positive lesion measured 2.2 mm microscopically.

Seven of ten mice in Transfected Group 2 were imaged routinely by IVIS. These mice received
intranasal and intraperitoneal luciferin, along with shaving of the operative limb and chest. All
primary tumors were confirmed by presence of a bioluminescent signal from the leg region that
was inoculated. Six mice showed evidence of a pulmonary metastatic lesion by IVIS. These lesions
were seen at an average of 50 days (range 44 – 62) after inoculation with tumor cells. The smallest
pulmonary lesion that was IVIS positive measured 1.4 mm microscopically. The largest non-IVIS
positive lesion measured 3.8 mm microscopically.

The two mice in Transfected Group 3 were imaged routinely by IVIS to monitor luminescence and
primary tumor size over time. Primary tumor was first detected on day 12 via IVIS imaging for
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both mice. Primary tumor luminescent intensity increased linearly over time as the size of the
tumor increased. There was a slight drop in intensity from day 21 to day 33 (Figures 4a-4c).

Discussion
Prior to 1975, osteosarcoma treatment was limited in scope and often ended in amputation.
Advances in chemotherapeutic agents led to the widespread use of adjuvant and neo-adjuvant
therapy. Concurrent refinement of surgical technique and a paradigm shift from amputation to limb
preserving therapy has led to an improved prognosis. Despite these advances, overall prognosis
for osteosarcoma remains grave. The most significant challenge surrounding osteosarcoma is its
potential for early metastasis and the nature of metastatic lesions that remain elusive to early
detection. Indeed, it is estimated that patients presenting with pulmonary metastases have a fiveyear survival rate of less than 20%. Whereas chemotherapeutic agent expansion in the last 20 years
has shown only minimal gains with regard to mortality, new avenues for treatment are actively
being sought, including immunotherapy.

Relevant animal models are needed to examine the response of pulmonary metastases to various
treatment agents and the primacy of an immunocompetent model cannot be understated. Further,
being orthotopically driven allows cell selection, self-seeding, and other processes to occur in vivo
that may have an effect on the pathogenesis of this disease and, in turn, on treatment success. The
resulting metastatic lesions have a unique subset of cellular characteristics secondary to all of these
processes that take part in an orthotopic model. Studies recapitulated in immunocompromised
animals,8-10,21-23 by inducing tumorigenesis via intravenous or subcutaneous cell injection, or use
of a transfection method with antigenic vectors do not exploit these essential principles.24-25
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Comparing the results of the WT cell line to Transfected Group 1, the only clinically significant
difference between the groups was the time from inoculation to detection of tumor growth. On
average, the transfected tumors took about twice as long to present; thereafter, growth rates were
similar. It is not clear why this pattern occurs, but it is consistent with other studies our lab is
conducting. We have speculated that it is likely resulting from the additional genetic material that
must be transcribed due to insertion of the luciferase vector. In vitro analysis of the transfected cell
line did not demonstrate a loss of cell viability with propagation. In vivo, inoculation rates as well
as metastatic rates appear to be similar between the two groups and consistent with previously
reported rates for this cell line.20 The smallest detectable lesion by IVIS measured 5.3 mm, which
is larger than the detection limit for MRI or micro CT. However, the specificity of the lesions is
100% in this model because tumors from this cell line will fluoresce, whereas pulmonary nodules
could be caused by factors other than cancer. The other advantage is the much shorter length of
time under anesthesia as well as the anesthesia being less deep. These issues become much more
important for survivability during testing once the animal becomes metastatic. In addition, IVIS is
a more cost effective tool and logistically easier to perform compared to MRI.

With the addition of intranasal luciferin and shaving of the chest, the sensitivity of IVIS imaging
to detect pulmonary metastasis improved. For Transfected Group 1 that did not receive intranasal
luciferin, IVIS imaging detected a signal intensity in three out of six mice with histologicallypositive pulmonary metastasis. With the addition of intranasal luciferin to Transfected Group 2,
IVIS imaging detected a signal intensity in six out of seven mice with histologically-positive
pulmonary metastasis. The sensitivity to detect pulmonary metastasis was 50% in Transfected
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Group 1 compared to an improved sensitivity of 85.7% in Transfected Group 2 with the addition
of intranasal luciferin and shaving of the chest.

Pulmonary metastasis was also detected much earlier on IVIS with the addition of intranasal
luciferin and shaving of the chest. On average, pulmonary metastasis was detected on IVIS
imaging 50 days after inoculation in Transfected Group 2 compared to 85 days after inoculation
in Transfected Group 1 that did not receive intranasal luciferin (p = 0.0568). The smallest
pulmonary lesion that was IVIS positive measured 5.3 mm microscopically in Transfected Group
1 compared to 1.4 mm microscopically in Transfected Group 2. With the addition of intranasal
luciferin and shaving, pulmonary metastasis was detected much earlier and with much smaller
histologically sized lesions. The increased sensitivity of intranasal luciferin has been confirmed in
previous studies, as one study showed a nearly ten-fold increase in sensitivity on bioluminescent
imaging when comparing intranasal to intraperitoneal delivery of luciferin.26

The utility of IVIS imaging can also be extended to monitor temporal increases in tumor intensity
as the size of the tumor increases. Temporal increases in tumor intensity was demonstrated by the
data from Transfected Group 3, which showed that the tumor intensity (photons/second) increased
linearly over time as the size of the tumor increased. There was a slight drop in intensity from day
21 to day 33, which likely corresponded to central tumor necrosis or hypoxic areas of the tumor
bed as the tumor continued to grow in size. A depiction of potential tumor necrosis or hypoxia is
well visualized in Figure 4a for mouse T41 at day 33. Based on these data, it seems reasonable to
extend the application of IVIS imaging to monitor metastatic luminescence over time.
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Khanna et al. reported the results of orthotopically implanted K7M2 cells in BALB/c mice.20 They
found a tumor take rate of 95% and a pulmonary metastatic rate of 93.3% with an average of 5.4
metastatic lesions per mouse. All mice underwent a palliative amputation of their affected hind
limb once tumor volume reached approximately 450 mm3. Tumor latency (time from implantation
to detection) was 14 +/- 3.1 days which is consistent with the WT mice in our study; however, in
our study, tumors were larger and were removed, on average, ten days sooner. Metastases in the
Khanna study were enumerated using India ink via intratracheal injection at the time of euthanasia
instead of histology which is the clinical standard. In addition, they did not use a luciferase reporter
making it impossible to perform in vivo imaging.

Sottnik and colleagues developed a luciferase transfected orthotopic model of mouse osteosarcoma
in C3H mice using the DLM8 cell line.15 A plasmid transfection process was utilized. All mice
underwent palliative amputation of their hind limbs at various intervals following implantation.
They did find that amputations performed at seven days post implantation did not develop
metastases indicating that peripheral organ seeding does not occur at the time of inoculation and
metastatic potential requires maturation of the primary tumor bed. All mice amputated after day
seven in their study developed metastatic disease by 22 days post-implantation. They did not report
the rate of IVIS positive pulmonary lesions and did not have a non-metastatic line for comparison
(the K12 cell line for the K7M2).

Miretti et al. developed an orthotopic lentiviral luciferase transfected K5 osteosarcoma model in
BALB/c mice.14 They reported all mice had IVIS detectable metastatic lesions by 45 days posttumor implantation. The wild type and transfected cell lines had similar rates of primary tumor
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and spontaneous pulmonary disease development. They did not correlate tumor size by histology
to the IVIS results. A potential drawback to this study is the use of a lentivirus transfection process
which may have an effect on tumor infiltrating lymphocytes moreso than a plasmid vector, which
was used in our study.

There are some limitations to our model. First, the K7M2 cell line is murine in origin and not
human derived. However, the utility of murine derived tumor models is well established. The use
of xenograft models is an alternative; however, it is known that tumor characteristics are influenced
by the surrounding microenvironment. Thus, invasion of murine cells may affect the
tumorigenicity. The development of metastatic disease does take time following orthotopic
implantation. However, the use of orthotopic models most closely mimics the clinical course of
cancer progression in this disease.

This study establishes a new murine model for metastatic osteosarcoma in an immunocompetent
mouse using the K7M2-wt highly metastatic cell line transfected with a non-viral plasmid
luciferase vector. Bioluminescence and histopathology confirmed the establishment of a primary
tumor and metastasis to the lungs. The sensitivity of IVIS imaging was determined by comparison
of histopathological analysis of the lungs. To our knowledge, this is the first syngeneic
osteosarcoma using the K7M2 cell line that uses bioluminescence to survey and quantify
metastatic burden. The primary benefit of the preclinical model is that the immune system is intact,
metastatic disease is orthotopically driven, and it appears to have a comparable pathogenesis to its
wild type counterpart. The model can be used to examine promising immunomodulatory therapies
in the future using bioluminescence in vivo.
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Figure Legends
Figure 1a demonstrates extensive recurrent tumor growth after palliative amputation. No
pulmonary lesions appear to be present, although T13 (middle) had evidence of a pulmonary lesion
a week prior (not shown). Figure 1b shows bioluminescent signal consistent with pulmonary
metastasis after shielding of the lower extremities. The images were taken sequentially the same
day.
Figure 2a illustrates extensive pulmonary metastatic disease by IVIS. At necropsy, widespread
disease was found with near total obliteration of the chest cavity with tumor (Figure 2b).
Histologically, the classic spindle cell morphology is appreciated, with tumor invading the
diaphragm (Figure 2c).
Figure 3a show that, at128 days post-inoculation, a bioluminescent signal was detected in the
pulmonary region of mouse T16. This lesion (Figure 3b) measured 5.3 mm histologically and
was the smallest IVIS positive lesion.
Figure 4a illustrates temporal changes in luminescent intensity over time in transfected mice T41
and T42. Figure 4b shows a linear representation of the primary tumor luminescence and tumor
size over time for mice T41 and T42.
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Figure 1

Figure 1a demonstrates extensive recurrent tumor growth after palliative amputation. No
pulmonary lesions appear to be present, although T13 (middle) had evidence of a pulmonary
lesion a week prior (not shown). Figure 1b shows bioluminescent signal consistent with
pulmonary metastasis after shielding of the lower extremeties. The images were taken
sequentialy the same day.
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Figure 2

Figure 2a illustrates extensive pulmonary metastatic disease by IVIS. At necroscopy, widespread
disease was found with near total obliteration of the chest cavity with tumor (Fig. 2b).
Histologically, the classic spindle cell morphoplogy is appreciated, with tumor invading the
diaphragm (Fig. 2c).
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Figure 3

Figure 3a shows that, at 128 days post-inoculation, a bioluminescent signal was detected in the
pulmonary region of mouse T16. This lesion (Fig. 3b) measured 5.3 mm histologically and was
the smallest IVIS positive lesion.
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Figure 4

Figure 4a illustrates temporal changes in luminescent intensity over time in transfected mice T41
and T42. Figure 4b shows a linear representation of the primary tumor luminescence and tumor
size over time for mice T41 and T42.
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Table 1. Summary of tumor characteristics comparing the wild type and transfected cell lines.
Wild Type

Transfected

11/12

9/10

16.8 ± 2.0

34.7 ± 2.2

<0.0001*

11.91 ± 0.8

12.5 ± 1.0

0.6526

Mouse Weight at Time of Tumor Harvest (g)

23.6 ± 0.4

25.2 ± 0.5

0.0175*

Average Primary Tumor Weight (g)

2.7 ± 0.3

3.1 ± 0.3

0.4490

Time from Inoculation to Death (Days)

67.5 ± 10.2

81.33 ± 11.2

0.3748

Average Weight at Death

24.35 ± 0.9

24.19 ± 1.0

0.9053

9/10

6/7

1.0000

Inoculation Rate
Time from Inoculation to Primary Tumor

P-Value
1.0000

Detection (Days)
Time from Detection of Primary Tumor to Tumor
Removal (Days)

Metastatic Rate

* Statistically significant difference, p < 0.05.
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Table 2. Summary of Tumor Characteristics Comparing Transfected Groups 1 and 2
Transfected

Transfected

P-value

Group 1

Group 2

Inoculation Rate

9/10

8/10

0.5921

Time from Inoculation to Primary Tumor

34.7 ± 2.2

22.5 ± 2.6

0.0032*

12.5 ± 1.0

12.1 ± 1.2

0.8299

Mouse Weight at Time of Tumor Harvest (g)

25.2 ± 0.5

22.6 ± 0.5

0.0037*

Average Primary Tumor Weight (g)

3.06 ± 0.26

2.19 ± 0.24

0.0269*

Time from Inoculation to Death (Days)

85.33 ± 12.6

50.17 ± 8.9

0.0568

Metastatic Rate

6/7

6/7

1.0000

IVIS positivity in histologically-confirmed mets

3/6

6/7

0.2127

Detection (Days)
Time from Detection of Primary Tumor to Tumor
Removal (Days)

* Statistically significant difference, p < 0.05.
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Chapter 8 Nanocapsule Delivery of IL-12
Justin E. Markel1, Ryan A. Lacinski1, and Brock A. Lindsey4
Abstract

Interleukin(IL)-12 is a protein that activates T cells and macrophages to kill tumor cells. However, despite this
cytokine showing strong antitumor activity in preclinical settings, translation to patients has been slowed by toxic side
effects, poor distribution to peripheral tissues, and improper dosing regimens. Osteosarcoma (OS) is an aggressive
primary tumor of bone that has shown particular responsiveness to recombinant (r)IL-12 in preclinical models.
Poly(lactic-co-glycolic) acid (PLGA) nanospheres, an FDA-approved drug delivery vector, may be viable delivery
vector for transporting biologically active IL-12 to tissues without disturbing normal homeostasis. In this chapter, we
explore the potential for using IL-12-loaded nanospheres (IL-12-NS, < 1 µm in diameter) to treat cancer, describe the
synthesis process, and examine a typical protein release profile while providing insight and future directions of
nanoscale tumor immunotherapeutics.

Section 1 Interleukin-12 immunotherapy – the past, present and future
A. Why IL-12?

Interleukin(IL)-12, a member of the IL-12 family of cytokines, has a long history of antitumor activity against a wide
range of preclinical cancer models[1, 2]. Originally characterized as a potent inducer of Natural Killer (NK) cell
cytotoxic activity, IL-12 is now recognized as a key regulator of the cell-mediated immune response and a bridge
between innate and adaptive immunity [3]. Although the immunostimulatory functions of IL-12 can be induced locally
with intratumoral (i.t.) injections, preclinical models suggest that more complete antitumor responses are achieved via
systemic administration [4]. By influencing the differentiation of CD4+ T helper (TH) cells into T helper type 1 (TH1)
cells, IL-12 coordinates antitumor immunity through pro-inflammatory M1 activation of macrophages and stimulation
of cytotoxic T (TC) cells [5-7]. Signaling through IL-12 is also crucial for the survival and reactivation of circulating
memory cells, making it an important component of long-term cancer remission [8]. Upon binding of the
heterodimeric p35p40 (p70) IL-12 protein to its type 1 cytokine receptor on the surface of T cells, Janus kinase-signal
transducer and activator of transcription protein (JAK-STAT) signaling pathways are propagated through the
downstream effector molecule STAT4 [9]. In addition to its effects on the immune system, IL-12 has strong antiangiogenic properties, making it an extremely attractive protein candidate for cancer therapies targeting metastasis
and/or highly vascularized tumors [10].
Osteosarcoma (OS) is characterized by extensive disruption of the genome [11] resulting in a plethora of neoantigens
that can stimulate an immune reaction if given the proper co-stimulatory signals [12], and evidence of IL-12’s
importance to OS immunology stems from a variety of sources: at the cytokine level, it was found that IL-12 gene
polymorphisms resulting in low serum IL-12 levels were associated with increased OS risk in a cohort of Chinese
patients, with affected individuals having significantly lower levels of circulating IL-12 compared to healthy controls
[13]. Moreover, IL-12 has been shown to upregulate Fas expression on OS tumor cells, an occurrence that inversely
correlates with metastatic potential by increasing the likelihood of Fas-Fas ligand (Fas L)-induced apoptosis [14-16].
In a preclinical murine model, specific targeting of lung metastases through aerosol gene therapy with a
West Virginia University School of Medicine Department of Orthopaedics
PO Box 9196 Morgantown, WV 26507-9196
No table of contents entries found.
4
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polyethyleneimine-transported plasmid increased parenchymal IL-12 mRNA expression while decreasing metastatic
burden [17].
At the cellular level, the relative abundance of IL-12-associated immune events in both the primary tumor
microenvironment (pTMic) and systemic tumor macroenvironment (sTMac) can influence the progression of disease.
Macrophages account for a large portion of the cellular content of OS primaries, and adopt anti- or pro-tumorigenic
phenotypes depending on activation status, namely classical (M1) or alternative (M2), respectively. Classical
activation of macrophages stimulates IL-12 production, TH1 polarization of TH cells, and the release of Type 1
interferons (IFNs) like IFN-γ that in turn stimulate additional inflammation and further M1 activation [18]. The drug
mifurmatide, a synthetic derivative of a cell wall component of Mycobacterium species, is approved in Europe for the
treatment of nonmetastatic OS and is an M1-activator of macrophages [19, 20]. Still, immunosuppressive influences
from the tumor can override IL-12 signaling cascades and cause macrophages to adopt alternative M2 phenotypes,
bestowing actions that are mainly pro-tumorigenic. These cellular changes are then reflected in both the pTMic and
the sTMac, where the immune cell composition (A.K.A., the “immunophenotype,” for more information see Chapter
“X”) can be assembled to yield insights regarding prognosis. Indeed, the presence of IL-12-secreting M1-activated
macrophages (as determined by inducible nitric oxide synthase [INOS] protein expression) in the OS pTMic has been
shown to correlate negatively with metastasis [21]. Figure 1 displays a visual summary of the major effects of IL-12
signaling.

Fig. 1: Visual Summary of the Major Effects of IL-12 Signaling

B. The Past and Present (1994-2019)
Building upon a plethora of exciting preclinical data from multiple tumor types, the first Phase I clinical trial
examining the clinical utility of intravenous (i.v.) recombinant human IL-12 (rhIL-12) for human cancer began in the
spring of 1994 [22]. Upon enrollment in the study, all subjects were administered a preliminary rhIL-12 test dose and,
if tolerated, were given a subsequent series of six high-intensity 5-day treatment cycles every fifteen days. Here,
objective tumor responses were observed in only two of the 40 subjects, with the majority of patients experiencing
lymphopenia, elevated liver enzymes (occasionally dose-limiting), flu-like symptoms, and transiently increased serum
IFN-γ levels that paradoxically diminished as treatment continued. Nevertheless, data from this study prompted a
Phase II trial in renal cell carcinoma (RCC) that ended prematurely due to dose-limiting toxicities (DLTs); it was later
realized that the test doses given to patients in the Phase I study produced an immunoprotective effect of unknown
etiology that improved drug tolerability [23]; further studies investigating the clinical utility of rhIL-12 were thus
motivated to construct more conservative regimens with designated rhIL-12 acclimation periods.
In an attempt to mitigate systemic toxicities, most subsequent studies began to move away from i.v. rhIL-12 [24] and
focus instead on subcutaneous (s.c.) and locoregional routes of delivery. One notable exception includes a 2004 Phase
II clinical trial that compared the efficacy of i.v. to s.c. delivery of rhIL-12 in relapsed and refractory non-Hodgkin’s
lymphoma (NHL). In this study, although the objective response rates were suboptimal, patients receiving i.v.
administration showed higher response rates (40%) than those dosed subcutaneously (7%); importantly, the inclusion
of a rhIL-12 primer dose coupled with less protein per treatment cycle allowed for improved patient tolerability in the
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i.v. administration group [25]. A concurrent Phase II trial conducted for advanced cervical cancer using a similar
regimen observed increased cell-mediated immune responses that did not associate with increased survival [26]. Other
studies investigating i.v. therapy used dose titration to decrease toxicity and increase the longevity of IFN-γ responses
(an effect that was shown to associate with clinical response) [27].
In the late 1990s, two Phase I clinical trials of s.c. rhIL-12 therapy in patients with advanced RCC and metastatic
melanoma showed positive responses while markedly reducing the frequency of DLTs [28, 29]. Unfortunately, future
investigations in RCC were stopped once a multicenter Phase II trial comparing rhIL-12 to IFN-α2a reported no
increased efficacy [30]. Intraperitoneal (i.p.) and intravesicular (i.vs.) injections of rhIL-12-containing solutions for
metastatic ovarian and bladder cancer, respectively, have also shown satisfactory patient tolerability without
appreciably improving survival [31-33]. Of note, one Phase II study carrying particular importance to OS cytokine
immunotherapy followed relapsed follicular NHL patients treated with s.c. rhIL-12 in combination with the anti-CD20
monoclonal antibody rituximab. Here, researchers observed decreased survival rates in the combination group versus
rituximab alone [34]; these findings were later attributed to a life-threatening state of immune system over-activation
known as T cell exhaustion (TCE) [35], characterized by lymphocyte anergy, systemic inflammatory response
syndrome (SIRS), and ultimately multiple organ failure (MOF). As TCE is a phenomenon inherently associated with
OS disease progression [36], the exhaustive side effects of IL-12 administration must be adequately addressed to
prevent further exacerbation of this deadly condition; these studies highlight both the importance of proper dosing
strategies as well as the value of an adequate immune monitoring platform (see Chapter “X”) when administering
potentially immune-exhaustive experimental therapeutics.
Although they have presented a mixed bag of clinical findings, studies investigating locoregional IL-12 delivery in
combination with other immunostimulatory cytokines, monoclonal antibodies, and radiation have also been
investigated. Direct modifications to the IL-12 protein itself, such as fusion to necrosis-targeting antibodies for
enhanced delivery to irradiated sites [37] and peptide truncation to decrease toxicity [38] have been published, as well
as the effectiveness of IL-12 administration as an adjuvant for cancer vaccination [39]. For OS, one study showed that
IL-18, a member of the IL-1 family of cytokines with similar properties to IL-12, has particular efficacy against OS
when given in combination with IL-12 [40].
Another method of IL-12 delivery include the use of genetically-engineered cell types to increase i.t. IL-12 levels
upon introduction into the pTMic. Fibroblasts, dendritic cells (DCs), mesenchymal stem cells, T lymphocytes (e.g.,
CAR T cells), and even tumor cells themselves have been engineered to release supra-physiological levels of IL-12
within the pTMic for the purposes of increasing the immunogenicity of tumor antigens [41-46]. Viruses and DNA
vaccines carrying IL-12-coding genes to metastatic sites have also been studied; in 2003, Shu-Fang Jia et al. eliminated
OS pulmonary metastases using aerosol therapy to direct an IL-12-coding polycationic DNA carrier directly to the
lungs of mice [17]. Although this method of IL-12 delivery did not translate to the clinic, it was one of the first
instances displaying the in vivo efficacy of IL-12 against metastatic OS. In 2007, a Phase I trial for pediatric cancer
(including seven OS patients) was published combining cancer vaccines with genetically-engineered IL-12 secreting
DCs; while intranodal administration resulted in antigen-specific IFN release in vitro, no OS patients displayed
noticeable improvement following vaccination [47].
Without toxic loading doses, s.c. and i.v. administration of rIL-12 does not ensure adequate distribution to peripheral
tissues. To solve this issue, IL-12 can be encapsulated within biodegradable organic polymers that release their
contents in a slow and controlled manner, thereby reducing side effects and prolonging antitumor activity. In 1999,
Kuriakose et al. showed that tumor regression with a single i.t. dose of rIL-12-loaded polylactic (PLA) microspheres
(IL-12-MS, > 1 µm in diameter) was superior to multiple doses of free rIL-12 in a head and neck tumor xenograft
model following the transfer of human peripheral blood lymphocytes [48]. These data were further supported a year
later when Egilmez et al. discovered that tumor regression from IL-12-MS was superior not only to i.t., but also i.p.
free rIL-12 in a Line-1/BALB/c murine alveolar lung adenocarcinoma model [49]. Shortly thereafter, i.t. injection of
rmIL-12-loaded PLA microspheres was found to regress primary MT-901 breast cancer tumors while simultaneously
inducing systemic antitumor immunity in the form of circulating, antigen-primed memory T cells that prevented tumor
growth following rechallenge [50].
One possible answer to many of the above problems could be rIL-12-loaded poly(lactic-co-glycolic) acid (PLGA)
nanospheres (IL-12-NS, < 1 µm) for i.v. delivery. PLGA colloidal systems provide protection for and enhance the
stability of the entrapped compound while providing enhanced delivery to target tissues. Indeed, while many other
researchers have moved towards i.t. formulations, other literature continues to support the notion that cancers
(including OS) induce systemic immune dysfunctions unrelated to the immunophenotype of the primary lesion. By
using flow cytometry to assess splenic immunophenotypes, systemic immunotherapies like anti-programmed death
ligand 1 (PD-L1) can reverse malignancy-induced immunosuppression [36]; therefore, the long-term goal is to use
the PLGA capsule as a barrier to allow safe transit of IL-12-NS through the blood to the peripheral tissues, where they
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can release their protein slowly over extended periods of time. Much of the remainder of this chapter will describe the
process of synthesizing IL-12-NS for systemic administration.
C. The Future
Analogous to human immunodeficiency virus (HIV) anti-retroviral therapy (ART), rIL-12 will most likely represent
one component of an immunotherapeutic “cocktail” tailored to the specific immunological needs of each patient. That
said, there are certain themes that have arisen from three decades of IL-12 research that must be considered, of which
PLGA encapsulation may help solve:
1. Large bolus loading doses of rIL-12 are required to ensure adequate tissue distribution when delivered
systemically, often resulting in DLTs that can be somewhat attenuated by dose escalation. Upon administration of
IL-12-NS, PLGA encapsulation delays the release of entrapped IL-12 thereby allowing for increased delivery to
peripheral tissues.
2. I.v. rIL-12 dosing regimens require multiple injections including dose titrations to prevent unwanted proinflammatory reactions (DLTs). IL-12-NS have intrinsic dose titration properties, as encapsulated protein is
released slowly and continually as the PLGA coating hydrolyzes in aqueous environments. Additionally,
preliminary in vitro data show that one sample of IL-12-NS continues to elute protein up to 14 days, which may
drastically reduce the number of injections needed per patient.
3. I.v. rIL-12 cannot be targeted to specific areas of interest without direct modification of the protein itself, which
may lead to decreased biological function. Due to the presence of free carboxylic acid moieties, PLGA nanospheres
can undergo a number of different surface modifications that allow for control over their in vivo biodistribution
properties; some common conjugates that have been tested include monoclonal antibodies for specific cell
targeting, albumins to increase the enhanced permeation and retention (EPR) effect, and chitosan for enhanced lung
delivery via the formation of transient microaggregates in pulmonary capillaries [51-53].
To illustrate the concept of using IL-12-NS for the treatment of OS, consider the following scenario. OS induces
systemic immune suppression in mice (Figure 2A) that can be reversed by checkpoint blockade using anti-PD-L1
(Figure 2B); that is, their systemic immunophenotype returns to baseline status (see Chapter “X” for more details).
However, baseline status does not provide enough immune stimulation to effectively reduce tumor burden in mice
with advanced disease. On the other end of the spectrum, when patients in the aforementioned Phase II study of
rituximab/rhIL-12 combination therapy for relapsed and refractory NHL succumbed to DLTs, their
immunophenotypes were pushed past stimulation and into the realm of overstimulation and TCE (Figure 2D).
However, in a background of anti-PD-L1 checkpoint blockade providing disinhibition of activated T cells, slow and
sustained delivery of low dose rIL-12 (which is generally considered safe [54]) from hydrolyzing PLGA nanospheres
to the sTMac may provide the systemic stimulation necessary to effectively reduce disease burden while still
remaining beneath the exhaustion threshold (Figure 2C); from this example, it is clear that a real-time
immunophenotypes monitoring platform, like the one described in Chapter “X”, would be of considerable value for
this application.
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Fig. 2. Hypothetical application of IL-12-NS for the treatment of metastatic OS. A) Pathologic immune suppression observed in
patients with OS. B) Systemic treatment of metastatic OS with the immune checkpoint blocker anti-PD-L1 reverses malignancy-induced
immunosuppression back to baseline but does not improve survival. C) Systemic treatment of metastatic OS with IL-12-NS in the
background of anti-PD-L1 T cell disinhibition provides adequate immune stimulation to reduce disease burden without falling into the
realm of exhaustion. D) Toxic loading doses of free IL-12, which are necessary to ensure adequate distribution to peripheral tissues, push
the immune system into a state of exhaustion leading to SIRS, MOF, and ultimately death.

Section 2 Production of IL-12-loaded PLGA nanospheres
A. Double solvent emulsion-evaporation method: the basics
Synthesizing protein-loaded PLGA nanospheres via the double solvent emulsion-evaporation (DSEE) method (AKA,
the water-in-oil-in-water [w1/o/w2] method) involves three main steps: 1) primary emulsion (w1/o), 2) double
emulsion, and 3) nanosphere isolation and purification. First, the drug of choice is suspended in an aqueous solution
to create the internal aqueous phase (w1). The internal aqueous phase (w1) is then added to a solution of organic solvent
(o) containing polymer and agitated briefly (usually via homogenization or sonication) to create the primary emulsion
(w1/o, Figure 3A); some commonly used organic solvents include dichloromethane (DCM), acetone (AC), and ethyl
acetate (EA). During this step, the emulsion can be kept in an ice bath to counteract the rise in temperature caused by
agitation. Next, the primary emulsion (w1/o) is added to the external aqueous phase (w 2) and agitated again to form
the double emulsion (w1/o/w2, Figure 3B). The w2 phase contains a stabilizer (usually polyvinyl alcohol [PVA]) to
prevent coalescence of the resulting emulsion droplets [55]. As the agitation/shear force increases, the droplets and
hence resulting particles become smaller [56]. To solidify the droplets and form particles, the organic solvent is
evaporated at the water/air interface with stirring. As the organic solvent evaporates, the PLGA precipitates thereby
encapsulating the internal aqueous phase in a spherical matrix (Figure 3C). The last step involves removal of excess
PLGA and non-encapsulated protein via a series of washes, flash-freezing, and lyophilization for long-term storage.
By minimizing contact between the internal aqueous phase and organic solvent, this method of synthesis is suitable
for the encapsulation of bioactive proteins [57].

Fig. 3. Basic process for the creation of biodegradable micro/nanospheres using the double solvent emulsion-evaporation technique.
A) The internal aqueous phase (w1), which contains the bioactive compound of interest, is combined with polymer dissolved in an organic
solvent (o) and agitated to create the primary emulsion (w 1/o). B) The primary emulsion is then dispersed in the external aqueous phase
(w2) and agitated to form the double emulsion (w1/o/w2). C) The double emulsion is stirred to remove the organic solvent via evaporation
which solidifies the droplets into micro/nanospheres.
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B. Double solvent emulsion-evaporation method of encapsulating rIL-12 w/ homogenization
The primary emulsion is formed by adding aqueous rIL-12 to a small beaker containing PLGA in DCM and agitating
on ice (Figure 4A). The double emulsion is formed by combining the primary emulsion with an aqueous solution of
PVA/NaCl and agitating for eight minutes on ice (Figure 4B); the addition of salt to the external aqueous phase
increases protein encapsulation while decreasing the surface area of the resulting product [58]. Both agitation steps in
the homogenization method are done with a standard tissue homogenizer tip set at medium speed (~ 175000 RPM).
The double emulsion is then stirred overnight at room temperature (RT) to evaporate off the DCM (Figure 4C), and
the resulting product is a mixture of both microspheres and nanospheres; the morphology of the resulting product prior
to centrifugation can be seen in Figure 4D. To remove the microspheres, the colloid is centrifuged at low g (< 1000
x g) and the resulting supernatant aspirated and stored on ice. Once microspheres are removed, the nanospheres in the
supernatant are harvested by ultracentrifuging (> 50,000 x g), washing to remove non-encapsulated protein and excess
PLGA, flash-frozen, and lyophilized for long-term storage (Figure 4E). Figure 4F displays the resulting product once
the microspheres and excess protein and PLGA are removed. Zeta potential (ζ) is a physical property that determines
colloidal stability and hence propensity of suspended particles to flocculate; IL-12-NS made via the homogenization
method (IL-12-HNS) have a ζ of -15.1 ± 1.25 mV.

Fig. 4. Stepwise procedure for double solvent emulsion-evaporation method of encapsulating rIL-12 w/ homogenization. A) To
form the primary emulsion, aqueous rIL-12 is added to PLGA dissolved in DCM and homogenized for six minutes at 17500 RPM. B) To
form the double emulsion, the primary emulsion is dispersed in an aqueous solution of 2% PVA/0.8% NaCl and homogenized for eight
minutes at 17500 RPM. C) The double emulsion is stirred overnight to evaporate off the DCM, forming the products shown by scanning
electron microscopy (SEM) in (D), a mix of microspheres and nanospheres. The red arrow is pointing to a microspheres, and the blue
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arrow is pointing to a next of nanospheres. E) The microspheres are excluded and the nanospheres harvested via centrifugation (< 1000 x
g) and ultracentriguation (> 50,000 x g), respectively. Following a series of washes, flash-freezing, and lyophilization, the final nanosphere
product. (F). Scanning electron micrograph of the nanosphere product formed via the homogenization method of PLGA nanosphere
synthesis.

C. Double solvent emulsion-evaporation method w/ ultrasonication
First, the primary emulsion is formed by using a microprobe sonicator set at 50W to agitate aqueous rIL-12 in PLGA
dissolved in DCM in an ice bath (Figure 5A). For this application, each emulsion is formed in a glass test tube to
minimize time needed to create a homogeneous mixture. The primary emulsion is then transferred to another test tube
containing 1% PVA in water, and the solution is sonicated on ice for another 10 seconds at 50W power to create the
double emulsion (Figure 5B). The double emulsion is then stirred for at least three hours to evaporate the organic
solvent, washed, flash-frozen, and lyophilized for long-term storage (Figure 5C); a scanning electron micrograph of
the final nanosphere product is shown in Figure 5D. Due to the type of agitation used, the ultrasonication method
does not require an extra isolation step as in the homogenization method. The zeta potential of IL-12-NS made via the
ultrasonication method (IL-12-SNS) have a ζ of -36.35 ± 2.85 mV.

Fig. 5. Stepwise procedure for
double solvent emulsion-evaporation method of encapsulating rIL-12 w/ ultrasonication. A) To form the primary emulsion, aqueous
rIL-12 is added to PLGA dissolved in DCM and sonicated at 50W for 10 seconds. B) To form the double emulsion, the primary emulsion
is dispersed in an aqueous solution of 1% PVA and sonicated again at 50W for 10 seconds. C) The double emulsion is stirred for three
hours to evaporate off the DCM, washed, flash-frozen, and lyophilized for long-term storage. (D) Scanning electron micrograph of the
nanosphere product formed via the ultrasonication method of PLGA nanosphere synthesis.
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Section 3 In vitro IL-12 release characterization – Elution Study
A. Characterizing nanosphere protein release profile via an in vitro elution study
Once a batch of IL-12-NS is synthesized, the next step is to characterize how the protein is released over time, called
protein elution. To conduct an in vitro elution profile, a known quantity of suspended nanospheres is shaken vigorously
at 37 °C and sampled once every 24 hours. At the end of the study, the amount of biologically-active protein eluted
each day can be measured using enzyme-linked immunosorbent assays (ELISA) and expressed as a percent of total
protein eluted throughout the entire release profile.
To understand how the encapsulated protein is released, it is important to consider the ultrastructure of a PLGA
nanosphere. When the second emulsion is formed, protein becomes wound up in tiny strands of PLGA, (much like a
ball of string), which coalesces and precipitates into a sphere as the organic solvent is removed. During this process,
protein becomes both entrapped within the polymer matrix (Figure 6A, top right panel, blue arrow) and adsorbed to
the outer surface (Figure 6A, top left panel, red arrow), producing a characteristic biphasic elution curve shown in
Figure 6B. The burst phase, which normally occurs between baseline and two days, is due to the adsorbed protein on
the surface of the nanospheres being released upon resuspension in aqueous medium (Figure 6A, bottom panel). The
controlled release phase is due to entrapped protein (Figure 6A, bottom panel), and is released slowly over time as
the PLGA hydrolyzes via the reaction in Figure 6C. The elution characteristics can be altered by varying a number
each synthesis parameter, however, an in-depth discussion of nanosphere modification is beyond the scope of this
book.

Fig. 6. Release characteristics of a
typical protein-loaded PLGA nanosphere elution profile. A) Top two panels: PLGA spheres were loaded with FITC-tagged bovine
serum albumin (BSA) and imaged via confocal microscopy to show the distribution of protein both adhered to the surface (left) and
entrapped within the matrix (right). Bottom panel: Schematic showing the mechanism of protein release from PLGA nanospheres creating
a biphasic release profile, shown in (B) as a percent of total protein released. C) Schematic showing the hydrolysis of PLGA into lactic
and glycolic acid.

B. Elution Profiles: Homogenization and Ultrasonication Methods

We will now compare the release profiles of IL-12-HNS and IL-12-SNS loaded with recombinant mouse
(rm)IL-12. At eight days, rmIL-12-loaded-HNS at a concentration of 1 billion particles/mL released ~3500
pg of p70 rmIL-12, or 0.7 pg per 100,000 particles. SNS, which have higher solubility and less tendency to
flocculate, were suspended at a concentration of 100 billion/mL and released a total of ~230,000 pg of
rmIL-12 over 14 days, averaging 0.46 pg per 100,000 particles. Therefore, although IL-12-HNS have a
more efficient protein release profile per capsule, it is likely that SNS will carry more clinical impact due
to their superior solubility properties and extended release profile. Figures 7A and 7B shows the release
profiles as a function of cumulative protein eluted per day/total protein eluted for both HNS and SNS,
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respectively. Approximately 70% of the total protein for both methods is released over the first 48 hours
during the burst phase, where the remaining 30% is spread over 6 (7A) and 12 (7B) days during the
sustained release phase for HNS and SNS, respectively.

Fig. 7. Comparative analysis of
rmIL-12-HNS and rmIL-12SNS elution profiles. A) Elution of 1 billion rmIL-12-HNS/mL over the span over eight days showing the
characteristic biphasic release profile, with ~70% total IL-12 being released within the burst phase (Day 0 – Day 2) and the remainder
during the sustained release phase (Day 2- Day 8). B) Elution of 100 billion rmIL-12-SNS/mL over the span over 14 days showing the
characteristic biphasic release profile, with ~70% total IL-12 being released within the burst phase (Day 0 – Day 2) and the remainder
during the sustained release phase (Day 2- Day 14). Y values display the cumulative protein eluted per day/total protein eluted; each value
is an average of n = 2 biological replicates.

Section 4 Conclusions and Future Perspectives
IL-12 has a long and controversial history as an agent for cancer immunotherapy. However, one central theme that
has emerged over the years is that proper dosing is a key factor determining both safety and therapeutic efficacy. As
of yet, the line separating what is helpful from harmful has not been established, and the number of variables with
potential immunological influences (e.g., tumor type, co-morbidities, prior therapies, age, sex, etc.) further
complicates the scenario. Therefore, the next step will be to conduct extensive dose escalation trials that evaluate the
effects of rIL-12-NS on the systemic immunophenotype, paying careful attention to the warning signs of
overstimulation. Additionally, for future attempts at IL-12 tumor immunotherapy to be successful, a reliable and
efficient means of assessing immune status must be developed; as such, this project has evolved alongside that
discussed in Chapter “X”.
The importance of establishing systemic immunity to a malignancy is supported by earlier observations that suggest
that the antitumor efficacy of rIL-12 is maximized upon systemic administration. Indeed, studies have shown that
tumor-induced immunosuppression can be reversed with immunotherapy, and that immunotherapy is only successful
following the activation of secondary immune organs [59]. However, systemic rIL-12 delivery in humans has thus far
proven difficult due to toxic loading doses being needed to ensure adequate tissue delivery. PLGA encapsulation,
which effectively reduces the amount of available rIL-12 at one time, may be a promising method for delivering
controlled doses of IL-12 to tissues without massive disruption of normal homeostatic processes. In theory, unlike the
destructive inflammatory syndromes induced by introducing free rIL-12 into the bloodstream, IL-12-NS-laden tissues
would slowly and continually influence the sTMac to favor pathways that support cell-mediated immunity while
shifting the macrophage polarization status towards an M1 bias. In turn, priming tissues for a cell-mediated immune
response may increase the chances that circulating effector cells can respond appropriately when encountering tumor
antigen.
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Abstract Osteosarcoma, the most common malignant bone tumor in children and adolescents, remains a
complicated disease to treat; no new treatments have been developed in more than three decades. Due to the
importance of the immune system in osteosarcoma disease progression, immunotherapeutic strategies have been
explored to potentially improve long-term survival. Understanding the immune system in osteosarcoma will be key to
optimizing treatments and improving patient outcomes. Many subtypes of white blood cells have been studied in
association with osteosarcoma disease progression. In particular, neutrophil-lymphocyte ratios are correlated with a
poor prognosis. Macrophage polarization can be altered late in osteosarcoma progression to an M2
immunosuppressive phenotype, which promotes tumorigenesis and metastasis. This relationship is likely due to the
association between M2 macrophages and T H2 cells, which are also immunosuppressive. T cells in osteosarcoma
express markers of dysfunction, including PD-1, CTLA-4, and Tim-3. Furthermore, Tregs are an important cell type in
osteosarcoma that prevent an appropriate immune response to the malignantly transformed cells. Similarly, myeloid
derived suppressor cells (MDSCs), which are upregulated in osteosarcoma, cause immunosuppression and have
specifically been shown to inhibit NK cells. Utilizing this knowledge about the immune changes in osteosarcoma,
antibodies targeted against PD-1, PD-L1, and CTLA-4 have been employed in osteosarcoma treatment, termed
checkpoint blockade. Additionally, the immune system has been stimulated and primed for an immune response with
cytokines, CAR-T cells, dendritic cells, and peptide vaccines. Tracking the immune system throughout disease and
treatment of patients with osteosarcoma could allow for a personalized approach to immunotherapy.

I. Introduction
Despite being the most common malignant bone tumor in children and adolescents, osteosarcoma remains a difficult
tumor to treat. Over the past three decades, no new treatments for osteosarcoma have been developed; thus,
improvements in long term survival have remained stagnant since the first addition of chemotherapy for the disease.
Nonetheless, although osteosarcoma has been deemed a highly pleomorphic, immunologically cold tumor historically
speaking, more recent data has suggested immunotherapy may be successful. 1 Recent studies have shown
osteosarcoma to be an immunologically “hot” cancer as both the innate and adaptive immune systems are affects not
only in the local tumor microenvironment but also systemically. In order to overcome non-response and
immunoresistance, both of which have been problematic in immunotherapy, it logically follows that we should also
attempt to understand the impact of osteosarcoma on the immune system. One mechanism by which these alterations
can be assessed involves immunophenotyping various tissue samples from the patient, including tumor biopsies,
metastatic tumor biopsies, splenic biopsies, and serum samples. Immunophenotyping, commonly performed by
immunohistochemistry (IHC) or flow cytometry, allows us to quantify particular subsets of white blood cells using
highly specific fluorescent antibodies. Furthermore, the cell surface epitopes marked by these antibodies can also be
quantified to assess the status of the immune cell in question. Thus, this chapter outlines the known immunological
alterations that occur with osteosarcoma disease progression and subsequently discusses the immunotherapies that
have been explored to combat this malignancy.
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II. Assessing Osteosarcoma Disease Progression
A. Osteosarcoma Immunology: Innate Immune System

Myeloid Lineage
1. Granulocytes
The most prominent granulocyte in osteosarcoma immunopathology is the neutrophil, which is one of the main players
in the acute inflammatory response. Following injury or infection, the affected tissue releases interleukin(IL)-8, which
is a neutrophil chemoattractant and degranulation agent. Upon arrival to the site of the insult, they release
inflammatory mediators and phagocytose cellular debris. As neutrophils are one of the first immune cells to arrive in
infected tissues, it is likely that they contribute to the tumor microenvironment although the details of this are not well
defined. Indeed, little work has been done to examine neutrophils in the context of osteosarcoma disease progression;
however, there are a few studies with some indirect evidence to support a role for neutrophils in tumor progression.
Postoperative infections have been associated with significantly increased event-free survival and 5-year overall
survival (100% and 100% with infection versus 54% and 43% without, respectively; P = 0.01 2), while high neutrophillymphocyte ratios (NLR) are associated with poor prognoses (P < 0.05); furthermore, multivariate Cox regression has
shown that NLR is a top risk factor associated with death in osteosarcoma patients.3, Osteosarcoma patients have also
been found to have high serum levels of IL-8, as well as polymorphisms in its coding gene that are linked to increased
likelihood of metastasis.4,5 High expression levels of another neutrophil chemoattractant, CXCL5, has also been linked
to advanced clinical stage and metastasis.6 Interestingly, both IL-8 and CXCL5 have been found to have direct effects
on osteosarcoma tumor cells themselves by inducing migration and invasion. Anther cell type, related to neutrophils,
polymononuclear myeloid derived suppressor cells (PMN-MDSCs) will be discussed further in the MDSC section
below.

2. Mononucelar Phagocytic System: Monocytes, Macrophages, and Dendritic Cells
a. Monocytes
Monocytes are antigen-presenting cells (APCs) that are one of the main means of communication between the innate
and adaptive arms of the immune system. They are produced in the bone marrow and migrate to areas of inflammation
where they differentiate into macrophages or dendritic cells. Early in vitro studies found that monocytes were cytotoxic
to osteosarcoma tumor cells leading to the belief that they contributed to tumor immunosurveillance7, 8; however,
multiple in vivo studies have suggested a more immunosuppressive role for monocytes in the context of a developing
malignancy. Notably, it was discovered that in osteosarcoma patients, circulating T cell immunoglobulin and mucindomain containing-3 (Tim-3) positive monocytes suppress antitumor T helper type 1 (T H1) responses by interacting
with Tim-3+ T cells, naïve CD4+ T cells, and galectin-9 (Gal-9)-expressing T regulatory cells (Treg). Additionally, a
group in 2017 found clinical relevance in the ratio of absolute peripheral monocyte count after initial treatment divided
by absolute monocyte count before initial treatment (monocyte ratio); when a patient’s monocyte ratio was greater
than 1, he or she was over 5 times more likely to develop metastases compared to patients with ratios less than or
equal to 1 (OR 5.367; 95% CI, 3.083-9.343).9 Osteosarcoma cells release the cytokine IL-34 which recruits
inflammatory monocytes to areas of tumorigenesis; upon arrival, they mature into tumor-associated macrophages
(TAM) discussed in the subsequent section.
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b. Macrophages
Macrophages, derived from circulating monocytes, reside in many tissues throughout the body and phagocytose
cellular debris, tumor cells, and pathogens. Tissue-resident macrophages can produce a diverse response to
inflammation, infection, healing, and cancer based on the cytokines in the local microenvironment. Furthermore,
macrophages can be delineated into a number of subsets based on their cell surface expression, including classically
activated (M1) macrophages, alternatively activated (M2) macrophages, TAMs, and myeloid derived suppressor cells
(MDSCs). Specifically, in tumorigenesis, TAMs of the M1 subtype have a protective effect while the M2 subtype and
MDSCs suppress anti-tumor immune responses.10 The M1/M2 TAM subpopulations will be discussed here while
MDSCs will be discussed in a subsequent section.
In osteosarcoma, immunohistochemical stains of resected primary tumors have shown macrophages to be the
predominant infiltrating cell type.11 A number of studies have shown a correlation between TAMs and metastases in
osteosarcoma. 10-12 Similar to their activity in other solid tumors, M1 macrophages have been shown to suppress
tumorigenesis in osteosarcoma. One in vitro study demonstrated that IFN-activated CD86+HLA-DR+ M1
macrophages can inhibit osteosarcoma cell growth.13 In patients, the quantity of M1 macrophages, defined by iNOS
positivity, in the primary tumor was negatively correlated with metastatic disease (p = 0.001). 11 This observation may
be related to the ability of the M1 macrophage to promote a TH1 anti-tumor response. 10 Although M1 macrophages
may be the first to invade the primary tumor, in vivo studies have shown that early F4/80+CD163- M1 macrophages
are replaced by F4/80+CD163+ M2 macrophages between the first and third weeks of tumor establishment. 14
According to one group’s in vivo study, M2 TAMs are likely recruited to the primary tumor due to IL-34
overexpression by osteosarcoma cells.15 In contrast to M1 macrophages, CD163+M2 macrophages generate a TH2
response.16 Furthermore, in vitro studies of M2 macrophages have shown these cells enhance the migratory capacity
of osteosarcoma cells.17 M2 TAMs likely promote tumorigenesis via immunosuppression, production of matrix
degrading enzymes, and stimulation of angiogenesis. Notably, CD163+ M2 macrophages have been shown to correlate
with increased density of CD31+ blood vessels and CD146+ vascular cells in vivo. 11 Furthermore, patients with a
higher proportion of CD163+ M2 macrophages present with metastases.18 In addition to stimulating neoangiogenesis,
M2 macrophages overexpress epidermal growth factor (EGF), which can bind epidermal growth factor receptor
(EGFR) on osteosarcoma cells to promote growth.14
Although many studies attempt to stratify M1 and M2 populations, cancer is a complex disease process that may
stimulate a more intermediate TAM phenotype. For example, Buddingh, et al. found that a higher percentage of TAMs,
irrespective of M1 or M2 phenotype, was correlated with a higher overall survival rate in patients.12 Similarly, a Phase
III clinical trial found a higher overall survival rate and higher rate of metastasis free survival in patients whose primary
tumor samples showed >50% CD163+ M2-like macrophages with a trend toward significance for CD68+ M2
macrophages.16 Furthermore, one group’s in vivo study mimicked these observations; both M1 markers, Cxcl9 and
iNos, and M2 marker, Tgm2, were significantly elevated in splenic biopsies of all tumor bearing mice. Taken together,
these findings suggest that macrophage polarization in malignancy is complex and requires more than one cell marker
to accurately capture polarization. 19

c. Dendritic cells
Like macrophages, conventional dendritic cells (cDCs) are derived from circulating monocytes and serve to prime
and activate a T cell response against neoantigens produced by tumor cells. 20, 21 CDCs can be divided into cDC1 cells
and cDC2 cells with the CD103+ cDC1s performing the roles of antigen presentation and cytotoxic T cell (T c)
activation. In early in vitro studies, CD14+ DCs, isolated cDC1s, and isolated cDC2s respectively cultured with
osteosarcoma cell lines showed significantly decreased expression of maturation markers, including CD80, CD83,
CD86, CD40, HLA-DR, and CCR7. 20, 22 Furthermore, in contrast to control cDC1 cells, which express IL-12, cDC1s
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cultured with osteosarcoma cells increased expression of IL-10 but did not express IL-12. Isolated cDC2s cultured
with osteosarcoma cells also significantly increased IL-10 production. Elevated levels of IL-10 primes the TH2
response and suppresses the T H1 response, which may inhibit an adequate immune response to the primary tumor. 20
Although in vitro studies of cDCs have shown a possible role for DCs in osteosarcoma pathogenesis, it should be
noted that a lower level of DCs have been found to infiltrate pediatric tumors, including osteosarcoma, when compared
to adult onset tumors. The relative lack of infiltrating DCs and taken with the observation that osteosarcoma can
suppress a cDC-induced TH1 antitumor response may suggest a role for vaccination with tumor-antigen loaded
dendritic cells in treatment of osteosarcoma, which will be discussed later. 23

d. Myeloid Derived Suppressor Cells
Myeloid derived suppressor cells (MDSCs) constitute a population of myeloid cells that have failed to achieve
maturation to dendritic cells, monocytes, or granulocytes. Associated with pathology, especially chronic inflammation
and cancer, MDSCs can be categorized as CD11b+HLA-DR-CD14+CD15- monocytic MDSCs (M-MDSCs) or
CD66b+CD15+CD14-/dimCD33dimHLA-DR- polymononuclear MDSCs (PMN-MDSCs) in humans.24 While M-MDSCs
suppress T cell activity via both antigen dependent and independent mechanisms, including production of reactive
oxygen species through arginase (Arg) and nitric oxide synthase (iNOS), the PMN-MDSCs suppress T cell activity
mainly by an antigen dependent pathway.25 For patients with solid tumors, increased levels of MDSCs have been
correlated with lower overall survival.26 In vivo studies of MDSCs in murine osteosarcoma models show elevated
levels of both PMN-MDSCs and M-MDSCs in peripheral blood and spleen (Unpublished data). 27 Although elevated
early in the disease process, the M-MDSC cell levels trended downward as the disease progressed while the PMNMDSC population remained stable as shown in Figure 1. (Unpublished data) Similarly, in pediatric sarcoma patients,
CD14+HLA-DRlo/- M-MDSCs were found to be increased compared to healthy controls. 28 Regarding HLA-DR, a
marker for antigen presenting cells of the myeloid lineage, a decrease has been shown on monocytes of patients with
aggressive sarcoma, which is postulated to be one of the initial steps in development of M-MDSCs from monocytes.
28,29 Studies done in vivo have shown that HLA-DR expression decreases on myeloid-type cells as PD-L1 expression
increases. Specifically, the ratio of PD-L1 to HLA-DR (P[1]/M[II]) in peripheral blood increased with osteosarcoma
and trended upward in both peripheral blood and spleen as the disease progressed. Moreover, the systemic M-MDSC
P[1]/M[II], including blood, bone marrow, and spleen tissues, showed a positive correlation with the lung M-MDSC
ratio that was significant in blood (Figure 2: R = 0.972; p < 0.01) and spleen (Figure 2: R = 0.998; p < 0.01) and
trending toward significance in bone marrow. (Unpublished data).
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Fig. 1. Systemic PMN-MDSCs remain relatively constant while M-MDSCs decrease during disease progression in vivo. ***p=0.001,
**p=0.01, *p=0.05.

IL-18 expression has also been shown to be elevated in vivo on MDSCs with osteosarcoma disease progression.
As inhibition of IL-18 decreased levels of MDSCs in both peripheral blood and the primary tumor, this cytokine may
play a role in the development and recruitment of MDSCs. 27 A more immature population of MDSCs has also been
identified as Lin-(including CD3, CD14, CD15, CD19, and CD56) HLA-DR-CD33+ but was not found to be elevated
in pediatric sarcoma and has not been studied further.25,28 Certainly, due to the apparent role of MDSCs in malignancy,
these cell populations may be targeted to improve treatment strategies, as will be discussed with treatment strategies.

Fig. 2. Ratio of PD-L1 to HLA-DR (P[1]/M[II]) on M-MDSCs correlated with ratio of M-MDSCs in the lung in vivo.

B. Osteosarcoma Immunology: Adaptive Immune System

Lymphoid Lineage

1. T Lymphocytes

a. Helper T Cells
Helper T (TH) cells, commonly defined as being CD4+, can generate several different types of immune response:
TH1 or TH2 being the most common. TH1 cells primarily secrete IFN and TNF cytokines enhancing both the effector
and memory functions of CD8+ cytotoxic T cells (CTLs). 30-31 CD4+ TH cells can also enhance the antitumor response
by optimizing the cDC response, which in turn stimulates the CTLs. 32 Regarding tumor rejection in particular, TH1
cells can recruit NK cells and macrophages to form an antitumor response. Often considered to be in opposition of
TH1 cells, TH2 response involves IL-4, IL-5, and IL-13, which together activate a humoral response.30 Although IL-4
recruits macrophages and eosinophils in murine models, both IL-4 and IL-13 have been shown to activate
macrophages toward an M2-like immunosuppressive phenotype.30,33,34 The role of another distinct CD4+ TH cell type,
TH17, has been debated for its potential antitumor function.35 One in vitro study found that IL-22, commonly produced
by TH17 cells in vivo, stimulated the proliferation and invasion of two different osteosarcoma cell lines. 36 Thus, an
abundance of CD4+ TH17 cells in the primary tumor might suggest a poor prognosis.
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While numerous studies have shown that CD4+ TH can improve the antitumor response, one group has shown that
CD8+ CTLs can have an antitumor effect in osteosarcoma without CD4 + TH aid.31 Nonetheless, for adult osteosarcoma,
CD4+ TH cells likely play a role in the immune process as this cell type represented the predominant TIL and
demonstrated lytic activity against several osteosarcoma cell lines. 37 Furthermore, an in vivo study of the immunologic
changes during osteosarcoma pathogenesis showed that percentages of CD45+CD4+CD8- TH trended downward in the
peripheral blood and spleen as the disease progressed, which is shown in Figure 3 (Unpublished data). Similarly, for
peripheral blood samples of patients with osteosarcoma, there was a decreased overall numbers of CD4+ T cells.28 In
addition to the overall decrease in CD4+ T cells, patients with osteosarcoma exhibited increased expression of PD-1
and Tim-3, markers of T cell dysfunction and exhaustion, respectively, in CD4+ TH cells compared to patients without
osteosarcoma. 38-40 Furthermore, elevated levels of Tim-3+CD4+ T cells in the peripheral blood was shown to be
correlated with later stage of disease and increased expression of IFN and IL-2, which stimulate a T cell response.
Elevated levels of peripheral Tim-3+CD4+ T cells also correlated with decreased overall survival in osteosarcoma
patients. 41

Fig. 3. Helper T cells decrease systemically during disease progression in vivo. *p=0.05.

In addition to traditional TH cells, CD4+CXCR5+ follicular T helper (TFH) cells, which promote a B cell response
and maintain germinal centers in secondary lymphoid organs have been found to be of importance in osteosarcoma.
42-43 Indeed, levels of CXCR3-CCR6- TH2-type cells and CXCR3+CCR6+ TH17-type cells were found to be nearly two
times greater in osteosarcoma patients while levels of CXCR3+CCR6- TH1-type cells were lower. Furthermore, TFH
levels were found to be elevated peripherally in patients with both metastatic and high grade osteosarcoma, specifically
the TH1 and TH17 types but not the TH2 subtypes.42 Although CD4+ TH and TFH have been shown to play a role in the
disease process of osteosarcoma, these cells have received less attention than CTLs.

b. Cytotoxic T cells
Data accumulated from a number of human cancers have shown that the number, type, and location of tumor
infiltrating lymphocytes (TILs) in the primary tumor can be prognostic for overall survival. In particular, an increased
number of CD8+ TILs has been shown to correlate with increased survival rates and decreased rates of recurrence. 44
CD8+ TILs are also prominent in osteosarcoma as they represent the major infiltrating cell type in pediatric
osteosarcoma and make up 15.5% of infiltrating cells in adult osteosarcoma. 45, 37 An early study of primary tumor
samples from patients with high-grade osteosarcoma found CD3+CD8+ TILs to predominate infiltrating inflammatory
cells. As the pattern of CD3+CD8+ CTL infiltration did not differ significantly from benign bone tumor samples, CD8 +
TILs in osteosarcoma were not thought to have any prognostic significance. 46 Later, in a retrospective study, it was
found that higher CD8+ TIL density correlated with improved survival in osteosarcoma. Additionally, in this study, a
positive relationship between the CD8/Foxp3 TIL ratio and overall survival was observed. 47 This relationship between
CD8+ cells and Foxp3+ cells has been mirrored in other cancer types as CTLs have been shown to upregulate T reg cells.
47, 48 In addition to demonstrating a relationship with overall survival, levels of CD8 + TILs have also been found to
correlate with pretreatment metastases; patients presenting with metastases had lower levels of CD8 + TILs.16 Further
studies of primary tumors in patients with poor disease outcome showed that higher density of CD3 +CD8+ TILs
correlated with increased expression of PD-L1 on tumor cells and immune cells, which may be a mechanism by which
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the tumor evades the immune system and causes T cell exhaustion. 49,50,19 Furthermore, patients with high expression
of PD-L1 had a median overall survival of 28 months while median survival for patients with low PD-L1 expression
was 89 months.50 PD-1 has also been shown to be upregulated on CD8+ T cells in patients with osteosarcoma.37 Thus,
the PD-1/PD-L1 axis has become an attractive therapeutic target in osteosarcoma. Overall, CD8+ TILs have been
shown to improve outcomes in osteosarcoma, as they have cytolytic activity, but can be subject to T cell exhaustion
in patients with severe disease.37
Peripheral CD8+ CTLs have also been shown to have significant role in the pathogenesis of osteosarcoma. One in
vivo study demonstrated that the percentages of CD45+CD4-CD8+ CTLs decreased in the peripheral blood and spleen
as the disease progressed as demonstrated in Figure 4 (Unpublished data). Nevertheless, the amount of circulating
CD8+ CTLs was found to be higher than levels of CD8+ T cells within the primary tumor in patients.37 Some of these
cells were found to express Tim-3, a marker of T cell exhaustion, and were particularly prevalent in patients at later
stages of disease. Furthermore, increased levels of Tim-3+CD8+ T cells in the periphery negatively correlated with
serum levels of IFN and TNF. Since these cytokines activate the T H1 response, as discussed previously, it follows
that overall survival was decreased in patients with high levels circulating Tim-3+CD8+ T cells.39,41 For pediatric
patients with osteosarcoma, cytotoxic T lymphocyte-associated protein 4 (CTLA-4), a T cell inhibitory receptor, was
found to be upregulated on CD8+ cells circulating in the peripheral blood. 28 This receptor has been theorized to be
another immunosuppressive immune escape mechanism that can create resistance in response to solitary immune
checkpoint blockade. Therefore, since CTLA-4 has been shown to play a role in osteosarcoma progression, this
receptor has become a target for immune blockade, which will be discussed in a subsequent section.

Fig. 4. In vivo osteosarcoma progression induces a decrease in percent population of systemic cytotoxic T cells. **p=.0.1, *p=0.05.

c. Regulatory T cells
Regulatory T cells (Tregs) play a role in peripheral self-tolerance. While these CD4+CD25+ T cells have been shown
to prevent autoimmunity, particularly in vivo, an abundance of these cells can also suppress anti-tumor immunity to
tumors overexpressing self-antigens. The Treg population has been identified as expressing CD25 (IL-2R),
glucocorticoid-induced TNF receptor (GITR), CTLA-4, and Foxp3 transcription factor. In vivo studies have shown
that the presence of T reg cells promotes tumor growth and inhibits CD8+ CTL immunogenic response to the tumor.51
For example, when CD4+CD25+ Treg cells are cocultured with CD8+ T cells, the CD8+ T cells show significant
suppression of proliferation and production of IFN, IL-2, and CD25.52 Interestingly, splenic Treg cells in vivo are
increased later in disease progression (Figure 5).19 Similarly, a retrospective study of human osteosarcoma samples
demonstrated that increased Foxp3+ Tregs infiltrating the tumor indicated a worse prognosis. In fact, as Foxp3 + Tregs
increased relative to CD8+ CTLs, survival decreased independent of primary metastasis and chemotherapy response.
This relationship is likely due to Treg mediated inhibition of CTLs.47 Furthermore, an increase in CD3+CD8-Foxp3+ T
cells has been found in local relapses of osteosarcoma, potentially suggesting a tumor escape mechanism. 49
Importantly, while Foxp3+ cells have classically been classified as Treg cells, it should be noted that recent evidence
suggests that Foxp3 can be upregulated in conventional TILs, which suggests that Foxp3 alone cannot be utilized to
delineate Treg populations.47 Also, despite the apparent role of T regs in the local tumor microenvironment, these cells
have not been shown to be elevated systemically in pediatric osteosarcoma. 28
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Fig. 5. Regulatory T cell populations (CD45+CD4+Foxp3+) are increased in the spleens of tumor bearing mice.

2. B Lymphocytes
In addition to tumor infiltrating T lymphocytes, B lymphocytes can also be found in the tumor microenvironment;
these cells, however, have been studied less than their T cell counterparts. 53 Activated B cells can generate
autoantibodies that promote an antitumor response in malignancy. 53,54 Furthermore, B cells may enhance the T cell
response via antigen presentation and costimulation. 53-55 For several malignancies, the presence of CD20+ TILs in
addition to CD4+ and CD8+ TILs has been correlated with better overall outcomes when compared to independent
CD20+ B cell or CD8+ T cell tumor infiltration, respectively.53,56,57 In particular, for soft tissue non-gastrointestinal
stromal tumor sarcomas, increased CD20+ TILs correlated with improved disease specific survival. 58 Additionally, a
study of pediatric patients with soft tissue sarcomas found increased memory class switched B cells. 28 Despite these
findings, utilizing CD20+ TILs as a prognostic indicator of disease outcome and survival may be difficult as some,
including immature and those producing IL-10 and TGF-, CD20+ B cells may suppress the antitumor response.53
Further study into the effects of CD20+ B cells should be done to elucidate the role of these cells in osteosarcoma.

3. Natural Killer Cells
As lymphocyte members of the innate immune system, natural killer (NK) cells play a role in immunosurveillance
and are defined by CD3 negativity as well as CD56 or CD16 positivity.59 In cancer specifically, these granulocytic
NK cells can release their cytotoxic granules to directly kill malignantly transformed cells. Released tumor cell
antigens are then presented to B and T lymphocytes via APCs to generate an adaptive immune response.60 NK cell
mediated killing is negatively correlated to expression of HLA class I molecules, which serves to maintain selftolerance. This mechanism, however, can be exploited by malignant cells in order to evade immunosurveillance. 60,61
In osteosarcoma, analysis of HLA class I expression in primary and metastatic tumors showed downregulation in 52%
and 88% of samples, respectively.62 To inhibit NK cells, HLA class I molecules on tumor cells interact with Killer
Immunoglobulin-Like Receptor (KIR), which is expressed on the NK cell surface and commonly upregulated in
malignancy.60,63 For patients with osteosarcoma, NK cells can express combinations of all three KIR molecules,
including KIR2DL1, KIR2DL2/2DL3, and KIR3DL1, and thus display decreased activity.63
Early in osteosarcoma disease pathogenesis, peripheral blood NKG2D + NK cells do not differ in number,
phenotype, or functionality.64 In general, however, circulating NK cells are commonly lower in osteosarcoma patients
compared to healthy patients.65,66 These findings may be explained by in vivo studies which suggest that
CD45+NKp46+ NK cells are significantly increased systemically with osteosarcoma. 19 As the disease progresses,
though, NK cell populations in the peripheral blood decrease. These in vivo findings may be explained by the relative
increase in M-MDSCs and PMN-MDSCs in osteosarcoma, which inhibit NK cells (Unpublished data). Due to the
potent anti-tumor activity of NK cells but dysregulation in osteosarcoma, these cells have become an important focus
for future clinical trials.66
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III. Assessing Immunotherapeutic Response in Osteosarcoma
A. Checkpoint Blockade
Immune checkpoints serve to preserve self-tolerance and prevent autoimmunity and excess immune stimulation;
however, these pathways can also be used by tumor cells as a means of escaping immune system detection. Due to
their role in tumor immune tolerance, these T cell checkpoint molecules, programmed death receptor 1 (PD-1) and
CTLA-4, are therapeutic targets for advanced cancers.67 Since the PD-1/PD-L1 axis has been shown to negatively
impact overall survival in patients with osteosarcoma, these molecules are of particular interest. 49,50,68 In vivo anti-PD1 treatment facilitated macrophage mediated decrease in both micro and macrometastases but not primary tumor
growth.68,69 Specifically, Ki-67, a marker of tumor cell proliferation, expression decreased while TUNEL, a marker of
cell apoptosis, expression increased in tumor tissue. 69 Anti-PD-1 also increased CD4+ T cell, CD8+ T cell, NKp46+
NK cell, and F4/80+CD11b+ macrophage infiltration into lung metastases.68,69 Furthermore, anti-PD-1 shifted the
macrophage polarization from CD163+ M2 to CD86+ M1 macrophages in lung metastases, which facilitates an
antitumor response.69 Importantly, treatment with anti-PD-1 downregulated tumor cell expression of PD-L1, which
suggests utilization of another mechanism for immune suppression.68
Therapeutic strategies have also targeted PD-L1 in an attempt to interrupt the PD-1/PD-L1 axis. Similar to antiPD-1 treatment, anti-PD-L1 treatment downregulated expression of PD-L1 by primary tumor and metastatic
osteosarcoma cells. Increased length of treatment in vivo did not enhance response to anti-PD-L1, which further
suggests another pathway for immune suppression. Interestingly, following treatment with anti-PD-L1, CD8+ TILs
showed decreased PD-1 expression and increased CTLA-4 expression 70,19 CTLA-4 is a membrane glycoprotein
expressed by activated effector T cells and tumor cells which represses T cell proliferation, cell cycle progression, and
cytokine production.71 Furthermore, in response to anti-PD-L1, the tumor cells upregulated CD80 and CD86, which
bind to CTLA-4 to inhibit T cell activation.71,72 Thus, blockade of both PD-L1 and CTLA-4 in vivo completely
controlled metastases and increased long-term survival to 60% from 0% shown with anti-PD-L1 treatment alone.
Combination of anti-PD-L1 treatment with doxorubicin did not similarly enhance long-term survival.70 In addition to
stimulating changes in tumor cells, in vivo anti-PD-L1 treatment also has an effect on systemic immune cells.
Specifically, total percentage of monocytes/macrophages increased in response to anti-PD-L1. Additionally, the
expression of M1 markers, Nos2 and Cxcl9 and M2 marker, Tgm2, decreased resulting in a near normal M1/M2
macrophage ratio and returned the immune phenotype to that of sham status (Figure 6). 19
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Fig. 6. In vivo treatment with anti-PD-L1 reduces macrophage markers to near normal.

Regarding the efficacy of immune blockade in humans, anti-PD-L1 has shown a durable response and prolonged
disease stabilization across a variety of tumor types.72 A Phase II Trial for pembrolizumab montherapy, an anti-PD-1
antibody, showed a confirmed partial response to treatment in 5% of patients with osteosarcoma. This response,
however, resulted in greater than 50% tumor shrinkage for 6 months. Use of muramyl tripeptide
phosphatidethanolamine (Mifamurtide), which will be discussed later, has been suggested to enhance immune cell
infiltration into metastases thereby potentially improving the efficacy of pembrolizumab in osteosarcoma. 73 Efficacy
of anti-PD-1 treatment may also be enhanced by combination therapy. For example, trabectedin, an antitumor
medication approved in Europe for treatment of soft tissue sarcomas, decreases osteosarcoma tumor cell proliferation
and lung metastases in vivo. Following this treatment, CD8+ TILs exhibited upregulation of PD-1 suggesting a
potential role for trabectedin in immune blockade. Indeed, treatment with both trabectedin and anti-PD-1 inhibited
tumor growth and enhanced T cell activation to a greater degree than either treatment alone. 74

B. Other Immunotherapeutics
1. Cytokine Stimulation
Cytokines play an important role in the coordination of immune response against tumor antigens. Due to their
unique ability to modulate the immune system, these molecules have been of interest for immunotherapy and have
been implemented as treatment in a number of malignancies. One such cytokine, interferon alpha (IFN), has
demonstrated the ability to inhibit proliferation and induce apoptosis in tumor cells as well as inhibit angiogenesis. 67
Early studies of IFN showed the ability to inhibit growth of osteosarcoma cell lines in vitro and xenograft
osteosarcoma tumor growth in vivo.67, 75-76 Relatively little clinical data is available regarding IFN treatment in
osteosarcoma. Two early clinical studies showed 5-year recurrence free survival as well as a 10-year metastases free
survival rate and a disease specific survival rate of 39% and 43%, respectively. 77-80 Furthermore, with elevated dose,
the disease-free survival rate increased to 63% with higher treatment dose, indicating a possible dose-response
relationship that mirrors in vivo studies. 77,78,80 Combination therapy including methotrexate, doxorubicin, and cisplatin
with pegylated IFN-2b demonstrated improved event free survival and overall survival; however, these differences
were not significant.81
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IL-2 is another cytokine that has been implemented as immunotherapy for malignancy, specifically osteosarcoma.
Produced mostly by antigen-stimulated CD4+ T cells with some production by NK cells, CD8+ T cell, and activated
DCs, IL-2 stimulates growth and differentiation in CD8+ T cells, maintains CD4+ Treg populations, and drives
differentiation of CD4+ T cells into effector cells.82 Early in vitro studies of IL-2 suggest it indirectly stimulate NK
cell activity by increasing IFN.83 Furthermore, IL-2 has been shown to stimulate lymphokine activated killer cells
(LAK), which can be primed to form an anti-tumor response; thus, IL-2 has received attention as a potential therapeutic
agent. 67, 82, 84-86 IL-2 combined with autologous LAK cells first demonstrated the ability to mediate tumor regression
in a study of twenty-five metastatic patients that had failed standard chemotherapy. 82, 84 In patients with metastatic
osteosarcoma at diagnosis, the 3-year event free survival rate and overall survival rate were 34.4% and 45.0%,
respectively, with IL-2 treatment. 67, 85 Despite the positive tumor response in patients, IL-2 may simultaneously
stimulate high levels of Treg cells, thereby stimulating an environment tolerant of tumorigenesis rather than stimulating
an anti-tumor response. 51
2. Dendritic Cell Vaccines
Dendritic cells have the ability to prime the adaptive immune system, specifically a T cell response, in response to
tumor antigens; however, in osteosarcoma and other malignancies, these DCs fail to mature and adequately stimulate
a T cell response. 20,21,23,87 Thus, priming a patient’s own dendritic cells ex vivo against tumor antigens has become a
potential immunotherapy for patients with advanced disease. 87 In vivo studies of tumor-lysate pulsed DCs showed
significantly increased CTL response and IFN levels while levels of IL-4 were decreased. Increased expression of
costimulatory CD86, CD83, CD205, and CD209 in the DCs correlated with the allogenic T cell response. 88
Furthermore, combining the tumor-lysate DC treatment with anti-CTLA-4 antibody treatment increased the number
CD8+ TILs, decreased the amount of Foxp3+ Treg cells in metastatic tumor and the spleen, and increased serum levels
of IFN. This combined treatment reduced the metastatic tumor burden and prolonged overall survival. 79 Similarly, in
vivo studies combining tumor-lysate pulsed DCs with agonist anti-GITR increases the number of CD8+ TILs,
increased serum IFN, decreased serum IL-10, and decreased numbers of CD4+Foxp3+ Treg cells in the spleen.90
In response to treatment with tumor-lysate pulsed DCs, patients with metastatic pediatric malignancy generated a
specific T cell response allowing for tumor regression. Levels of IFN levels were increased 10-fold in response to
tumor antigen in these patients.91 In patients with pediatric sarcoma treated with tumor-lysate pulsed DCs, patients
having an immune response had a 73% 5-year overall survival rate while those without a response had a 37% 5-year
overall survival rate.92 In contrast, patients with advanced soft tissue sarcoma treated with DCs pulsed with autologous
tumor lysate had increased levels of IFN and IL-12, which stimulate a TH1 response; nonetheless, only 1 of 35 patients
achieved a partial response. These findings suggest that immune stimulation is not enough to overcome advanced
malignancy.93
3. Genetically Modified T Cells
Chimeric antigen receptor T cells consist of a specific antibody derived single-chain variable fragment (scFv) with
a T cell signaling domain such that the effector function is released when the target cell is bound. One challenge with
this therapy, particularly for osteosarcoma, is identifying a tumor antigen that is highly expressed on tumor cells with
low expression in healthy tissues.94 As HER2 gene amplification has been reported in osteosarcoma, and is particularly
linked with poor outcome, administration of HER2-CAR T-cells in patients with osteosarcoma resulted in stable
disease for 24% of patients.94-95 Three of these patients had the tumor removed with one having more than 90%
necrosis. IL-8 was found to be significantly elevated one week after infusion and remained elevated for 4 weeks while
levels of HER2-CAR-T cells lasted for approximately 6 weeks without toxicity. 95 Pediatric sarcoma has also been
shown to strongly express GD2, a glycosphingolipid.94 Although GD2-CAR T cells demonstrated lytic activity against
GD2+ tumor cells in vitro, the in vivo efficacy of treatment was poor. Poor in vivo efficacy was attributed to the
presence of MDSCs. However, addition of all-trans retinoic acid (ATRA) improved efficacy, likely by depleting of
M-MDSCs and diminishing the suppressive capacity of PMN-MDSCs.96 Additionally, CD166, a protein that mediates
communication between adjacent cells and has been implicated in tumorigenesis, has been found to be exclusively
expressed in four human osteosarcoma cell lines. CD166-CAR-T cells efficiently suppressed tumor growth in tumor
xenografts without significant toxicity to healthy organs.97
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Similar to CAR-T cells, T cells can be genetically engineered to express T cell receptors against particular tumor
antigens; however, unlike CAR-T cells, the response is dependent upon HLA haplotype. 98 Genetically engineered
lymphocytes reactive with NY-ESO-1, a cancer/testis antigen expressed in 80% of synovial cell sarcomas, have been
shown to facilitate an objective partial response in four of six patients with metastatic synovial cell sarcoma without
significant toxicity.99 The NY-ESO-1 antigen has been shown to be specific to a variety of tumors including
osteosarcoma; however, the level of expression can vary between tumors. Interestingly, NY-ESO-1 expression can be
upregulated in vitro in response to demethylating agent 5-aza-2’-deoxycytidine (decitabine) thus suggesting that the
CAR-T cell therapy utilized against synovial cell sarcoma may be successful in osteosarcoma. Indeed, further in vivo
studies showed that pre-treatment with decitabine allowed for localization of the NY-ESO-1 CAR-T cells to the tumor
site. The combination treatment of decitabine and CAR-T cells decreased tumor volume when compared to controls.100
Due to its success with B cell malignancies, genetically modified T cell therapies represent a promising alternative for
treatment of similarly complex malignancies such as osteosarcoma.
4. Macrophage Activation
Mifamurtide, a nonspecific immune modulator, is a synthetic Bacille Calmette-Guerin cell wall component that
can be delivered to macrophages, particularly in the lung, in the liposomal form to stimulate an anti-tumor response.101105 Liposomal muramyl tripeptide phosphatidethanolamine (L-MTP-PE) given to osteosarcoma patients increased
circulating levels of TNF and IL-6. Additionally, treatment with L-MTP-PE also increased circulating levels of
neopterin, a marker of macrophage activation, independent of IFN secretion.103 L-MTP-PE used in combination with
a three or four drug chemotherapy regimen including doxorubicin, cisplatin, high dose methotrexate with or without
ifosfamide (Phase III Trial INT-0133) showed improved overall 6-year survival and a trend toward improved event
free survival for patients with nonmetastatic osteosarcoma; no significant difference was noted between chemotherapy
regimens.105 While it was originally determined that there was no survival benefit to the addition of L-MTP-PE for
patients with metastases, a long term follow-up of those patients indicated a trend toward increased event free survival
and overall survival.106 The toxicities associated with L-MTP-PE are limited to chills and fever, which are likely
facilitated by the release of TNF and IL-6.93 Due to the survival benefits and limited toxicity, MTP has been approved
for treatment of patients with osteosarcoma by the European Medicine Agency. 67,102
5. Peptide Vaccines
Peptide vaccines had previously gained popularity due to the potential for stimulating T cell response against tumorassociated antigens.107 Vaccines involving tumor lysates, peptides, and proteins have been employed in sarcoma. 67,108111 The SART3 protein was found in osteosarcoma cell lines and thus may be a useful peptide vaccine to stimulate
CTLs against osteosarcoma tumors.108 Furthermore, papillomavirus binding factor protein was also found in
osteosarcoma and may similarly serve as an antigenic peptide to stimulate an immunologic response against tumor
tissue.109 Indeed, in a small Phase II trial in which patients with soft tissue sarcoma were treated with personalized
peptide vaccines, 64.7% of patients developed an IgG response with 12 patients demonstrating epitope spreading.
Furthermore, 70.6% of patients developed a CTL response following treatment. These patients with refractory
sarcoma had a mean survival time of 9 months while palliative care in similar instances facilitates an 8 month survival
time.110 Due to their positive anti-tumor effects, peptide vaccines potentially represent feasible alternative for treatment
of osteosarcoma; however, additional studies are required to optimize outcomes. 107

IV. Future Perspectives
As the field of flow cytometry evolves and we improve our ability to analyze single tissue samples with more and
more antibodies and fluorochromes, the field of immunology and subsequently personalized medicine is also
improving. However, these enhancements come with added responsibility as the proteins studied are highly labile ex
vivo, which can result in poor data generation and thus false assumptions from the data. Therefore, a standardized
process of tissue handling and preparation will become crucial to the process of data acquisition for this potential
therapeutic tool. If done correctly, though, this tool has the potential to open many doors for the treatment of
osteosarcoma using immunotherapeutics. Furthermore, previously popular treatments could be used much more

282

efficiently and appropriately in dosing regiments as we can follow the patients’ disease progression and recovery in
real time as suggested in Figure 7.

Fig. 7. Example osteosarcoma patient blood sample.
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PROTEIN-CONTAINING PLGA NANOSPHERES

FIELD
[0001]

Various embodiments disclosed herein relate generally to preparation of protein-containing

nanospheres.
[0002]

Various embodiments disclosed herein relate to immunophenotyping for immune analysis.

BACKGROUND
[0003]

Immunostimulation is an important mechanism that 1) prevents malignant transformed

cells from proliferating and/or colonizing metastatic sites and 2) clears established viral and bacterial
infections. Immunotherapy cancer treatment may involve monoclonal antibody blockade of specific
immune checkpoints, including the Programmed Death-Ligand 1 (PD-L1) and Cytotoxic TLymphocyte-Associated Protein 4 (CTLA-4) axes.
[0004]

Historically, the focus has been on the tumor microenvironment and the immune response.

However, it is well documented that in order to have a lasting immunological response and cure the
disease the response must be a systemic one. Many groups have looked at the immunophenotyping
of treatments to help to explain what is happening immunologically to the patient in real time. This
information will become key as immunotherapeutics for multiple disease become more mainstream
and developing an living database of these responses will push the process forward tremendously.
[0005]

Preclinical studies have shown that interleukins can induce antitumor responses against

many malignancies. Interleukin-12 (IL-12), an immunostimulatory cytokine whose antitumor activity
is maximized when given systemically, induces such antitumor responses. While high-dose IL-12
administration may have toxic side effects, low doses of IL-12 are considered safe.
[0006]

Poly(D,L-lactic acid-co-glycolic acid) (PLGA) drug delivery vectors are FDA approved and

can elute a wide variety of substances as the polymer coating breaks down. For therapeutic purposes,
encapsulating peptides, potentially including immunostimulatory interleukin proteins, within PLGA
nanospheres may allow for systemic delivery and tissue deposition without the need for toxic loading
doses. In order to be used in systemic settings, nanospheres must be able to achieve safe and effective
blood-borne travel through the circulatory system of an organism.
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SUMMARY
[0007]

In light of the present need for improved methods of cytokine administration, a brief

summary of various exemplary embodiments is presented. Some simplifications and omissions may
be made in the following summary, which is intended to highlight and introduce aspects of certain
embodiments disclosed herein, but not to limit the scope of the disclosure. Detailed descriptions of
various embodiments adequate to allow those of ordinary skill in the art to make and use the concepts
disclosed herein will follow in later sections.
[0008]

According to various embodiments disclosed herein, a protein may be encapsulated in a

nanosphere. This encapsulation process may be performed by making a double emulsion, where a first
water phase is emulsified in an oil phase, and the oil phase is emulsified in a second water phase. The
protein may be a cytokine, which is a small protein (~5–20 kDa) important in cell signaling. Suitable
cytokines include:
interleukins, produced by T-helper cells;
lymphokines, produced by lymphocytes;
monokines, produced exclusively by monocytes;
interferons, involved in antiviral responses;
colony stimulating factors, which support the growth of cells in semisolid media; and
chemokines, which mediate chemoattraction between cells.
[0009]

In various embodiments, the protein encapsulated in the nanosphere may be cytokines with

three-dimensional structures having a bundle of four α-helices, which may be interferons, interleukins,
e.g., interleukin-2 or interleukin-12, or non-immunological cytokines, including erythropoietin and
thrombopoietin. The protein encapsulated in the nanosphere may be interleukin-12 (IL-12).
[0010]

The oil phase may be prepared by dissolving from 2.5% w/v to 17% w/v of poly(lactic

acid-co-glycolic acid) (PLGA) in an organic solvent. A first aqueous phase is made by suspending a
protein in an aqueous medium. Finally, a second aqueous phase is made by dissolving polyvinyl alcohol
(PVA) in water.
[0011]

The PLGA may comprise from 50% to 90% lactide, and the organic solvent may be a

halogenated C1-C3 organic solvent, a C2-C3 nitrile solvent, a C2-C5 alkyl ester solvent, a C3 to C5
ketone solvent, or a mixture thereof. The PLGA may comprise from 75% to 90% lactide. The PLGA
may comprise from 50% to 75% lactide, and the organic solvent may be a halogenated C1-C3 organic
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solvent, acetonitrile, a C3 to C4 ketone solvent, or a mixture thereof. In various embodiments, the
PLGA comprises from 50% to 90% lactide, and the organic solvent may be acetonitrile, acetone, ethyl
acetate, or dichloromethane.
[0012]

The protein-containing aqueous medium is added to the oil phase to form a first emulsion,

with agitation. The first emulsion is added to the PVA-containing aqueous phase to form a second
emulsion, with agitation. The organic solvent is then evaporated from the second emulsion to form
an aqueous solution; and PLGA nanospheres containing the protein from the second aqueous phase
are recovered from the aqueous solution.
[0013]

In various embodiments, the protein-containing aqueous medium may be added to the oil

phase to form a first emulsion, with agitation by a tissue homogenizer at a rate of 13,000 RPM to
20,000 RPM. The first emulsion may be added to the PVA-containing aqueous phase to form a second
emulsion, with agitation by a tissue homogenizer at a rate of 13,000 RPM to 20,000 RPM. The organic
solvent is then evaporated from the second emulsion to form an aqueous solution; and PLGA
nanospheres containing the protein from the second aqueous phase are recovered from the aqueous
solution.
[0014]

In various embodiments, the protein in the protein-containing aqueous medium is a

cytokine. Suitable cytokines include interleukins, lymphokines, monokines, interferons, colony
stimulating factors, and chemokines. The protein may be a cytokines with a three-dimensional
structures having a bundle of four α-helices, e.g., interleukins, e.g., interleukin-2 or interleukin-12, or
non-immunological cytokines, including erythropoietin and thrombopoietin.
[0015]

In various embodiments, the protein in the protein-containing aqueous medium is IL-12.

IL-12 may be incorporated into PLGA nanospheres by agitating the first and second emulsions with
a tissue homogenizer at a rate of 13,000 RPM to 20,000 RPM. IL-12 is incorporated into the resulting
PLGA nanospheres with an encapsulation efficiency of about 0.5% to about 2.1%.
[0016]

In various embodiments, the protein-containing aqueous medium is added to the oil phase

to form a first emulsion, with agitation by ultrasonication. The first emulsion is added to the PVAcontaining aqueous phase to form a second emulsion, with agitation by sonication. Agitation during
formation of either or both of the first and second emulsions may comprise sonication at a power
level of 30 W to 50 W, 30 W to 40 W, or 40 W to 50 W, for a period of time of 5 sec to 30 sec, 10 sec
to 30 sec, 10 sec to 20 sec, or 10 sec to 15 sec. The organic solvent is then evaporated from the second
emulsion to form an aqueous solution; and PLGA nanospheres containing the protein from the
second aqueous phase are recovered from the aqueous solution.
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[0017]

In various embodiments, the protein-containing aqueous medium is added to the oil phase

to form a first emulsion, with agitation by a tissue homogenizer at a rate of 13,000 RPM to 20,000
RPM. The first emulsion is added to the PVA-containing aqueous phase to form a second emulsion,
with agitation by sonication at a power level of 30 W to 50 W, 30 W to 40 W, or 40 W to 50 W, for a
period of time of 5 sec to 30 sec. The organic solvent is then evaporated from the second emulsion
to form an aqueous solution; and PLGA nanospheres containing the protein from the second aqueous
phase are recovered from the aqueous solution.
[0018]

In various embodiments, the protein in the protein-containing aqueous medium is IL-12.

IL-12 may be incorporated into PLGA nanospheres by sonication at a power level of 30 W to 50 W,
for a period of time of 10 sec to 20 sec. IL-12 is incorporated into the resulting PLGA nanospheres
with an encapsulation efficiency of about 2% to about 85%, about 4.5% to about 70%, about 5% to
60%, about 7% to about 50%, about 8% to about 40%, about 10% to 30%, or about 5% to 10%.
[0019]

Various embodiments disclosed herein are directed to a nanosphere comprising a

poly(lactic acid-co-glycolic acid) matrix and a protein, where a first portion of the protein is adsorbed
onto a surface of the nanosphere and a second portion of the protein is incorporated into the
poly(lactic acid-co-glycolic acid) matrix at a core of the nanosphere. The nanosphere is produced by
making a double emulsion, where a first, protein-containing, water phase is emulsified in an oil phase,
and the oil phase is then emulsified in a second water phase. The protein may be a cytokine, such as
IL-12. The IL-12 may be incorporated into the nanosphere with an encapsulation efficiency of about
0.5% to about 85%, about 1% to about 70%, about 2% to 60%, about 3% to about 50%, about 4%
to about 40%, about 5% to 30%, about 0.5% % to 10%, about 1% to 8%, or about 2% to 5%.
[0020]

Various embodiments disclosed herein relate to a method of encapsulating a protein in a

nanosphere, by preparing an oil phase by dissolving from 2.5% w/v to 17% w/v of poly(lactic acidco-glycolic acid) (PLGA) in an organic solvent containing an optional first surfactant; preparing an
aqueous phase containing polyvinyl alcohol and at least one additive selected from the group
consisting of mammalian serum, trehalose, and a second surfactant; and suspending the protein in an
aqueous medium. The first surfactant may be a sorbitan fatty acid ester. The aqueous medium is added
to the oil phase to form a first emulsion. The first emulsion is agitated, and the first emulsion is added
to the aqueous phase to form a second emulsion, which is then agitated. The organic solvent is
evaporated from the second emulsion to form an aqueous solution; and poly(lactic acid-co-glycolic
acid) nanospheres containing the protein are recovered from the aqueous solution. The aqueous phase
may contain polyvinyl alcohol and mammalian serum, e.g., fetal serum. The aqueous phase may
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contain polyvinyl alcohol and the second surfactant, where the first surfactant is a sorbitan fatty acid
ester; and the second surfactant is a polyoxyethylene sorbitan fatty acid ester.
[0021]

Various embodiments disclosed herein relate to a nanosphere comprising a poly(lactic acid-

co-glycolic acid) matrix and a protein, where a first portion of the protein is adsorbed onto a surface
of the nanosphere; and a second portion of the protein is incorporated into the poly(lactic acid-coglycolic acid) matrix at a core of the nanosphere. The nanosphere further comprises at least one
additive selected from the group consisting of mammalian serum albumin, trehalose, and a surfactant..
The nanosphere may comprise mammalian serum albumin and a surfactant. The nanosphere may
comprise mammalian serum albumin, a first surfactant, and a second surfactant. In many disease
states, e.g., cancer and autoimmune disorders, the human immune system is in constant flux. In order
to treat such diseases, the medical practitioner must be able to assess the immune system of a patient
in real time, and to follow the immune system status over time. When cancer, infections, and/or
autoimmune disorders are being with immunomodulating agents, regardless of whether they are
immunosuppressive or immunostimulating, the medical practitioner must be able to follow the impact
of such agents on the immune system.
[0022]

Various embodiments disclosed herein relate to a method allowing systemic analysis of the

immune system from a finger stick blood draw that can be analyzed at a testing site. The response of
the immune system to a disease state, e.g., cancer or an autoimmune disease, may be analyzed at a
selected time, and the immune response to a treatment protocol may be followed over the course of
a disease or treatment.
[0023]

This diagnostic method is useful in the treatment, surveillance, and diagnosis of many

diseases, including cancer, autoimmune diseases, and infections. As immunomodulating agents
become more common, the method provides the medical practitioner with the ability to assess the
status of the immune system at a specific time in the pathogenesis of a disease, and allows prediction
as to which immomodulating treatment would be most effective in combating the disease. This will
increase the overall effectiveness of treatment, and allow improved assessment of the status of the
patient in the disease process. This information can also be organized in a living database of immune
profiles across disease specific categories that will allow practitioners to be more informed on the
treatments they will be giving based on previous experiences.
[0024]

Various embodiments disclosed herein relate to a method of controlling an

immunophenotype in a patient suffering from a disease which impacts the immune system, including
steps of determining an initial immunophenotype, or immune status, of a patient; and either:
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administering a first drug which stimulates the immune system if the initial immunophenotype
shows immunosuppression; or
administering a second drug which suppresses the immune system if the initial
immunophenotype shows overstimulation of the immune system.
[0025]

After administering the selected drug, the patient’s immunophenotype is monitored as a

function of time; and administration of the first and/or second drug may be adjusted if the patient’s
immunophenotype falls outside a desired range.
[0026]

Various embodiments disclosed herein relate to a method of controlling an

immunophenotype in a patient suffering from a disease which impacts the immune system, by
determining a disease state of a patient, where the disease state includes a diagnosis and an initial
immunophenotype; and comparing the disease state of the patient to a plurality of disease states within
a database, where each disease state in the database includes a diagnosis, an initial immunophenotype,
and a treatment protocol. Based on the comparison between the patient’s disease state and disease
states and treatment protocols from the database, a treatment protocol is selected from the database,
where the treatment protocol involves administering an immunomodulating drug. The method may
include administering the immunomodulating drug to the patient; monitoring the patient’s
immunophenotype as a function of time after administering the drug; and adjusting administration of
the immunomodulating drug if the patient’s immunophenotype falls outside a desired range.
[0027]

Immunophenotyping of a patient’s blood sample requires the ability to analyze and assess

the data appropriately. This system will allow the appropriate dosing, treatment, and corrections to
be made across several disease states. As the collection of data increases the growing database will
also be able help direct medical professionals to diagnosis, treat, and dose immunotherapeutics in the
broadest sense.

BRIEF DESCRIPTION OF THE DRAWINGS
[0028]

The patent or application file contains at least one drawing executed in color. Copies of

this patent or patent application publication with color drawings will be provided by the Office upon
request and payment of the necessary fee.
[0029]

In order to better understand various exemplary embodiments, reference is made to the

accompanying drawings, wherein:

294

[0030]

FIGS. 1A and 1B show distribution of fluorescein isothiocyanate-labeled bovine serum

albumin protein in a PLGA nanosphere.
[0031]

FIG. 1C shows a biphasic protein elution curve from PLGA nanospheres, due to initial

release of adsorbed protein on the surface of the nanospheres, followed by controlled release of
protein entrapped with the PLGA nanospheres.
[0032]

FIG. 1D shows the mechanism of biphasic protein release from PLGA nanospheres.

[0033]

FIG. 2 shows fluorophore distribution over a 67-minute period in BALB/c mice inoculated

with 1 mg/kg of Alexa Flour® 647-loaded nanospheres dissolved in sterile saline by either
intraperitoneal (mouse on left) or intravenous (mouse on right) injection.
[0034]

FIG. 3 shows the effect of sonication on IL-12, where IL-12 was ultrasonicated at three

different wattages for 10, 20, 30, 40, or 60 seconds.
[0035]

FIGS. 4A and 4B show scanning electron microscopy (SEM) images of unloaded (blank)

poly(lactide-co-glycolide) acid (PLGA) nanospheres lyophilized without 25 mM trehalose at 11,000X
(FIG. 3a) and 13,000X (FIG. 3b) , respectively.
[0036]

FIG. 4C shows scanning electron microscopy (SEM) images of unloaded (blank) PLGA

nanospheres lyophilized with 25 mM trehalose at 5,000X magnification.
[0037]

FIG. 5A shows PLGA) nanospheres loaded with FITC-conjugated bovine serum albumin

visualized for protein incorporation via confocal microscopy.
[0038]

FIGS. 5B and 5C show scanning electron microscopy (SEM) images of lyophilized

recombinant mouse IL-12-loaded PLGA nanospheres at 8,000X and 25,000X magnification,
respectively.
[0039]

FIGS. 6A and 6B show size distribution analyses of unloaded (blank) PLGA acid

nanospheres and recombinant mouse IL-12 (IL-12)-loaded PLGA nanospheres run at 1:50 and 1:14
dilution factors in water at 25 degrees Celsius, respectively.
[0040]

FIGS. 6C and 6D show zeta potential distributions for unloaded blank and IL-12-loaded

PLGA nanospheres at a 1:50 dilution factor in water at 25 degrees Celsius, respectively.
[0041]

FIG. 7A and 7B shows the estimated total amount of protein eluted over time from

recombinant mouse IL-12-loaded PLGA nanospheres. in terms of total protein (FIG. 7A) and protein
per 100,000 particles (FIG. 7B).
[0042]

FIG. 7C shows the encapsulation efficiency (EE) of recombinant mouse IL-12-loaded

nanospheres calculated using the area under the curve (AUCs) of each elution profile for three
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different particle concentrations (500 million particles/mL, 750 million particles/mL, and 1 billion
particles/mL).
[0043]

FIGS. 8A to 8C show IL-12-loaded nanospheres prepared using sonication under varying

conditions of sonication power and sonication time.
[0044]

FIG. 9 shows the elution profiles of IL-12 from nanospheres prepared using sonication

under varying conditions of sonication power and sonication time.
[0045]

FIG. 10 shows the elution profile of IL-12 from PLGA nanospheres prepared using high-

speed stirring, using a nanosphere concentration of 750 million particles/mL, as a function of stirring
speed.
[0046]

FIG. 11 shows application of IL-12 from PLGA nanospheres for the treatment of

metastatic osteosarcoma.
[0047]

FIG. 12 shows the effect of trehalose and a magnesium compound on IL-12 elution from

PLGA nanospheres.
[0048]

FIG. 13 shows the effect of fetal bovine serum (FBS) on IL-12 elution from PLGA

nanospheres.
[0049]

FIG. 14 shows the effect of surfactants, alone or in combination with FBS, on IL-12 elution

from PLGA nanospheres.
DETAILED DESCRIPTION: PLGA NANOSPHERES
[0050]

Poly(D,L-lactic acid-co-glycolic acid) (PLGA) drug delivery vectors are FDA approved and

can elute a wide variety of substances as the polymer coating breaks down into harmless Krebs cycle
intermediates. Drug solubility, bioavailability, and stability can all be altered by the organic coating
allowing for large shifts in the pharmacokinetic and pharmacodynamics properties of the encapsulated
substrate. For tumor and infection therapeutic purposes, encapsulating IL-12 within PLGA
nanospheres may allow for systemic delivery and tissue deposition without the need for toxic loading
doses. The negatively charged surface are repelled by the glycocalyx, and along with their smaller size
allows for increased deposition in the interstitial space where they can elute their contents undisturbed.
To date, however, the successful encapsulation of IL-12 within submicron scale PLGA particles has
not been achieved. In order to be used in systemic settings, nanospheres must be able to achieve safe
and effective blood-borne travel through the microvasculature of an organism (with capillaries being
approximately 4-9 microns in diameter) with minimal risk of forming emboli.
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[0051]

A PLGA nanosphere with an encapsulated protein may be created by:
preparing an oil phase by dissolving from 2.5% w/v to 17% w/v of PLGA in an organic
solvent;
preparing an aqueous phase by dissolving from 1% w/v to 3% w/v of polyvinyl alcohol in an
aqueous solvent;
suspending a protein in an aqueous medium;
adding the aqueous medium to the oil phase to form a first emulsion, and homogenizing the
first emulsion;
adding the first emulsion to the aqueous phase to form a second emulsion, and homogenizing
the second emulsion;
evaporating the organic solvent from the second emulsion to form an aqueous solution; and
recovering PLGA nanospheres containing the protein from the aqueous solution.

[0052]

In various embodiments, the protein may be a cytokine selected from the group consisting

of interleukins, lymphokines, monokines, interferons, colony stimulating factors, and chemokines.
The cytokine may be an interleukin or a non-immunological cytokine.
[0053]

The cytokine may have an N-terminal signal sequence, a four-helix bundle comprising four

helices labeled A through D, and an optional C-terminal extension following the D helix. The cytokine
may lack a substantial C-terminal extension, and may be a granulocyte-macrophage colony-stimulating
factor, a granulocyte colony-stimulating factor, interferon alpha-1, interferon beta, interferon gamma.
interferon kappa, interferon tau-1, interferon omega-1, or an interleukin (IL) selected from the group
consisting of IL-2, IL-3, IL-4, IL-5, IL-5, IL-6, IL-7, IL-9, IL-10, IL-11, the alpha chain of IL-12, IL13, IL-15, IL-19, IL-20, IL-21, IL-22, IL-23, IL-24, IL-26, and IL-27.
[0054]

In various embodiments, the cytokine may be an immunological cytokine that either

enhances cellular immune responses; or enhances antibody responses. If the cytokine is an
immunological cytokine that enhances cellular immune responses, the cytokine may be selected from
the group consisting of tumor necrosis factor-alpha (TNFα), interferon-gamma (IFN-γ), and
interleukin-12 (which stimulates the production of IFN-γ and TNFα). If the cytokine is an
immunological cytokine that enhances antibody responses, the cytokine may be selected from the
group consisting of transforming growth factor beta (TGF-β), IL-4, IL-10, and IL-13.
[0055]

In various embodiments, the protein to be encapsulated in a nanosphere may be a globular

protein. Suitable globular proteins may include serum albumin proteins; enzymes, e.g., esterases;
hormones, e.g., insulin; and transporter proteins.
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[0056]

In various embodiments, PLGA nanospheres may be used to encapsulate pharmaceutical

active ingredients; vitamins; nutraceutical active ingredients, e.g., phytochemicals; and organic dyes or
contrast agents. PLGA nanospheres may be used for controlled release of a variety of drugs, including
poorly soluble Class III and Class IV drugs.
[0057]

To create the oil phase, from 2.5% w/v to 17% w/v of PLGA is dissolved in an organic

solvent. The PLGA may contain from 50% to 90% lactide, from 65% to 90% lactide, or from 75%
to 90% lactide. The organic solvent may be a halogenated C1-C3 organic solvent, e.g.,
dichloromethane, chloroform, or 1,1,1-trichloroethane; a C2-C3 nitrile solvent, e.g., acetonitrile or
propionitrile; or a C2-C5 alkyl ester solvent, e.g. ethyl acetate or butyl acetate; or a C3 to C5 ketone
solvent, e.g., acetone or pentanone. The organic solvent may be a semipolar solvent with a dipole
moment between 1.1 and 3.5. The oil phase may be made by dissolving PLGA in the organic solvent
at room temperature (RT) with stirring, where the stirring may be at 300 to 600 RPM, 350 to 550
RPM, or 425 to 500 RPM.
[0058]

In various embodiments, the solvent selection may be made based on a lactide content in

the PLGA. If the PLGA contains 75% to 90% lactide, the organic solvent may be a halogenated C1C3 organic solvent, C2-C3 nitrile solvent, or a C2-C5 alkyl ester solvent, or a C3 to C5 ketone solvent.
If the PLGA contains less than 75% lactide, the organic solvent may be a halogenated C1-C3 organic
solvent, acetonitrile, or a C3 to C4 ketone solvent.
[0059]

To create the aqueous phase of the emulsion, from 1% w/v to 3% w/v of polyvinyl alcohol

(PVA) is dissolved in an aqueous solvent, which may be water or a buffered saline solution, e.g.,
phosphate buffered saline.
[0060]

Next, a protein, e.g., IL-12 or bovine serum albumin, was suspended in an aqueous

medium, which may be a buffered saline solution, e.g., phosphate buffered saline, and the resulting
protein suspension was added to the PLGA-containing oil phase, which may be subjected to rapid
stirring, e.g., 10,000 to 20,000 RPM; 12,000 to 19,500 RPM; 13,000 to 19,000 RPM; 15,000 to 18,000
RPM, or 16,000 to 17,500 RPM, to produce a first emulsion. Alternatively, the protein suspension
may be added to the PLGA-containing oil phase with sonication to produce the first emulsion.
[0061]

The first emulsion is then added to the PVA aqueous phase with rapid stirring, e.g., 10,000

to 20,000 RPM; 12,000 to 19,500 RPM; 13,000 to 19,000 RPM; 15,000 to 18,000 RPM, or 16,000 to
17,500 RPM; with homogenization; or with sonication to produce a second emulsion. The organic
solvent is then evaporated from the second emulsion. PLGA nanoparticles containing the protein
from the aqueous medium are recovered by centrifugation, and flash-frozen in liquid nitrogen and/or
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lyophilized.
[0062]

When the second emulsion is formed, protein becomes wound up in strands of the PLGA

matrix polymer, which coalesces and precipitates into a sphere as the organic solvent is removed.
During this process, protein becomes both entrapped within the polymer matrix (Figure 1A, where
the protein is fluorescein isothiocyanate-labeled bovine serum albumin [BSA-FITC]) and adsorbed to
the outer surface (Figure 1B), producing a characteristic biphasic elution curve shown in FIG. 1C. The
burst phase, which normally occurs between baseline and two days, is due to the adsorbed protein on
the surface of the nanospheres being released upon resuspension in aqueous medium (FIG. 1D). The
controlled release phase is due to entrapped protein (FIG. 1D), and is released slowly over time as the
PLGA hydrolyzes.
[0063]

For purposes of comparison, the above process may be carried out using a buffered saline

solution instead of a protein suspension, and adding this saline solution to the PLGA-containing oil
phase to produce the first emulsion. Upon adding this first emulsion to a PVA aqueous phase, proteinfree blank nanoparticles may be produced.
[0064]

Blank nanospheres and IL-12-loaded PLGA nanospheres were synthesized using the above

techniques. The morphology of blank and protein-loaded PLGA nanospheres was determined via
scanning electron microscopy to be spherical in shape with a mean particle diameter of 50 nm to 500
nm, 100 to 250 nm, 100 to 150 nm, or 175 to 225 nm. In various embodiments, IL-12-loaded PLGA
nanospheres may have a diameter of 100 to 150 nm. Blank, i.e., protein-free nanospheres may have a
diameter of 175 to 225 nm.
[0065]

The zeta potentials of both blank and IL-12 loaded PLGA nanospheres were also

determined in a deionized water medium. The zeta potential is the potential difference between the
dispersion medium and the stationary layer of fluid attached to the dispersed particle, and was
determined to range from -15 to -25 mV, respectively, following the introduction of 12.5 - 25 ug rmIL12 for protein loading during synthesis. As the magnitude of the zeta potential increases, the stability
of the nanosphere dispersion increases.
[0066]

Protein was eluted from the nanospheres in a nanosphere release buffer. The amount of

IL-12 (percent) encapsulated and released (encapsulation efficiency, EE) by the nanospheres was
estimated using the area under the curve (AUC) of each elution profile, the particle concentration (PC;
particles/mL), the total volume of synthesized particles (V, mL), and the total mass of IL-12 (mg)
added during synthesis via the following equation:
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𝐴𝑈𝐶𝐸𝑃
∗𝑃𝐶∗𝑉
100,000

𝐸𝐸 = (𝑇𝑜𝑡𝑎𝑙 𝐼𝐿−12 𝑎𝑑𝑑𝑒𝑑 ) ∗ 100%

[0067]

(1)

Elution may be measured by dispersing from 200 million particles/mL to 100 billion

particles/mL, from 300 million particles/mL to 50 billion particles/mL, from 400 million
particles/mL to 20 billion particles/mL, or from 500 million particles/mL to 1 billion particles/mL
of protein-loaded PLGA nanospheres in a nanosphere release buffer, and analyzing the resulting
dispersion for bioactive protein concentrations released over time. In the case of IL-12, the total
amount of rmIL-12 eluted from the aforementioned particle concentrations was determined by area
under the curve (AUC) analysis to be from 1500 to 4,000 pg. The amount of IL-12 eluted per 100,000
nanospheres was determined to be 0.3 to 0.45 pg/100,000 nanospheres, respectively, with the most
efficient elution kinetics being obtained at a concentration of 750 million particles/mL and the least
efficient elution kinetics being obtained at a concentration of 1 billion particles/mL for the particles
made via the homogenization method. Based on equation (1), the average encapsulation efficiency
(EE) was determined to range from 0.4% to 0.5%. The highest EE was obtained at a concentration
of 750 million particles/mL.
[0068]

To determine whether the synthesized nanospheres could indeed encapsulate protein and

not merely adsorb it to the outer wall, PLGA nanospheres containing fluorescein isothiocyanatelabeled bovine serum albumin were synthesized. The resulted nanospheres were imaged via confocal
microscopy to visualize the internal structure. Analysis confirmed that labeled BSA was successfully
incorporated within the nanospheres.
[0069]

To determine whether the contents of PLGA nanospheres distribute systemically and

without causing injury following various administration routes, PLGA nanospheres loaded with the
fluorescent dye Alexa Fluor® 647 were injected into female mice, either intravenously through the tail
vein or intraperitoneally, and monitored via in vivo imaging systems. Both routes of administration
resulted in systemic distribution of nanosphere contents, as depicted in FIG. 2, without any signs of
morbidity or mortality.
[0070]

Similar techniques may be used to encapsulate a water-insoluble free base or salt of a drug,

or a water-insoluble dye or contrast agent, in a PLGA nanosphere, where the term “water-insoluble”
means that the drug or salt is less soluble in water than in the organic solvent dissolving the PLGA
polymer. Similar techniques may be used to encapsulate a soluble drug, dye, or contrast agent, where
controlled release by a PLGA polymer is desired to provide a therapeutically safe and effective dose
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while avoiding toxic side effects from rapid initial release.
[0071]

To create the oil phase, from 2.5% w/v to 17% w/v of PLGA is dissolved in an organic

solvent, e.g., a halogenated C1-C3 organic solvent; a C2-C3 nitrile solvent; a C2-C5 alkyl ester solvent;
or a C3 to C5 ketone solvent. To create the aqueous phase of the emulsion, from 1% w/v to 3% w/v
of polyvinyl alcohol (PVA) is dissolved in an aqueous solvent, which may be water or a buffered saline
solution, e.g., phosphate buffered saline.
[0072]

Next, a water-insoluble free base or salt of a drug, a water-insoluble dye, or a contrast agent,

is suspended in an aqueous medium, and the resulting protein suspension was added to the PLGAcontaining oil phase, which may be subjected to rapid stirring or sonication to produce a first emulsion.
[0073]

The first emulsion is then added to the PVA aqueous phase with rapid stirring or sonication

to produce a second emulsion. The organic solvent is then evaporated from the second emulsion.
PLGA nanoparticles containing the drug, dye, or contrast agent from the aqueous medium are
recovered by centrifugation, and may be lyophilized.
[0074]

Various further modifications to the process for nanosphere preparation may increase

encapsulation efficiency, and change the elution profile of the nanospheres. Preparation of
nanospheres using a protein solution made by suspending 12.5 micrograms of IL-12 in 1.2 mL DPBS
containing 1.5% w/v trehalose produces nanospheres with delayed release. The initial burst phase is
delayed to second day after the start of the elution study, but encapsulation efficiency is decreased.
[0075]

Preparation of nanospheres using a protein solution made by suspending 12.5 micrograms

of IL-12 in 1.2 mL DPBS containing 2% w/v Mg(OH) 2 produces nanospheres with decreased
encapsulation efficiency.
[0076]

Preparation of nanospheres using a protein solution made by suspending 12.5 micrograms

of IL-12 in 1.2 mL DPBS containing 3% to 15%, 5% to 12%, 8% to 12%, or about 10% serum or
fetal serum produces nanospheres with delayed release. The initial burst phase is delayed to the second
day after the start of the elution study, and encapsulation efficiency is increased. If the IL-12
suspension is incubated with fetal serum for 24 hours prior to nanosphere preparation, the burst phase
is delayed to the third day after the start of the elution study. For in vitro studies, any type of fetal serum
may be used, e.g. fetal bovine serum or fetal murine serum. Alternatively, human serum may be used.
For in vivo studies, where nanospheres are administered to a human or non-human patient, selection
of serum should be specific to the species to be treated. For treatment of cattle, nanospheres made by
suspending IL-12 in DPBS containing fetal bovine serum may be used. For treatment of mice,
nanospheres should be made with DPBS containing fetal murine serum. For treatment of humans,
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nanospheres should be made with DPBS containing human serum. Administering nanospheres
treated with serum or fetal serum from one species to a different species may cause graft vs. host
disease.
[0077]

The presence of surfactants during nanosphere preparation increases encapsulation

efficiency. The surfactants may be incorporated into the PLGA-containing oil phase, or into the
PVA/water phase. Suitable surfactants include oil-soluble sorbitan fatty acid esters (Span 20, Span 40,
Span 60, and Span 80, for example), and/or water-soluble polyoxyethylene sorbitan fatty acid esters
(Tween 20, Tween 40, Tween 60, and Tween 80, for example). In various embodiments, nanospheres
may be prepared with a PLGA-containing oil phase containing 4% to 20% w/w of a Span surfactant,
a PVA/water phase containing 2% to 10% w/v of a Tween surfactant, or both. For example,
the oil phase may contain 4% to 20% w/w Span 60, 10% to 16% w/w Span 60, or about 14%
w/w Span 60;
the PVA/water phase may contain 2% to 10% w/v Tween 80, 3% to 8% w/v Tween 80, or
4% to 6% w/v Tween 80; or
the oil phase may contain 4% to 20% w/w Span 60 and the PVA/water phase may contain 2%
to 10% w/v Tween 80.
[0078]

The presence of both a surfactant and fetal serum greatly increases encapsulation efficiency.

Preparation of nanospheres using a protein solution made by suspending 12.5 micrograms of IL-12
in 1.2 mL DPBS containing 10% fetal serum produces nanospheres with an IL-12 encapsulation
efficiency of between 2% and 10%, between 4% and 8%, or between 5% and 7%. Preparation of
nanospheres using a protein solution made by suspending 12.5 micrograms of IL-12 in 1.2 mL DPBS
containing 10% fetal serum which has been incubated in the DPBS for 24 hours produces
nanospheres with an IL-12 encapsulation efficiency of between 10% and 50%, between 20% and 45%,
or between 30% and 40%. Preparation of nanospheres using a protein solution made by suspending
12.5 micrograms of IL-12 in 1.2 mL DPBS containing both 10% fetal serum and a surfactant produces
nanospheres with an IL-12 encapsulation efficiency of between 50% and 95%, between 60% and 85%,
or between 70% and 80%. In various embodiments, use of a protein solution containing a cytokine,
fetal serum, and a surfactant synergistically increases encapsulation efficiency of the cytokine in PLGA
nanospheres.
EXAMPLES
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[0079]

In the following examples, dichloromethane (DCM, #320269), PLGA (Resomer RG 756

S, 75% lactide, #719927), NaCl (#7647-14-5), and poly(vinyl alcohol) (#341584) were purchased from
Sigma Aldrich (St. Louis, MO). Fluorescein isothiocyanate-labeled bovine serum albumin (BSA-FITC,
#A23015), Penicillin-Streptomycin (Pen-Strep, 10,000 U/ml, #15140122) and Alexa Fluor® 647
carboxylic acid, tris(triethylammonium) salt were purchased from Thermofisher Scientific (Waltham,
MA). Recombinant mouse IL-12 (p70, rmIL-12, #577008) and Mouse IL-12 ELISA MAX deluxe
ELISA kits (#433606) were purchased from Biolegend (San Diego, CA).
[0080]

Gibco Fetal Bovine Serum Qualified Heat Inactivated US Origin (HI-FBS, #MT35011CV)

and Dulbecco’s Phosphate-Buffered Salt Solution 1X (DPBS, #21031CV) were purchased from
Fisher Scientific (Pittsburgh, PA).
[0081]

Female BALB/c mice (6-8 weeks of age) (#000651) were purchased from the Jackson

Laboratory (Bar Harbor, ME).
PART A. IL-12 STABILITY STUDIES.
Example 1. Stability of IL-12 in acidic and basic solutions.
[0082]

To determine if IL-12 could handle the acidic nanoenvironment of a PLGA nanosphere,

the recovery of bioactive recombinant mouse IL-12 following a three hour exposure to solutions of
varying pH. Specifically, IL-12 was incubated for 3 hours in a solution of pH 1, a solution of pH 3, a
solution of pH 7.4, a solution of pH 11, and a solution of pH 13. The results are shown in Table 1.
The percentage of active IL-12 recovered, relative to an initial concentration, was determined using
enzyme-linked immunosorbent assay (ELISA) to determine the amount of protein in its native, and
hence biologically-active, conformation.
Table 1. IL-12 stability as a function of pH.
pH

IL-12 Recovery (%)

1

0% ± 0%

3

39.7% ± 8.44%

7.4

100% ± 0%

11

96.6% ± 6.08%

13

0% ± 0%
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[0083]

As seen in Table 1, IL-12 has good stability at a pH value of 7.4 to 11, and is subject to

denaturation outside this range.
Example 2. Stability of IL-12 in organic solvents.
[0084]

As discussed above, the double emulsion method of synthesizing PLGA nanospheres

requires that the PLGA be dissolved in an organic solvent. Therefore, the stability of IL-12 was tested
in several aprotic solvents of varying polarity. The organic solvents tested, in order of increasing
hydrophilicity, were dichloromethane (DCM), ethyl acetate (EA), and acetone (AC). While DCM
dissolves PLGA the best, it is also the most hydrophobic and hence may have the greatest effect on
the biological activity of IL-12. PLGA is poorly soluble in acetone, but this solvent is the most polar
and therefore may affect the bioactivity of IL-12 the least.
[0085]

IL-12 was added to a 1:1 solution of solvent and phosphate-buffered salt Solution, and

stirred to completely remove the organic solvent; the remaining bioactive IL-12 concentrations were
then determined using ELISA and expressed as a percentage, relative to an initial concentration. The
results are shown in Table 2. Interestingly, AC had the most detrimental effect on the protein with
only 43% (SE = 1.06%) recovered, while EA showed the highest recovery at 63% (SE = 0.77%);
DCM left approximately half of the protein in its native form (49%, SE = 0.55).
Table 2. IL-12 stability as a function of organic solvent.

[0086]

Solvent

IL-12 Recovery (%)

DCM

49% ± 0.55%

EA

63% ± 0.77%

AC

43% ± 1.06%

Unless otherwise indicated, DCM was used to create nanosphere batches in further

examples. Although use of DCM as a solvent led to reduced protein recovery, when compared to
ethyl acetate, DCM dissolves PLGA better and results in better nanosphere morphology.
Example 3. Stability of IL-12 upon sonication.
[0087]

To form emulsions when synthesizing PLGA nanospheres, IL-12 may be subjected to

sonication twice. Ultrasonication during nanosphere preparation results in more uniform and smaller
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nanospheres. However, sensitive proteins like IL-12 become denatured when exposed to intense
agitation.
[0088]

Therefore, various sonication wattages and times were tested to determine suitable

conditions for IL-12-loaded PLGA nanosphere synthesis. IL-12 was suspended in a phosphatebuffered salt solution, and sonicated at 30 Wats, 40 Watts, or 50 Watts. The duration of sonication
was 10, 20, 30, 40, or 60 seconds. and compared to baseline. The bioactive IL-12 concentrations
remaining after sonication were then determined using ELISA and expressed as a percentage, relative
to an initial concentration. IL-12 was found to be more sensitive to time than wattage, as protein
recovery past 30 seconds was less than 10% for all wattages, as seen in FIG. 3. The scanning electron
microscopy (SEM) images of various IL-12-loaded batches are shown in FIGS. 4A to 4C. The box in
FIG. 3 indicates the combination of times/wattages that recover the most protein, i.e., sonication at
30 Watts to 50 Watts for 5 to 30 sec.
[0089]

Unless otherwise indicated, nanospheres made by sonication in subsequent examples were

prepared using:
Sonication at 30 Watts for 10 to 20 sec;
Sonication at 40 Watts for 10 to 15 sec; or
Sonication at 50 Watts for 10 to 15 sec.
PART B. STUDIES ON PLGA NANOSPHERES.
Example 4. Synthesis of PLGA nanospheres
[0090]

To create an oil phase, 800 mg of PLGA was dissolved in 32 ml DCM at room temperature

for two hours using a magnetic stir bar at 500 RPM.
[0091]

To create an aqueous phase of the emulsion, 2400 mg PVA and 96 mg NaCl were dissolved

in 120 ml deionized water and microwaved for 10 second bursts in a standard kitchen microwave on
setting HIGH until clear. The aqueous phase was then cooled on ice.
[0092]

The first emulsion (w1) was made by suspending a material to be encapsulated in 1.2 mL

DPBS and added the resulting suspension to the oil phase, which was stirred at 17,500 RPM using a
tissue homogenizer for 6 minutes. The stirring was performed on ice. As a control, blank particles
were made with no encapsulation material suspended in the DPBS.
[0093]

The second emulsion (w2) was formed by slowly pouring the first emulsion into 120 ml of

the aqueous phase. During addition of the first emulsion, the aqueous phase was stirred with the tissue
homogenizer at 17,500 RPM. Following addition of the first emulsion, stirring was continued for a
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total of 8 minutes. The resulting suspension was then stirred for 16 hours with a magnetic stir bar at
750 RPM to evaporate the organic solvent.
[0094]

Once the solvent was evaporated, the resulting solution was centrifuged at 3500 RPM three

times; following each centrifugation step, a pellet of nanospheres is recovered and resuspended, while
the supernatant produced during centrifugation is collected and stored on ice. The nanospheres were
then washed twice via ultracentrifugation at 20,000 RPM for 40 minutes at 4 degrees Celsius, flashfrozen in liquid nitrogen, and stored at -20 degrees Celsius.
[0095]

The nanospheres may then be lyophilized under vacuum to remove water from the

nanospheres.
[0096]

The properties of nanospheres obtained are summarized in Table 3. Nanospheres

containing FITC-labeled BSA, described in Table 3, were imaged via confocal microscopy to visualize
the internal structure. As shown in FIG. 5A, Z-stacking analysis confirmed that FITC-labeled BSA
was successfully incorporated within the nanospheres.
[0097]

The morphology of both blank (FIGS. 4A to 4C) and IL-12 loaded (FIGS. 5B and 5C)

PLGA nanospheres was determined via scanning electron microscopy (SEM) to be spherical in shape,
with a mean particle diameter of 201.7 ± 6.7 nm (FIG. 6A) and 138.1 ± 10.8 nm (FIG. 6B),
respectively. Zeta potentials of both blank and loaded PLGA nanospheres were also determined, with
a decrease in the magnitude of the voltage from -21.3 ± 0.808 mV (FIG. 6C) to -15.1 ± 1.249 mV
(FIG. 6D), respectively.
[0098]

Nanospheres containing the Alexa 647 dye and fluorescein isothiocyanate-labeled bovine

serum albumin (BSA-FITC) were also successfully prepared using the above procedure.
Table 3. Nanosphere Properties.
Encapsulation
Material

Amount/1.2
mL DPBS

Nothing
Alexa 647
BSA-FITC
IL-12

-5 mg
5 mg
0.025 mg

Nanosphere
Diameter
(nm)
201.7 ± 6.7
--138.1 ± 10.8

Example 5. Nanosphere IL-12 Elution Profile.
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Zeta Potential
(mV)
-21.3 ± 0.81
---15.1 ± 1.25

Nanosphere
Concentration
(Particles/mL)
6.49 x 109 ± 6.19 x 108
--1.66 x 109 ± 4.45 x 108

[0099]

PLGA nanospheres encapsulating IL-12 were obtained by the process of Example 4. Three

different concentrations (500 million particles/mL, 750 million particles/mL, and 1 billion
particles/mL) of IL-12-loaded PLGA nanospheres were prepared in 500 µl of nanosphere release
buffer (NRB, 10% HI-FBS and 100 units/ml Pen-Strep in DPBS). The suspensions were then
centrifuged for 15 minutes at 4° C to pellet the nanospheres, after which a 250 ul aliquot of the
supernatant was removed and stored at 4° C. While on ice, 250 µl NRB was then added to the pellet
to bring the total volume back up to 500 µl, which was resuspended and incubated at 37° C with
constant agitation (750 RPM) for 24 hours. This process was repeated for a total of 12 samples over
12 days (1 time point sample/24 hours). Each aliquot was stored at 4 degrees Celsius for at least 24
hours to equilibrate with the release buffer before determining IL-12 concentration via ELISA. The
aliquots were analyzed via ELISA for bioactive IL-12 concentrations released over time.
[00100]

The total amount of IL-12 eluted was determined by ELISA and subsequent area under

the curve (AUC) analysis to be:
1907.66 ± 162.00 pg at a nanosphere concentration of 500 million particles/mL,
3329.77 ± 162.67 pg at a nanosphere concentration of 750 million particles/mL, and
3415.64 ± 848.94 pg at a nanosphere concentration of 1 billion particles/mL.
[00101]

The amount of IL-12 eluted per 100,000 nanospheres was determined to be:
0.3815 ± 0.03240 pg/100,000 particles at a nanosphere concentration of 500 million
particles/mL,
0.4440 ± 0.02169 pg/100,000 particles at a nanosphere concentration of 750 million
particles/mL, and
0.3416 ± 0.08489 pg/100,000 particles at a nanosphere concentration of 1 billion particles/mL.

[00102]

The 750 million particles/mL sample reported the most efficient elution kinetics of the

three concentrations tested.
[00103]

As seen in FIG. 7A, IL-12 concentration eluted as a function of time at a nanosphere

concentration of 750 million particles/mL is significantly greater than IL-12 concentration eluted as a
function of time at a nanosphere concentration of 500 million particles/mL. However, there is little
difference between IL-12 elution as a function of time at a nanosphere concentration of 750 million
particles/mL and IL-12 elution as a function of time at a nanosphere concentration of 1 billion
particles/mL. Also as seen in FIG. 7A, IL-12 nanoparticles show a biphasic elution profile, with a
burst phase lasting about 2 days and a sustained release phase lasting about from about day 3 to day
11. Moreover, the total amount of IL-12 eluted over time at a nanosphere concentration of 750 million
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particles/mL is about 75% greater than the total amount of IL-12 eluted at a nanosphere
concentration of 500 million particles/mL. However, the total amount of IL-12 eluted at a nanosphere
concentration of 1 billion particles/mL is only about 2.6% greater than the total amount of IL-12
eluted at a concentration of 750 million particles/mL. As seen in FIG. 7B, IL-12 concentration eluted
per 100,000 particles, as a function of time, is greater at a nanosphere concentration of 750 million
particles/mL than at a concentration of either 500,000 particles/mL or 1 billion particles/mL.
[00104]

As shown in FIG. 7C, the encapsulation efficiency (EE) of recombinant mouse IL-12

(rmIL-12)-loaded nanospheres was calculated using the area under the curve (AUCs) of each elution
profile for the three different particle concentrations investigated, using Equation 1. The amount of
IL-12 eluted per 100,000 nanospheres was determined to be 0.44% at a nanosphere concentration of
500 million particles/mL, 0.50% at a nanosphere concentration of 750 million particles/mL, and
0.39% at a nanosphere concentration of 1 billion particles/mL. The average encapsulation efficiency
(EE) is 0.443% ± 0.0551%. Due to differing elution kinetics from the tested concentrations, EE was
reported for all three concentrations and subsequently averaged to reflect overall EE.
[00105]

Based on the above data, increasing the nanosphere concentration above 750 million

particles/mL may not offer a significant increase in the elution profile of the drug, possibly due to
reduced encapsulation efficiency at high particle concentrations. However, this may be due to the
constraints of eluting particles in vitro in a small volume (500 µL) of elution solvent. Elution in a larger
volume, e.g., a larger volume of an in vitro elution solvent or an in vivo blood supply, may provide an
increased elution profile as the nanosphere concentration increases above 750 million particles/mL.
Example 6. In vivo Alexa 647-loaded PLGA nanosphere substrate biodistribution.
[00106]

PLGA nanospheres loaded with the fluorescent dye Alexa 647, described in Table 1, were

injected into female BALB/c mice. In a first group of mice, the dye-loaded PLGA nanospheres were
injected intravenously through the tail vein. In a second group of mice, the dye-loaded PLGA
nanospheres were injected intraperitoneally. Dye distribution was monitored via IVIS imaging over a
76-minute period. At 35 minutes post-injection, both routes of administration resulted in systemic
distribution of nanosphere contents, as depicted in FIG. 2. Intravenous injection resulted in
generalized distribution of labeled dye through the body of the subject mouse. Intraperitoneal
injection resulted in localized distribution of labeled dye within the abdominal cavity of the subject
mouse, with the most intense distribution of the dye within the peritoneal cavity. Distribution
occurred without any signs of morbidity or mortality.
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PART C. STUDIES ON PLGA NANOSPHERES WITH SONICATION.
Example 7. Synthesis of PLGA nanospheres with sonication.
[00107]

To create an oil phase, 250 mg of PLGA was dissolved in 1.51 ml DCM at room

temperature. 1 g PVA was dissolved in 100 ml deionized water to create an aqueous phase. The
aqueous phase was then cooled on ice. The first emulsion (w1) was made by suspending 12.5
micrograms of IL-12 in about 20±6 microliters DPBS and adding the resulting suspension to the oil
phase with sonication at 30 to 50 Watts for 10 to 20 sec..
[00108]

The second emulsion (w2) was formed by slowly adding the first emulsion into 5 ml of the

aqueous phase. During addition of the first emulsion, the aqueous phase was subjected to sonication
at 30 to 50 Watts for 10 to 30 sec. The resulting suspension was then stirred for 3 hours with a
magnetic stir bar at 1,000 RPM to evaporate the organic solvent.
[00109]

Once the solvent was evaporated, nanospheres were recovered from the resulting solution

via three ultracentrifugation treatments at 10,000 g for 15 minutes at 4 degrees Celsius, flash-frozen
in liquid nitrogen, and stored at -20 degrees Celsius.
[00110]

The nanospheres may then be lyophilized under vacuum to remove water from the

nanospheres.
[00111]

FIG. 8A shows IL-12-loaded nanospheres prepared using sonication at a sonication power

of 30 Watts and a sonication time ranging from 10 sec to 20 sec (Batches 30W10S, 30W15S, and
30W20S of Table 2).
[00112]

FIG. 8B shows IL-12-loaded nanospheres prepared using sonication at a sonication power

of 40 Watts and a sonication time ranging from 10 sec to 15 sec (Batches 40W10S and 40W15S of
Table 2).
[00113]

FIG. 8C shows IL-12-loaded nanospheres prepared using sonication at a sonication power

of 50 Watts and a sonication time ranging from 10 sec to 15 sec (Batches 50W10S and 50W15S of
Table 2).
[00114]

As seen in Table 4, sonication with 30 Watts to 50 Watts power for 10 to 20 sec generally

produces IL-12 loaded PLGA nanospheres with an encapsulation efficiency of about 5% to about
10%, and a zeta potential of between -30 and -40 mV.
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Table 4. Impact of Sonication Conditions on Nanosphere Properties
Sonication
Power
30 W
40 W
50 W

Particle
Batch
30W10S
30W15S
30W20S
40W10S
40W15S
50W10S
50W15S

Sonication
Time
10 sec
15 sec
20 sec
10 sec
15 sec
10 sec
15 sec

Encapsulation
Efficiency (%)
9.67 ± 4.25
7.60 ± 3.45
4.84 ± 0.80
6.23 ± 1.29
6.92 ± 0.44
8.80 ± 1.88
5.20 ± 3.10

Zeta Potential
(mV)
-36.15 ± 2.25
-38.15 ± 4.75
-31.75 ± 6.35
-31.55 ± 8.35
-33.55 ± 7.35
-36.35 ± 2.85
-35.50 ± 4.90

Example 8. Elution of PLGA nanospheres prepared with sonication.
[00115]

The IL-12-loaded nanospheres shown in Table 2 were tested for elution characteristics by

the procedure of Example 5. Protein concentration per day was determined by ELISA, and the total
protein released was determined using the area under the raw elution curve.
[00116]

Elution curves obtained by the above procedure are shown in FIG. 9. The elution curve

for each batch of Table 2 shows a biphasic curve with an initial burst phase and a sustained release
phase. The burst phase is due to the adsorbed protein on the surface of the nanospheres being released
upon resuspension in aqueous medium, while the controlled release phase is due to protein entrapped
within the PLGA matrix. As seen in FIG. 8, for a constant sonication period, e.g., 10 sec., the initial
rate of drug release during the burst phase decreases as the sonication power increases. In a batch
sonicated for 10 sec at 30 W power (30W10S), between 60% and 65% of the IL-12 is eluted within
one day. In a batch sonicated for 10 sec at 50 W power (50W10S), less than 50% of the IL-12 is eluted
within one day. This suggests that the percentage of protein within the PLGA matrix in the
nanosphere core increases as the sonication power increases.
PART D. IMPACT OF STIRRING SPEED ON PLGA NANOSPHERES.
Example 9.
[00117]

To create an oil phase, 800 mg of PLGA was dissolved in 32 ml DCM at room temperature

for two hours using a magnetic stir bar at 500 RPM.

310

[00118]

To create an aqueous phase of the emulsion, 2400 mg PVA and 96 mg NaCl were dissolved

in 120 ml deionized water and microwaved for 10 second bursts in a standard kitchen microwave on
setting HIGH until clear. The aqueous phase was then cooled on ice.
[00119]

An IL-12 suspension was made by suspending 25 micrograms of IL-12 in 1.2 mL DPBS.

[00120]

Nanospheres were prepared as described in Example 4.

[00121]

To observe the impact of stirring speed on encapsulation efficiency of IL-12 in a PLGA

nanosphere, and elution profile of IL-12 from PLGA nanospheres, stirring during preparation of the
first and second emulsions was done at speeds of 13,125 RPM; 15,312 RPM; 17,500 RPM; 19,688
RPM; 21,875 RPM; 24,063 RPM; and 26,250 RPM. Encapsulation efficiency as a function of agitation
speed is shown in Table 5.
Table 5. Encapsulation Efficiency as a function of stirring speed.
Setting on Tissue
Homogenizer
3
3.5
4
4.5
5
5.5
6

[00122]

Agitation Speed (RPM)
13,125
15,312
17,500
19,688
21,875
24,063
26,250

Encapsulation Efficiency
(%)
0.68
0.50
2.06
0.94
0.70
0.50
0.15

As seen in FIG. 10, the elution profile of IL-12 from PLGA nanospheres prepared using

high-speed stirring rather than sonication, at a nanosphere concentration of 750 million particles/mL,
is highly dependent on stirring speed. Stirring at 17,500 RPM gives a high encapsulation efficiency,
and a total drug release over a 12-day period of about 4500 pg IL-12. Stirring at about 13,000 to about
20,000 RPM gives an acceptable drug release over a 12-day period of about 3500 pg IL-12 or greater.
Stirring at greater than about 22,000 RPM gives a low encapsulation efficiency, and a total drug release
over a 12-day period of less than 3,000 pg IL-12. The optimum stirring speed for producing IL-12
loaded PLGA nanospheres is about 17,500 RPM.
PART E. EFFECT OF NANOSPHERES ON RELEASE OF A SOLUBLE CYTOKINE.
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Example 10. Release of Free IL-12 vs. Nanosphere-Encapsulated IL-12.
[00123]

Osteosarcoma (OS) induces systemic immune suppression in mice that can be reversed by

the checkpoint blocker anti-PD-L1, as shown in FIG. 11. Using anti-PD-L1, their systemic
immunophenotype returns to baseline status, relieving immunosuppression from OS. However,
baseline status does not provide enough immune stimulation to effectively reduce tumor burden in
mice with advanced OS. See FIG. 11, line A. However, patients in a Phase II study of a rituximab/IL12 combination therapy, where IL-12 was administered as a free peptide, for relapsed and refractory
Non-Hodgkin lymphoma (NHL) showed signs of dose-limiting toxicity (DLT). Their immune status,
or immunophenotype, was pushed past the level of stimulation and into the realm of a life-threatening
state of immune system over-activation known as immune cell exhaustion. See FIG. 11, line C. The
goal is to stimulate the immune system above baseline levels, without overstimulation or immune cell
exhaustion.
[00124]

However, in a background of anti-PD-L1 checkpoint blockade providing disinhibition of

activated T cells, slow and sustained delivery of low dose IL-12 (which is generally considered safe)
from hydrolyzing PLGA nanospheres (IL-12-NS) to the systemic tumor macroenvironment may
provide the systemic stimulation necessary to effectively reduce tumor burden while still remaining
beneath the exhaustion threshold, as shown in FIG. 11, line B. A real-time immunophenotype
monitoring platform, like the one described herein, would be of considerable value for this application.
[00125]

Thus, use of biodradable PLGA nanospheres as a delivery vehicle for a soluble drug allows

administration of a therapeutically effective low dose. This is useful where the difference between an
effective dosage of a drug and a toxic dose are small.
PART E. EFFECT OF NANOSPHERE ADDITIVES ON RELEASE OF A SOLUBLE
CYTOKINE.
Example 11.
[00126]

Seven batches of nanospheres containing the drug IL-12 were prepared. The elution profile

of these batches was obtained by following the procedure of Example 5, with sonication at 50 Watts
power for 10 sec.
[00127]

The first batch was made by following the procedure of Example 7, using a protein solution

made by suspending 12.5 micrograms of IL-12 in about 20±6 microliters DPBS and a PVA/water
phase. No additives not listed in Example 7 were included. Upon elution of the first batch by the
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method of Example 5, the drug was released with an initial burst phase lasting 1 to 2 days, and a peak
IL-12 concentration of ~65,000 pg/mL, reached on the second day, as shown in FIG. 12.
[00128]

The second batch was made by following the procedure of Example 7, except that a protein

solution made by suspending 12.5 micrograms of IL-12 in about 20±6 microliters DPBS containing
1.5% w/v trehalose was used. For the second batch, the drug was released with an initial burst phase
lasting 3 days, and a peak IL-12 concentration of ~75,000 pg/mL, reached on the third day. As seen
in FIG. 12, the presence of trehalose in the protein solution used to make nanospheres significantly
increased the overall drug release (measured as area under the curve), compared to drug release from
nanospheres made without additional additives.
[00129]

The third batch was made by following the procedure of Example 7, except that a protein

solution made by suspending 12.5 micrograms of IL-12 in about 20±6 microliters DPBS containing
2% w/v Mg(OH)2 was used. Upon elution of the third batch by the method of Example 5, the drug
was released with an initial burst phase lasting 1 day, and a peak IL-12 concentration of ~10,000
pg/mL. As seen in FIG. 12, the presence of Mg(OH)2 in the protein solution used to make
nanospheres decreased the overall drug release, compared to drug release from nanospheres made
without additional additives.
[00130]

For the fourth batch, nanospheres were made by following the procedure of Example 7,

using a protein solution made by suspending 12.5 micrograms of IL-12 in about 20±6 microliters
DPBS containing 10% fetal bovine serum (FBS). Upon elution by the method of Example 5, the drug
was released with an initial burst phase lasting 3 days, and a peak IL-12 concentration of ~115,000
pg/mL, reached on the second day. The presence of 10% FBS in the protein solution significantly
increased the overall drug release (measured as area under the curve), compared to drug release from
nanospheres made without additional additives, as seen in FIG. 13.
[00131]

For the fifth batch, nanospheres were made by following the procedure of Example 7,

using a protein solution made by suspending 12.5 micrograms of IL-12 in about 20±6 microliters
DPBS containing 10% fetal bovine serum (FBS), where the protein solution was incubated for 24
hours prior to production of nanospheres. Upon elution by the method of Example 5, the drug was
released with an initial burst phase lasting 3 days, and a peak IL-12 concentration of from ~105,000
pg/mL to ~110,000 pg/mL, reached on the third day. As seen in FIG. 13, the presence of 10%
incubated FBS in the protein solution significantly increased the overall drug release from the
nanospheres (measured as area under the curve), compared to drug release from either nanospheres
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made without additional additives, or nanospheres made using FBS in the absence of an incubation
step.
[00132]

For the sixth batch, nanospheres were made by following the procedure of Example 7,

using a PVA/water phase containing 4% w/v Tween 80. Upon elution by the method of Example 5,
the drug was released with an initial burst phase lasting 1 day, and a peak IL-12 concentration of from
~120,000 pg/mL to ~125,000 pg/mL. As seen in FIG. 14, the presence of Tween 80 in the protein
solution increased the peak drug release from the nanospheres by about a factor of 2, compared to
peak drug release from nanospheres made without additional additives. The presence of Tween 80
also substantially increased overall drug release.
[00133]

For the sixth batch, nanospheres were made by following the procedure of Example 7,

using a PVA/water phase containing 10% w/v FBS and 4% w/v Tween 80. Upon elution by the
method of Example 5, the drug was released with an initial burst phase lasting 1 day, and a peak IL12 concentration of about ~580,000 pg/mL. As seen in FIG. 14, the presence of both FBS and Tween
80 in the protein solution increased the peak drug release from the nanospheres by about a factor of
about 9, compared to a peak drug release of ~65,000 pg/mL from nanospheres made without
additional additives. The presence of both FBS and Tween 80 also:
increased the peak drug release from the nanospheres by about a factor of about 4.5, compared
to a peak drug release of ~115,000 pg/mL from nanospheres made with FBS alone; and
increased the peak drug release from the nanospheres by about a factor of about 4.5, compared
to a peak drug release of ~120,000 pg/mL from nanospheres made with Tween 80 alone.
Table 6. Effect of Nanosphere Additives on Drug Release and Encapsulation Efficiency.
Additives
Total (pg)
None
Trehalose
Mg(OH)2
FBS
FBS (incubated
for 24 h)
Tween 80
Tween 80 + FBS

-207386.3905
26065.70647
285394.6775
654806.6577
419307.8952
1341061.532

Drug Release
Peak
(pg/mL)
65,000
75,000
10,000
~115,000
~110,000
~120.000
~580,000
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EE (%)
Per 100,000
Particles (pg)
-0.414
0.0521
0.571
1.31

Zeta
Potential

8.8
5.79
2.19
6.67
35.71

-36.35
-38.95
-22.4
-36.6
-39.7

0.839
2.68

17.39
87.54

-32.5
-35.6

Peak drug release, total drug release, drug release/100,000 particles, encapsulation

[00134]

efficiency (EE), and Zeta potential for these modified nanosphere batches are recorded in Table 6. As
shown in this table, the peak drug release and the overall drug release upon elution of the drug IL-12
from nanospheres can be increased by making the nanospheres in the presence of an additive selected
from the group consisting of trehalose, FBS, FBS with 24 hours incubation, a surfactant, or a mixture
thereof. Also, FBS with 24 hours incubation, a surfactant, or a mixture of FBS and a surfactant lead
to dramatic increases in encapsulation efficiency. The peak drug release and the overall drug release
upon elution can be synergistically increased by making the nanospheres in the presence of both FBS
and a surfactant.
DETAILED DESCRIPTION: MONITORING IMMUNOPHENOTYPES
Various embodiments disclosed herein relate to a technique allowing a medical professional

[00135]

to systemically analyze the immune system of a patient from two to three drops of blood obtained
using a finger stick blood draw obtained using a lancet and Microtainer®. The blood draw can be
done at the office of a medical professional; in a clinic; or in a hospital.
In various embodiments, the blood draw can be done at the office of a medical

[00136]

professional; in a clinic; or in a hospital. The blood draw can be analyzed at a testing site or a medical
facility.
[00137]

The blood sample may be analyzed for the level of an immunochemical naturally present

in the body of the patient, and/or for the level of an immunomodulatory drug administered to the
patient. The blood sample may be analyzed for the level of an immunochemical naturally present in
the body of the patient, as a function of time, allowing a medical professional to observe the effect of
a treatment regimen on the immunochemical levels. Blood draws may be taken and analyzed at regular
intervals, allowing a medical professional to assess changes in the immune status, or
immunophenotype, over the course of treatment.
[00138]

Referring to FIG. 11, there are four major immunophenotypes under consideration:
Suppression, e.g., immunosuppression induced by cancer, an autoimmune disease, or an
infection;
Baseline, e.g., the immune status of a disease-free subject;
Stimulation of the immune system above baseline levels; and
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Exhaustion, a life-threatening state of immune system over-activation known as immune cell
exhaustion (TCE), marked by characterized by lymphocyte anergy, systemic inflammatory
response syndrome, and/or organ failure.
FIG. 11 shows the change in the immunophenotype of an osteosarcoma cancer patient

[00139]

during treatment with a variety of immunomodulating therapies. The patient’s initial
immunophenotype is Suppression, due to cancer-induced immunosuppression. Programmed cell
death ligand 1 (PDL-1) is frequently expressed during osteosarcoma, so antibodies to PDL-1 (AntiPDL-1) may be administered. See FIG. 11, line A. Interleukin-12 (IL-12) has been shown to inhibit
tumor growth in osteosarcoma, so free IL-12 may be administered as an immunomodulator. See FIG.
11, line C.
At Time T1, Anti-PDL-1 appear to be ineffective in changing the patient’s

[00140]

immunophenotype, while IL-12 appears to have changed the immunophenotype to Stimulation.
However, at Time T2, as the treatment progresses, IL-12 causes toxic side effects, changing the
patient’s immunophenotype to Exxhaustion. At Time T2, Anti-PDL-1 changes the patient’s
immunophenotype to baseline, combatting the cancer-induced immunosuppression without
stimulating the immune system to fight the cancer.
As seen in FIG. 11, line B, combining Anti-PDL-1 with a low dose of IL-12 administered

[00141]

in PGLA nanospheres may stimulate the immune system to fight cancer without causing immune
system over-activation. Thus, monitoring the immunophenotype over time allows a medical
practitioner to adjust an immunomodulating therapy to provide immunostimulation without T-cell
exhaustion.
Data relating to the immune response to a cancer therapy may be entered into a database.

[00142]

For example, referencing FIG. 11, the following information may be entered into the database for any
given patient with a first disease which suppresses or overstimulates the immune system:
a)

type of disease;

b)

immunophenotype prior to treatment;

c)

treatment administered for the first disease;

d)

change in immunophenotype as a function of time;

e)

clinical outcome;

f)

medications taken by the patient for a second disease;

g)

disease stage or disease level;

h)

medical co-morbidities; and
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i)
[00143]

age of the patient.
It is important to note that changes in any one of those parameters may affect other

parameters. For example, if a patient undergoing treatment for a first disease which affects the immune
system is, after the initiation of treatment, diagnosed with a second disease, i.e., a medical comorbidity, either a causative agent of the second disease or a symptom of the second disease may
affect:
the clinical outcome of treatment of the first disease,
the change in the patient’s immunophenotype over time,
the stage or level of the first disease, and/or
the efficacy of treatment administered for the first disease.
[00144]

Similarly, a change in disease stage or disease level of the first disease, e.g., progression of

a cancer from stage 2 to stage 3, may affect the patient’s immunophenotype as a function of time,
protocols for treatment of the first disease, and the clinical outcome of treatment of the first disease.
[00145]

The database would thus include information on treatment of a variety of diseases with

immunomodulating drugs, and allow predictions on how a particular patient presenting with that
disease will respond to a given immunomodulating therapy.
[00146]

Use of such a database allows a medical professional to predict the response of a patient’s

immune system to a given disease state, and to predict changes in the patient’s immunophenotype
over the course of a disease or treatment. The database will useful in the treatment, surveillance, and
diagnosis of many diseases including cancer, autoimmune diseases, and infections.

As

immunomodulating agents become more common, such a database provides the ability to assess
where the status of the immune system at a specific time in the pathogenesis of a disease, and to
predict which immunomodulating treatments would be most effective in treating that disease.
[00147]

Each blood sample obtained from a patient’s finger stick blood draw may be analyzed for

the patient’s immunophenotype at the time of the blood draw. The results of the analysis, together
with information as to the patient’s disease state and current treatment, if any, may be compared to
data present in the database to develop a treatment plan which is most likely to effectively modulate
the patient’s immunophenotype. Blood draws may be taken and analyzed at regular intervals, allowing
a medical professional to assess changes in the immune status, or immunophenotype, over the course
of treatment. Data from the current patient may be added to the database, potentially improving
assessments of other patients.
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[00148]

This has massive commercial potential for analysis of a patient’s blood with complex

immunophenotyping, whether the analysis is for cancer, infection, or autoimmune diseases. The
database that can be created with cross referencing of diseases with immunophenotyping will be a
powerful tool to treat patients in the future. The database will be a living database that generates
constantly updating information on immunophenotyping and status of treatment.
[00149]

Immunophenotyping of a patient’s blood sample requires the ability to analyze and assess

the data appropriately. This system will allow the appropriate dosing, treatment, and corrections to
be made across several disease states. As the collection of data increases the growing database will
also be able help direct medical professionals to diagnosis, treat, and dose immunotherapeutics in the
broadest sense.
[00150]

Although the various exemplary embodiments have been described in detail with particular

reference to certain exemplary aspects thereof, it should be understood that the invention is capable
of other embodiments and its details are capable of modifications in various obvious respects. As is
readily apparent to those skilled in the art, variations and modifications can be affected while remaining
within the spirit and scope of the invention. Accordingly, the foregoing disclosure, description, and
figures are for illustrative purposes only and do not in any way limit the invention, which is defined
only by the claims.
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What is claimed is:
1.

A method of encapsulating a protein in a nanosphere, comprising:
preparing an oil phase by dissolving from 2.5% w/v to 17% w/v of poly(lactic acidco-glycolic acid) (PLGA) in an organic solvent;
preparing an aqueous phase by dissolving polyvinyl alcohol in water;
suspending the protein in an aqueous medium;
adding the aqueous medium to the oil phase to form a first emulsion, and agitating
the first emulsion;
adding the first emulsion to the aqueous phase to form a second emulsion, and
agitating the second emulsion;
evaporating the organic solvent from the second emulsion to form an aqueous
solution; and
recovering poly(lactic acid-co-glycolic acid) nanospheres containing the protein from
the aqueous solution.

2.

The method of claim 1, wherein the PLGA comprises from 50% to 90% lactide; and
the organic solvent is selected from the group consisting of halogenated C1-C3
organic solvents, C2-C3 nitrile solvents, C2-C5 alkyl ester solvents, C3 to C5 ketone
solvents, and mixtures thereof.

3.

The method of claim 2, wherein the organic solvent is acetonitrile, acetone, ethyl acetate, or

dichloromethane.
4.

The method of claim 1, wherein the PLGA comprises from 75% to 90% lactide.

5.

The method of claim 1, wherein the PLGA comprises from 50% to 75% lactide; and
the organic solvent is selected from the group consisting of halogenated C1-C3
organic solvents, acetonitrile, C3 to C4 ketone solvents, and mixtures thereof.
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6.

The method of claim 1, wherein the method comprises adding the aqueous medium to the oil

phase to form a first emulsion, and agitating the first emulsion with a tissue homogenizer at a rate of
13,000 RPM to 20,000 RPM; and
adding the first emulsion to the aqueous phase to form a second emulsion, and agitating the
second emulsion with a tissue homogenizer at a rate of 13,000 RPM to 20,000 RPM.
7.

The method of claim 1, wherein the method comprises adding the aqueous medium to the oil

phase to form a first emulsion, and agitating the first emulsion by sonication; and
adding the first emulsion to the aqueous phase to form a second emulsion, and agitating the
second emulsion by sonication.
8.

The method of claim 7, wherein:
agitating the first emulsion comprises sonication at a power level of 30 W to 50 W, for

a

period of time of 5 sec to 30 sec; and
agitating the second emulsion comprises sonication at a power level of 30 W to 50 W,
for a period of time of 5 sec to 30 sec.

8.

The method of claim 8, wherein:
agitating the first emulsion comprises sonication for a period of time of 10 sec to 20
sec; and
agitating the second emulsion comprises sonication for a period of time of 10 sec to
20 sec.

9.

The method of claim 1, wherein the protein is a cytokine or a globular protein.

10.

The method of claim 9, wherein the protein is a cytokine selected from the group consisting

of interleukins, lymphokines, monokines, interferons, colony stimulating factors, and chemokines.
11.

The method of claim 10, wherein the cytokine is selected from the group consisting of

interleukins and non-immunological cytokines.
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12.

The method of claim 9, wherein the protein is a cytokine having an N-terminal signal sequence,

a four-helix bundle comprising four helices labeled A through D, and no C-terminal extension
following the D helix.
13.

The method of claim 12, wherein the cytokine is a granulocyte-macrophage colony-stimulating

factor, a granulocyte colony-stimulating factor, interferon alpha-1, interferon beta, interferon gamma.
interferon kappa, interferon tau-1, interferon omega-1, or an interleukin selected from the group
consisting of IL-2, IL-3, IL-4, IL-5, IL-5, IL-6, IL-7, IL-9, IL-10, IL-11, the alpha chain of IL-12, IL13, IL-15, IL-19, IL-20, IL-21, IL-22, IL-23, IL-24, IL-26, and IL-27.
14.

15.

The method of claim 9, wherein the protein is an immunological cytokine that either:
a)

enhances cellular immune responses; or

b)

enhances antibody responses.

The method of claim 14, wherein the cytokine is an immunological cytokine that enhances

cellular immune responses, selected from the group consisting of TNFα, IFN-γ, and interleukin-12.
16.

The method of claim 15, wherein the cytokine is IL-12.

17.

The method of claim 14, wherein the cytokine is an immunological cytokine that enhances

antibody responses, selected from the group consisting of TGF-β, IL-4, IL-10, and IL-13.
18.

The method of claim 16, wherein:
the first and second emulsions are each agitated with a tissue homogenizer at a rate
of 13,000 RPM to 20,000 RPM; and
IL-12 is incorporated into the poly(lactic acid-co-glycolic acid) nanospheres with an
encapsulation efficiency of about 0.5% to about 2.1%.

19.

The method of claim 16, wherein:
the first and second emulsions are each agitated with sonication at a power level of 30
W to 50 W, for a period of time of 5 sec to 30 sec; and
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IL-12 is incorporated into the poly(lactic acid-co-glycolic acid) nanospheres with an
encapsulation efficiency of about 4.5% to about 10%.
20.

A nanosphere produced by the method of claim 1, the nanosphere comprising a poly(lactic

acid-co-glycolic acid) matrix and a protein, wherein:
a first portion of the protein is adsorbed onto a surface of the nanosphere;
a second portion of the protein is incorporated into the poly(lactic acid-co-glycolic acid) matrix
at a core of the nanosphere.
21.

The nanosphere of claim 20, wherein:
the protein is IL-12; and
the IL-12 is incorporated into the nanosphere with an encapsulation efficiency of about 0.5%

to about 10%.
22.

A method of encapsulating a protein in a nanosphere, comprising:
preparing an oil phase by dissolving from 2.5% w/v to 17% w/v of poly(lactic acidco-glycolic acid) (PLGA) in an organic solvent, optionally containing a first surfactant;
preparing an aqueous phase containing polyvinyl alcohol and at least one additive
selected from the group consisting of mammalian serum, trehalose, and a second surfactant;
suspending the protein in an aqueous medium;
adding the aqueous medium to the oil phase to form a first emulsion, and agitating
the first emulsion;
adding the first emulsion to the aqueous phase to form a second emulsion, and
agitating the second emulsion;
evaporating the organic solvent from the second emulsion to form an aqueous
solution; and
recovering poly(lactic acid-co-glycolic acid) nanospheres containing the protein from
the aqueous solution.

23.

The method of claim 22, wherein the aqueous phase contains polyvinyl alcohol and

mammalian serum.

322

24.

The method of claim 23, wherein:
the oil phase contains the first surfactant; and/or
the aqueous phase contains the second surfactant.

25.

The method of claim 24, wherein:
the first surfactant is a sorbitan fatty acid ester; and/or
the second surfactant is a polyoxyethylene sorbitan fatty acid ester.

26.

The method of claim 22, wherein the aqueous phase contains polyvinyl alcohol and fetal

serum.
27.

The method of claim 22, wherein the first surfactant is a sorbitan fatty acid ester.

28.

A nanosphere produced by the method of claim 22, the nanosphere comprising a poly(lactic

acid-co-glycolic acid) matrix and a protein, wherein:
a first portion of the protein is adsorbed onto a surface of the nanosphere;
a second portion of the protein is incorporated into the poly(lactic acid-co-glycolic acid) matrix
at a core of the nanosphere; and
the nanosphere comprises at least one additive selected from the group consisting of
mammalian serum albumin, trehalose, the first surfactant, and the second.
29.

The nanosphere of claim 28, wherein the nanosphere comprises mammalian serum albumin

and a surfactant.
30.

A dosage form, comprising a plurality of nanospheres produced by the method of claim 1,

each nanosphere comprising a poly(lactic acid-co-glycolic acid) matrix and a protein, wherein:
a first portion of the protein is adsorbed onto a surface of the nanosphere;
a second portion of the protein is incorporated into the poly(lactic acid-co-glycolic acid) matrix
at a core of the nanosphere.
31.

The dosage form of claim 30, wherein:
the protein is IL-12; and
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the IL-12 is incorporated into the nanosphere with an encapsulation efficiency of about 0.5%
to about 10%.
32.

A method of controlling an immunophenotype in a patient suffering from a disease which

impacts the immune system, comprising:
a)

determining an initial immunophenotype of a patient;

b)

if the initial immunophenotype shows immunosuppression, administering a first drug
which stimulates the immune system; or
if the initial immunophenotype shows overstimulation of the immune system,
administering a second drug which suppresses the immune system;

c)

after step (b), monitoring the patient’s immunophenotype as a function of time; and

d)

adjusting administration of the first and/or second drug if the patient’s
immunophenotype falls outside a desired range.

33.

A method of controlling an immunophenotype in a patient suffering from a disease which

impacts the immune system, comprising:
a)

determining a disease state of a patient, where the disease state includes a diagnosis
and an initial immunophenotype;

b)

comparing the disease state of the patient to a plurality of disease states within a
database, where each disease state in the database includes a diagnosis, an initial
immunophenotype, and a treatment protocol;

c)

based on the comparing step (b), selecting a treatment protocol from the database,
where the treatment protocol involves administering an immunomodulating drug.

34.

The method of claim 33, further comprising:
d)

administering the immunomodulating drug to the patient;

e)

after step (d), monitoring the patient’s immunophenotype as a function of time; and

f)

adjusting administration of the immunomodulating drug if the patient’s
immunophenotype falls outside a desired range.
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ABSTRACT
A protein may be encapsulated in a nanosphere by preparing an oil phase by dissolving from
2.5% w/v to 17% w/v of poly(lactic acid-co-glycolic acid) (PLGA) in an organic solvent; preparing
an aqueous phase by dissolving polyvinyl alcohol in water; and suspending the protein in an aqueous
medium. A double emulsion is produced by adding the protein-containing aqueous medium to the oil
phase to form a first emulsion, and agitating the first emulsion; and then adding the first emulsion to
the aqueous phase to form a second emulsion, and agitating the second emulsion. The organic solvent
is evaporated from the second emulsion to form an aqueous solution; and PLGA nanospheres
containing the protein are recovered from the aqueous solution. The protein may be an
immunomodulating drug, and may be used with a method of controlling an immunophenotype in a
patient suffering from a disease which impacts the immune system. The method of controlling an
immunophenotype includes determining a disease state of a patient, where the disease state includes
a diagnosis and an initial immunophenotype; comparing the disease state of the patient to a plurality
of disease states within a database, where each disease state in the database includes a diagnosis, an
initial immunophenotype, and a treatment protocol; and, based on the comparing step, selecting a
treatment protocol from the database, where the treatment protocol involves administering an
immunomodulating drug.
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